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1 Atherosclerosis 
Atherosclerosis is a chronic inflammation of the arterial wall and causes inter 
alia rearrangement of cellular and subcellular components. Besides some other 
diseases like thromboembolic disease, rhythm disorders and hypertension, 
atherosclerosis is the main contributor to cardiovascular diseases. 
Atherosclerotic lesions are mediated by modified low density lipoproteins (LDL) 
triggered immune cell influx, accumulation of dead mononuclear and vascular 
cells, reorganization of smooth muscle cells (SMC) as well as deposition of 
extracellular matrix like collagen. Most atherosclerotic lesions cause luminal 
narrowing comprising altered shear stress conditions, until unstable lesion 
rupture releases prothrombotic material into the lumen, initiating coagulation 
and causing occlusion. Dependent on the site of occlusion this may lead to 
myocardial infarction or stroke, two of the most important sources for illness and 
death in developed countries
1-3
.  
The onset of atherosclerosis is represented by the formation of a “fatty 
streak”, an accumulation of highly lipid-laden macrophages
4
. In a classification 
of plaque stages by Virmani and colleagues those intimal xanthomas still count 
for the non-atherosclerotic intimal lesions without necrotic core or fibrous 
depositions covering the lipid core, often referred to as fibrous cap
5
. Intimal 
macrophages phagocytose excess lipids, transform into “foam cells” and 
contribute together with activated endothelial cells and further intimal immune 
cells to the inflammatory milieu by secreting a great variety of cytokines, like 
Interleukin (IL)-1 and -6, and tumor necrosis factor (TNF)-α
6
, chemokines and 
proteases. Progressive atherosclerotic lesions finally evolve from this enhanced 
secretion of atherogenic factors. Those lesion stages were categorized by 
Virmani et al. as pathological intimal thickening comprising SMCs in a 
proteoglycan-rich matrix and extracellular lipid accumulations and as fibrous 
cap atheroma containing a well-formed necrotic core and a covering fibrous 
cap. Finally, matrix-metallo protease mediated weakening of the fibrous cap 
results in a higher susceptibility to plaque rupture followed by vessel occlusion. 
The role of disturbed flow in atherogenesis 
Besides the generally accepted notion that hyperlipidemia induced excess of 
modified LDL in the vessel wall is responsible for activation of the endothelial 
cell layer and thus increasing mononuclear cell recruitment
1, 3
, also alterations in 
laminar shear stress, preferentially occurring at branching points or curvatures 
activate the endothelium and cause enhanced mononuclear cell extravasation 
into the vessel wall
7, 8
. First evidence for shear stress dependent mononuclear 
cell extravasation was found in the mid-eighties by differently localizing 
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atherosclerotic plaques in areas of low shear stress
9, 10
 and later, plenty of 
evidence was found correlating shear stress mediated changes in expression 
pattern of chemokines, adhesion molecules, and microRNA (miR) to 
atherogenesis
11-13
. Recently, Harrison and colleagues were able to show that 
endothelial borne platelet-endothelial cell adhesion molecule (PECAM)-1, a 
transmembrane protein of the immunoglobulin superfamily (Ig-Sf), is 
responsible for a decreased susceptibility for atherosclerotic lesion formation at 
vascular sites exposed to high shear stress but shows atherogenic effects in 
areas of low shear stress
14
.  
Mononuclear cell recruitment thus is aggravated by an early activation 
of endothelial cells by both altered shear stress and modified LDL, 
accompanied by enhanced expression of adhesion molecules and chemokines. 
As atherosclerotic lesions contain a large number of effective immune cells, 
particularly monocytes and T lymphocytes
15-17
 the inflammatory recruitment of 
mononuclear cells is a process of central importance in initiation and 
progression of human atherosclerotic plaques, and has become a therapeutic 
target in the prevention and treatment of atherosclerosis. 
The leukocyte adhesion cascade 
The leukocyte adhesion cascade with its molecular effectors governs 
mononuclear cell extravasation into the vessel wall and is thus a complex and 
crucial mechanism mediating atherosclerotic lesion formation. It embraces a 
vast quantity of soluble and cell-bound molecular players orchestrating 
consecutive and defined steps of mononuclear cell infiltration
18-21
. Identifying 
molecular targets for therapeutic intervention would lead to new and powerful 
anti-inflammatory drugs
22. 
Selectin mediated leukocyte tethering and slow rolling 
The initial step in the leukocyte adhesion cascade consists of tethering of 
leukocytes to the endothelium, which is mainly mediated by glycosylated 
Leukocyte-, Platelet- and Endothelial-selectin (CD62-L, -P, -E) and their binding 
partner Platelet-selectin glycoprotein ligand (PSGL)-1
23, 24
. Selectins are C-type 
lectin family members binding their ligands in a calcium-dependent manner. 
Additional to the interaction of leukocyte PSGL-1 with endothelial expressed E- 
and P-selectin, an interaction of L-selectin and PSGL-1 both expressed by 
leukocytes enables secondary leukocyte capture, thereby further assisting 
leukocyte binding to endothelial cell
25, 26
. P-selectin is also expressed by 
activated platelets, PSGL-1 is additionally expressed by endothelial cells 
27, 28
 
and E-selectin also binds to glycosylated CD44 as well as E-selectin ligand 
(ESL)-1
29
, overall increasing the number of interacting cell types. Intriguingly, 
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P- and L-selectin mediated leukocyte tethering requires shear stress to support 
adhesion
30, 31
. Thus, adhesion strength grows while wall shear stress increases 
(catch bond), but with ever growing wall shear stress the adhesion strength 
decreases again (slip bond), possibly explaining why leukocyte tethering on 
selectins first increases and then decreases with rising wall shear stress
32
. 
Subsequent to adhesion, leukocytes start to roll along the endothelium 
searching for suitable conditions like chemokine gradients or hot-spots of 
increased cell adhesion molecule (CAM) expression and meanwhile integrating 
different inflammatory signals which can activate numerous signaling pathways 
facilitating further steps in the leukocyte adhesion cascade like arrest or 
transmigration. The rapid ligand interaction and dissociation rate of selectins 
allow leukocytes to tether and roll along endothelial cells under shear flow
33
. 
Beside E- and P-selectin mediated rolling of leukocytes, also integrins 
participate in leukocyte rolling via 47-integrin - mucosal vascular addressin 
cell-adhesion molecule (MADCAM)-1 interaction, very late antigen (VLA)-4 – 
vascular cell-adhesion molecule (VCAM)-1 interaction
34
 and lymphocyte 
function-associated antigen (LFA)-1 – intercellular adhesion molecule (ICAM)-1 
interaction
35
. Integrins are cell surface receptors consisting of two type I 
transmembrane glycoproteins, one α-subunit and one β-subunit, which are non-
covalently linked. Various combinations of 18 different α-subunits and 8 different 
β-subunits form at least 24 different heterodimers with diverse expression 
pattern, binding specificity and signaling properties
36
. 
The Arrest: Firm adhesion mediated by integrin - adhesion 
molecule interaction 
Additional to the 3 classical steps of the leukocyte adhesion cascade, namely 
selectin-mediated rolling, chemokine-triggered activation and integrin-mediated 
firm adhesion
37
, nowadays the step of chemokine-triggered activation is 
expanded by 2 distinct processes that are arrest from leukocyte rolling and a 
post-binding phase of adhesion stabilization
38
. Both are governed by integrin 
activation increasing integrin affinity and attenuating integrin dissociation. 
Activation of LFA-1 and VLA-4 for example involves conformational changes 
from a bent low-affinity to an opened intermediate- and high-affinity 
conformation enabling integrins to bind to their specific interaction partners 
ICAM-1 and VCAM-1, respectively, which mediates arrest of rolling 
leukocytes
39, 40
. A rapid chemokine - G-protein coupled receptors (GPCR) 
interaction is needed to activate integrins via inside-out signaling. Quick 
activation/deactivation cycles mark GPCRs as particularly suitable for 
controlling rapid events like leukocyte arrest under shear stress conditions
41-43
. 
For easy accessibility and protection from proteolytic degradation, chemokines 
are deposited on glycosaminoglycans (GAG) of endothelial cells’ luminal site by 
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activated endothelial cells, mast cells and platelets. For example, chemokines 
like CXCL4 and CCL5 are deposited by platelets thereby triggering monocyte 
arrest, mediated by chemokine - GPCR interaction
44, 45
. Moreover, not only an 
increase in ligand affinity subsequent to chemokine mediated activation, also 
the quantity of integrin molecules per cell determines the leukocyte adhesive 
strength
41, 46, 47
. 
Integrin clustering and allosteric conformational changes might trigger 
outside-in signaling and thus initiate activation of the full repertoire of signaling 
pathways
48
. Absence of 2 integrin mediated outside-in signaling or lack of 
guanine-nucleotide-exchange factors (GEF) important for outside-in signaling 
downstream-processes increased detachment of adherent leukocytes
49, 50
, thus 
pointing clearly to a post-arrest phase of leukocyte adhesion stabilization. 
Regulating integrin-mediated leukocyte adhesion activated by chemokines, at 
least 47 crucial proteins form a vast signaling network including at least 900 
proteins and more than 6000 protein-protein interactions, thus representing a 
likely target for specificity and diversity in leukocyte adhesion
38
. 
Intraluminal crawling 
Subsequent to firm adhesion of leukocytes to the endothelium and in 
preparation of crossing the vessel wall, leukocytes start to crawl on the 
endothelium seeking preferred sites for transmigration in a macrophage 1 
antigen (MAC-1)- and ICAM-1- dependent manner
51, 52
. An inhibition in 
leukocyte extravasation and leukocytes preferring the transcellular route were 
observed when crawling was disabled
52
. Directly after leukocyte – endothelial 
cell binding triggered by adhesion molecule – integrin interaction, leukocytes 
start to form protrusions crawling into the endothelial cell body and junctions. 
This enhances the area of leukocyte and endothelial cell interaction and thus 
also the interaction area of adhesion molecules and integrins. Tetraspanin 
(CD9, CD151, CD81) mediated adhesion molecule clustering with subsequent 
binding to cytoplasmic molecules like ERM (ezrin, radixin, moesin) proteins and 
cytoskeletal components like vinculin, -actinin and talin-1 enables outside-in 
signaling, which is important for proceeding of the transmigration progress
53, 54
. 
Endothelial cells form so-called transmigratory cups, ICAM-1 and VCAM-1 rich 
regions partly surrounding the leukocyte in order to initiate transendothelial 
migration
53, 55
. In addition, binding of ICAM-1 to its integrin binding partner  
MAC-1 activates a p38 mitogen-activated protein kinase (MAPK) and RAS 
homologue (RHO) GTPase mediated signaling cascade leading to enhanced 
endothelial cell contraction and hence spreading of junctions of adjacent 
endothelial cells. Recently, an ICAM-1-activated endothelial nitric oxide (NO) 
synthase-dependent pathway was identified in the microvasculature of 
endothelial cells facilitating leukocyte transendothelial migration by modification 
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of vascular-endothelial cell cadherin (VE-cadherin) phosphorylation
56
. VE-
cadherin is a crucial mediator of vascular permeability and tyrosine 
phosphorylation leads to loss of VE-cadherin mediated barrier function. 
Leukocyte transendothelial migration 
Crossing the vessel wall of postcapillary venules in order to reach the inflamed 
tissue underneath is the final step of the leukocyte adhesion cascade, which is 
part of a normal inflammatory reaction. Leukocyte transendothelial migration 
can be fast (<2-5 minutes), whereas passing the basement membrane can take 
much longer (>5-15 minutes)
38
. In pathological altered vessels leukocyte 
transendothelial migration also happens in arterioles, venules and even bigger 
arteries using a similar mechanism for leukocyte transendothelial migration 
through vascular endothelium. In general there are two distinct pathways of 
leukocyte extravasation, a paracellular route through the junctions of adjacent 
endothelial cells and a transcellular route where leukocytes prefer the thinnest 
site of the endothelial cell for crossing right through the cell body
57
. Carman and 
colleagues were able to provide evidence that transcellular migration occurs 
with an incidence of 5-20 % in an in vitro model of MCP-1 activated HUVECs
55
, 
another model demonstrated 30 % transcellular migration of T-lymphoblasts 
crossing TNF-stimulated human dermal microvascular endothelial cells
58
. 
Although transmigration rates are not consistent throughout different tissues 
stimulated by various triggers, the paracellular route seems to be the dominant 
one, likely due to the fundamental reorganization of cytoplasmic molecules 
necessary for transcellular migration. 
Paracellular transendothelial migration 
Leukocytes transmigrating on the paracellular route are guided through 
junctions of neighboring endothelial cells mainly by homophilic and heterophilic 
interactions of CAMs with integrins. Also re-localization of junctional CAMs 
away from cell-cell contacts to the luminal site of endothelial cells weakens the 
junctional barrier
59
 thus facilitating leukocyte transmigration on the paracellular 
route. In addition, re-localization of junctional CAMs increases their accessibility 
for leukocyte-borne interaction partners thus increasing firm adhesion
60. 
A number of CAMs are involved in guiding leukocytes through 
endothelial cell junctions. ICAM-1 and ICAM-2 interact with the integrin LFA-1 
thus leading the leukocyte through the junction. PECAM-1 and CD99 mediate 
late stage transmigration via homophilic interactions
20, 21
. Junctional adhesion 
molecule (JAM)-A, JAM-B, JAM-C and endothelial cell-selective adhesion 
molecule (ESAM) support transendothelial migration via both homophilic and 
heterophilic interactions with integrins
60-62
. Those adhesion molecules mediate 
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leukocyte extravasation in a tissue-, stimulus- and leukocyte-specific manner. 
For example, in cremasteric venules PECAM-1, ICAM-1, and JAM-A mediate 
leukocyte extravasation in response to interleukin-1
63
. An example for a 
leukocyte specific adhesion molecule is ESAM which mediates selectively 
neutrophil transmigration but does not influence T cell transmigration
64
.  
Transcellular transendothelial migration 
Leukocytes taking the transcellular route of transendothelial migration were 
shown in various inflammatory scenarios and in vitro models
55, 57, 58, 65, 66
. 
Intraluminal crawling constitutes the starting point of transcellular migration, 
where ICAM-1 mediated outside-in signaling triggers translocation of apical 
ICAM-1 to caveolae- and f-actin-rich regions and a potential caveolin-1 
transport to the basal plasma membrane
58, 65
. Actin and vimentin stabilize the 
endothelial-cell membrane, finally resulting in formation of channels through 
which leukocytes might pass. A lining of the cytoplasma/channel-lumen-
interface with the same molecules facilitating paracellular migration is likely
67
.  
Crossing the basement membrane and pericyte layer 
The basement membrane is a network discontinuously surrounding endothelial 
cells of venules and capillaries being composed of laminins, such as laminin 
411 (411; laminin 8) and laminin 511(511; laminin-10), and collagen type 
IV generated by endothelial cells and pericytes
68
. Laminins and collagen are 
interconnected by nidogen-2 and the heparin sulphate proteoglycan perlecan
69
. 
In unstimulated murine cremasteric venules, regions of low expression of 
basement membrane matrix proteins could be detected and those low 
expression regions were even enlarged after IL-1treatment
70
. Those low 
expression sites seem to be co-localized with gaps in the pericyte sheet, 
allowing leukocytes and chemoattractant molecules to pass through these 
areas of low hindrance
70-72
. Intriguingly, heparin-sulphate components of the 
basement membrane are able to bind chemokines and therefore accumulate 
those chemoattractant molecules
73
. After crossing the endothelial cell layer, an 
increased expression of laminin binding 61 integrin activated by PECAM-1 
interaction is likely, hence facilitating leukocyte migration through the basement 
membrane
74
. In addition to the concept of transmigration through physically 
permissive sites of the basement membrane, also transmigration due to 
biochemically permissive sites is under debate. Sites expressing laminin 511 
are proposed to hinder transmigration, in contrast to promoted transmigration 
through laminin 411
69
. In detail, mice lacking a subunit of laminin 411 showed 
compensatory expression of a laminin 511 subunit, leading to reduced T cell 
and neutrophil transmigration into inflamed central nervous system and into 
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inflamed peritoneum, respectively
75, 76
. In contrast, in vitro studies showed a 
higher ability to facilitate leukocyte transmigration of laminin 511
77
. In another 
study of mouse cremasteric venules, leukocyte permissive regions were 
deficient for both laminins
72
. 
 
 
Figure 1: The updated leukocyte adhesion cascade. 
The original three steps of the adhesion cascade are shown in bold: selectin-mediated rolling, 
chemokine-triggered activation and integrin-mediated adhesion. The figure has been extended by 
additional steps such as capture, slow rolling, adhesion strengthening and spreading, intravascular 
crawling and paracellular as well as transcellular transmigration. ESAM, endothelial cell-selective 
adhesion molecule; ICAM1, intercellular adhesion molecule 1; JAM, junctional adhesion molecule; 
LFA1, lymphocyte function-associated antigen 1; MAC1, macrophage antigen 1; MADCAM1, 
mucosal vascular addressin cell-adhesion molecule 1; PSGL1, P-selectin glycoprotein ligand 1; 
PECAM1, platelet/endothelial-cell adhesion molecule 1; PI3K, phosphoinositide 3-kinase; VCAM1, 
vascular cell-adhesion molecule 1; VLA4, very late antigen 4 (Ley et al.
38
) 
Junctional Adhesion Molecules 
Junctional Adhesion Molecules (JAMs) are transmembrane proteins belonging 
to the Ig-Sf. The first JAM protein recognized was JAM-A (CD321, JAM-1 or 
F11-receptor) initially called F11-receptor, as it was identified as a receptor for 
the platelet activating antibody F11
78
. Since initial studies were performed using 
endothelial and epithelial cells, the protein was named Junctional Adhesion 
Molecule based on its localization at cell-cell contacts. Later, further family 
members have been identified as JAM-B, JAM-C, JAM-4, ESAM and JAM-like 
(JAM-L) proteins. JAM-4, interacting with the PDZ domain (named after the first 
family members PSD-95, DLG, and ZO-1) of MAGI-1, is expressed at tight 
junctions (TJ) in epithelial cells
79
 and JAM-L is expressed by leukocytes and 
promotes adhesion to endothelial cells
80
 as well as coxsackie and adenovirus 
receptor (CAR) dependent neutrophil migration
81
. Detailed information on JAM-
A, JAM-B and JAM-C are to follow. 
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All JAM family members share similar structural characteristics (JAM-A 
shown exemplary in Fig. 2), e.g. two extracellular Ig-like domains stabilized via 
disulfide bonds. The intracellular domain consists of a single-span 
transmembrane segment and a short cytoplasmic tail containing a 
phosphorylation site for protein kinase C (PKC) as well as a PDZ-binding motif 
(JAM-A: FLV) at the C-terminus. 
 
 
Figure 2: Structure of human JAM-A.  
Ribbon drawing from human JAM-A dimer displaying one JAM-A molecule in blue and the other in 
orange. Disulfide bonds are shown in green. Two orthogonal views are shown (A/B). 
Immunoglobolin-like domain 1 (D1) is located distal, immunoglobulin-like domain 2 (D2) is located 
proximal to the C-terminus. (Prota et al.
82
) 
Junctional Adhesion Molecule A 
The complete sequence of murine JAM-A was first identified in 1998
83
 followed 
by the identification of the human JAM-A in 1999
84, 85
. JAM-A is highly 
conserved among mammals, with human, murine, bovine, and rodent JAM-A 
sharing about 70% amino acid identity
83, 86
. The crystal structures of the 
extracellular domain of murine JAM-A
87
 and human JAM-A
82
 (Fig.1) have been 
resolved, revealing two Ig-like domains being connected by a linker of 3 amino 
acids (VLV) resulting in a bent conformation with an angle of about 125°, which 
is stabilized by hydrogen bonding to both domains
87
. The membrane-distal D1 
of JAM-A, containing a dimerization motif (RVE), facilitates homodimer 
formation (Fig. 2). 
Expression and localization 
JAM-A is mostly abundant in the tight junctions of cell-cell interfaces of 
endothelial and epithelial cells of various organs including liver, kidney, 
pancreas, heart, brain, lymph nodes, intestine, lung, placenta, and vascular 
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tissue
83, 86, 88, 89
; moreover it is expressed by nearly every cell-type of lymphoid 
and myeloid origin
85, 87
. The junctional localization of JAM-A can be modified by 
inflammatory cytokines, as TNF-α and IFN-γ treatment of endothelial cells 
causes re-localization of JAM-A from the intercellular junctions to the luminal 
surface
59, 84
, while expression levels were left unchanged
59, 84, 90
.  
The re-localization of JAM-A might be facilitated by a TNF-induced relieve of 
JAM-A from actin
91
. In line with these findings, a MCP-1 facilitated JAM-A 
re-localization occurred also in brain endothelium. Internalization of JAM-A 
involving macropinocytosis is accompanied by Rho and Rho kinase as well as 
actin reorganization. JAM-A is transiently stored in endosomes and recruited to 
the apical site of endothelial cells
92
. 
Interaction partner and function 
An over-expression of JAM-A increases endothelial cell barrier-function as 
JAM-A interacts in a homophilic manner with neighboring molecules (in cis) and 
in dimeric state also with other dimers from adjacent cells (in trans)
87
, thus 
creating a tight, zipper-like structure (Fig. 3). The dimerization motif (RVE) 
responsible for homophilic binding obtains highly polar character and the 
competence to manage rearrangements being important for the transmigration 
process of leukocytes
82
. JAM-A homophilic interactions were shown to be 
essential for localization of JAM-A at TJs and for regulation of barrier function in 
epithelial cells
93
. 
The heterophilic interaction of JAM-A with the αLβ2-integrin LFA-1 
(CD11a/CD18) facilitates leukocyte adhesion and transmigration through the 
endothelial cell monolayer via integrin I-domain and JAM-A D2 interactions
94, 95
. 
Homophilic JAM-A binding affinities were observed to be weaker than 
heterophilic JAM-A-LFA-1 interaction
96
. Remarkably, Wojcikiewicz and 
colleagues postulate that the more potent LFA-1-JAM-A interaction might have 
dual purpose: on the one hand it mediates leukocyte adhesion to endothelial 
cell junctions and on the other hand it weakens JAM-A homophilic interactions, 
thereby opening the TJ and helping the leukocyte to transmigrate. To be 
mentioned, the authors assume that the in vitro situation only corresponds to 
JAM-A homophilic interaction in trans by comparing JAM-A homophilic to JAM-
A-LFA-1 binding forces, meaning that both homophilic interactions in parallel 
might strengthen the binding forces
96
. Furthermore, JAM-A is a reovirus 
receptor
97
 which binds via D1 to the viral attachment protein σ1
82
. 
Intracellular interactions of JAM-A take place with several different 
proteins containing PDZ domains. For example the junctional proteins zonula 
occludens-1 (ZO-1) and ALL-1 fusion partner from chromosome 6 (AF-6), both 
directly linked to the actin cytoskeleton
98, 99
, bind to JAM-A with their diverse 
PDZ domains
100
. Those interactions anchor JAM-A to the actin filament system, 
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enabling a quick actin-mediated re-localization of JAM-A. ZO-1 also may co-
localize JAM-A with other TJ proteins like occluding and cingulin
101
. Another 
PDZ domain dependent anchoring protein is the multi-PDZ domain protein 1 
(MUPP-1), which binds both JAM-A and claudin-1 by functioning as a 
multivalent scaffold protein recruiting various proteins to TJs
102
. Other PDZ-
domain dependent binding partners for JAM-A are calcium/calmodulin-
dependent serine protein kinase (CASK) and atypical PKC isotype specific 
interacting protein (ASIP)
103-105
, which may provide JAM-A with inside-out or 
outside-in signal transduction properties. 
JAM-A additionally plays a role in angiogenesis. Key studies were able 
to show basic fibroblast growth factor (bFGF)-induced angiogenesis via 
dissociation of the JAM-A/V3 integrin complex thus allowing JAM-A 
signaling
106
. Moreover, bFGF induced inhibition of angiogenesis in JAM-A 
deficient mice was demonstrated
107
. Furthermore, JAM-A regulates the motility 
of epithelial
93
 and endothelial cells
63, 108
, thus also playing a crucial role after 
mechanical injury of the vessel wall as conducted in stenting or in the 
inflammatory injury models like wire injury or ischemia/reperfusion injury. As 
angiogenesis and the formation of new blood vessels are of outmost importance 
for tumor growth, JAM-A is discussed as putative target for cancer therapy. 
 Recently, additional functions of JAM-A have been discovered, as JAM-
A mediated adhesion of CD34
+
 stem cells to the vascular wall after injury 
resulted in differentiation into endothelial progenitor cells, thus facilitating re-
endothelialization
109
. 
 
 
Figure 3: Homophilic JAM-A interactions in cis and in trans. 
Neighboring JAM-A molecules form homophilic interactions in cis via binding of dimerization motifs 
located at the membrane-distal Ig domain. JAM-A dimers situated on two adjacent cells (orange and 
blue) form JAM-A homophilic interactions in trans, thus creating a zipper like structure. 
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Pathobiology of JAM-A expressed by different (immune) cell types 
Evidence for a differing impact of JAM-A deficiency in diverse cell types 
pertaining to inflammatory diseases and tumor angiogenesis is growing 
strongly. To delineate each effect JAM-A deficiency exerts on the different 
pathobiological mechanisms the following will provide a short introduction into 
this complex topic.  
Endothelial Cells: 
The first report of a role for endothelial JAM-A in monocyte transmigration 
demonstrated an inhibition of monocyte transmigration using a blocking 
monoclonal antibody against JAM-A on cultured endothelial cells
83
. Additionally, 
using this antibody in an air-pouch model, first in vivo evidence for JAM-A 
mediated monocyte transmigration arose. Furthermore, treatment with a 
monoclonal antibody against JAM-A significantly inhibited leukocyte 
accumulation in the cerebrospinal fluid and infiltration in the brain 
parenchyma
110
. 
First evidence for endothelial JAM-A facilitating atherosclerotic lesion 
formation came from Ostermann and colleagues (2005) and Babinska et al. 
(2007). They showed an increase of endothelial JAM-A mRNA and protein in 
early lesions of carotid arteries from apolipoprotein E (Apoe) deficient mice after 
diet
111
 and in human atherosclerotic plaque biopsies
112
. The increase of 
endothelial JAM-A in human atherosclerotic plaque could also be validated by 
micro array technique
113
. 
Additionally, a role for endothelial JAM-A in other inflammatory models 
could be proven. In ischemia/reperfusion (I/R) experiments of murine liver, 
JAM-A was upregulated in hepatic venular endothelium during reperfusion, 
accompanied by increased neutrophil recruitment rates. Accordingly, 
endothelial JAM-A deficiency resulted in a decreased neutrophil recruitment to 
hepatic tissue after I/R in vivo
114
. Hyperplasia after wire injury of the carotid 
artery of Apoe deficient mice was significantly reduced in mice lacking JAM-A. 
Concomitantly, diminished neointimal macrophage content, decreased 
monocyte recruitment to injured eJAM-A
–/–
 carotid arteries ex vivo and 
decreased transmigration of monocytes through JAM-A/Apoe deficient 
endothelial cells under flow conditions in vitro were found.  
Monocytes: 
Not much is known about the specific role of JAM-A in monocytes regarding 
inflammatory diseases. The only indication is reduced monocyte adhesion to an 
explanted carotid artery perfused with monocytes treated with soluble 
JAM-A.Fc
111
. This treatment blocks monocyte adhesion in a VLA-4 independent 
manner. 
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T cells: 
Like monocytes VLA-4 independent T cell adhesion to an ex vivo perfused 
carotid artery can be blocked by soluble JAM-A.Fc
111
. Additionally, a reduction 
of T cell arrest under flow conditions and transendothelial chemotaxis towards 
SDF-1 after blocking JAM-A using antibody or soluble JAM-A.Fc in in vitro 
assays were demonstrated. 
Dendritic cells: 
In in vitro assays JAM-A deficiency in dendritic cells caused an increased 
random motility and transmigration across lymphatic but not blood 
microvascular endothelial cells
115
. In vivo experiments using JAM-A deficient 
mice revealed increased dendritic cell migration to lymph nodes, whereas an 
endothelial JAM-A deficiency did not alter dendritic cell transmigration rates. 
Adoptive transfer experiments transferring JAM-A deficient dendritic cells to 
JAM-A wild type mice revealed increased contact hypersensitivity, thus linking 
JAM-A deficiency mediated increase of dendritic cell transmigration rates to 
contact hypersensitivity.  
Neutrophils: 
Neutrophils deficient for JAM-A showed defective uropod retraction and 
aberrant transendothelial migration in inflammatory models of peritonitis and 
heart ischemia/reperfusion as well as in adhesion and transmigration assays in 
vitro
116
. In vivo, more JAM-A
–/– 
neutrophils adhered to the endothelium or were 
trapped in between the endothelium and the basement membrane compared to 
JAM-A
+/+ 
neutrophils, which was shown to be an endothelial JAM-A independent 
effect. Interestingly, morphologic analyses of JAM-A deficient neutrophils 
revealed long adhesive tails, a consequence of defective de-adhesion. 
Additionally, the motility of JAM-A
–/–
 neutrophils was significantly reduced 
compared to JAM-A
+/+ 
neutrophils, strongly hinting towards a defect in cell de-
adhesion. 
An impaired interstitial migration of murine neutrophils lacking JAM-A 
has been shown in cremasteric venules after leukotriene B4 (LTB-4) 
treatment
117
. Furthermore, a co-internalization of 1 integrins together with JAM-
A after inflammatory treatment could be demonstrated. As explanation for the 
decreased motility of neutrophils the authors suggest a JAM-A deficiency 
induced disruption of internalization of 1 integrins expressed by neutrophils 
after treatment with N-formyl-1-1methionyl-1-1leucyl-1-phenylalanine (fMLP). 
This might be mediated by the small GTPase Rap-1, which plays a role in 
integrin internalization
118
 and which activity is reduced in JAM-A deficient 
neutrophils. Interestingly, Western blotting and FACS analysis demonstrated 
unaltered amounts of total 1 integrin between JAM-A wild-type and deficient 
CHAPTER 1 
22 
1 
neutrophils, revealing no changes in expression level. The decrease of integrin-
internalization possibly causes the defect in directional migration and uropod 
retraction. 
The mechanism of JAM-A-regulated integrin internalization and 
recycling mediated by Rap-1 activity could also be shown in epithelial cells
119, 
120
. Like in neutrophils also the motility of epithelial cells is influenced by 
integrin internalization, mediated by cis dimerization of JAM-A D2 Ig-like 
domains as well as PDZ-guanine nucleotide exchange factor (GEF) 2/Afadin 
interaction. Another study reported enhanced random motility of JAM-A-
deficient endothelial cells, also providing data showing a role of JAM-A in 
endothelial cell motility through interactions with the junctional complex and the 
cytoskeleton via PSD95-Dlg-ZO-1
108
. 
Platelets: 
The human F11 receptor was first cloned from platelet F11R cDNA in order to 
determine its structure
121
. Later, the human F11 receptor was determined as the 
homologue of murine Junctional Adhesion Molecule, leading to the uniform 
nomenclature of Junctional Adhesion Molecules for both species
122
. A 
monoclonal antibody against this platelet membrane protein, called Mab F11, 
caused platelet aggregation, granule secretion and phosphorylation of 
intracellular proteins
78
. Another study demonstrated JAM-A phosphorylation in 
thrombin and collagen activated platelets, thus initially hinting towards a 
physiological role
121
. The authors believed that thrombocytic JAM-A displays 
two distinct functions. On the one hand, JAM-A mediates integrin GPIIb/IIIa 
dependent platelet aggregation, on the other hand JAM-A mediates platelet 
adhesion independent of integrins or fibrinogen receptors via homophilic JAM-A 
interactions with other cell types, thus playing a role in physiological processes 
important for platelet aggregation. Like murine JAM-A, cloning of human JAM-A 
into Chinese hamster ovary (CHO) cells revealed JAM-A accumulations on the 
cell surface and enhanced localization between two adjacent cells
122
. 
Interestingly, the intracellular moiety of JAM-A co-localized with cortical f-actin, 
but not with cell-spanning stress fibers. Compared to JAM-A
–/–
 CHO cells, more 
platelets adhered to immobilized JAM-A expressing CHO cells, contributing to 
the first evidence for JAM-A homophilic interactions. Definite indication for JAM-
A homophilic interaction came from Babinska and colleagues
123
. They were 
able to show specific adhesion of platelets to a matrix of immobilized JAM-A 
molecules or to activated HUVEC monolayers, which was inhibited by treatment 
with soluble JAM-A or JAM-A peptides mimicking N-terminal amino acid 
sequences. Recently, it was shown that thrombocytic JAM-A dampens integrin 
mediated outside-in signaling, thus decreasing platelets thrombotic potential by 
sustaining the inactive form therefor impairing platelet aggregation
124
.   
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Junctional Adhesion Molecule B  
JAM-B (VE-JAM, human JAM-2, murine JAM-3) shares the main part of the 
other JAM family members’ structure, besides its dimerization motif (ALE) and 
an additional disulfide bridge in domain 1. In general the dimerization motifs are 
conserved features of JAMs, implying that heterophilic dimerization may also 
take part with JAM-B as one of the interaction partners. Additionally, JAM-B is 
not as prevalently expressed as JAM-A. Therefor JAM-B expression is 
restricted to endothelial cells and localizes mainly in the junctions of high 
endothelial venules
125
 and of the heart
126
. Contrary to JAM-A, the expression of 
JAM-B was not detected in leukocytes
126
. Heterophilic interaction partners of 
JAM-B were found in the leukocyte integrin VLA-4 and in JAM-C
127, 128
. 
Intriguingly, the JAM-B/VLA-4 interaction was shown to be JAM-C dependent, 
as T cells lacking functional JAM-C did not show any JAM-B/VLA-4 interaction. 
Additional to endothelial cell expression, JAM-B is more abundant in tissues 
with chronic inflammatory diseases like asthma, bronchitis, interstitial nephritis, 
autoimmune hepatitis and alcoholic cirrhosis
129
. Using a model for murine 
allergic contact dermatitis, evidence was gathered that JAM-B also plays a role 
in leukocyte transmigration. After injection of neutralizing antibodies against 
JAM-B, mice showed reduced contact dermatitis as well as decreased 
leukocyte infiltration into the ear
130
. Summing up, the role of JAM-B in leukocyte 
transmigration and in vascular diseases seems not to be as crucial as JAM-A. 
Junctional Adhesion Molecule C 
Like its other family members, JAM-C (also known as JAM3, hJAM3 and 
mJAM-2) is expressed in endothelial cells, more precisely murine JAM-C was 
identified to be localized at high endothelial venules within lymph nodes and 
Peyer’s patches
131
. Human JAM-C has been additionally detected on platelets, 
and lymphocytes such as monocytes, natural killer cells, dendritic cells, B cells 
and a T cell subset
127, 129, 132, 133
. Dimerization (JAM-C dimerization motif: RIE) in 
homophilic manner via Ig domain 1 exists
134
, but also in a heterophilic manner 
with JAM-B
127
, MAC-1 (alphaMbeta2 integrin) and to a lesser extend alphaXbeta2 
integrin 
81, 133
. Intriguingly, binding affinity for JAM-C homodimers is weaker 
compared to JAM-C-JAM-B heterophilic interactions, possibly pointing towards 
a control mechanism for leukocyte adhesion through JAM-B expression
135
. First 
evidence for a role of JAM-C in human leukocyte transmigration was discovered 
when a blocking antibody against JAM-C or soluble JAM-C protein inhibited 
leukocyte transmigration across HUVECs
132
 additional to platelet-neutrophil 
interaction
133
. Later, an involvement of JAM-C in transmigration of leukocytes in 
different inflammation models like allergic dermatitis
130
, peritonitis
136
, acute 
pancreatitis
137
, pulmonary inflammation
138
 and ischemia/reperfusion injury
139
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has been shown, where neutralizing antibodies or blockade with soluble JAM-C 
protein reduced leukocyte infiltration. Interestingly, endothelial JAM-C 
overexpression in the last three models mentioned resulted in increased 
leukocyte influx and exacerbated inflammation, which strongly indicates a role 
of JAM-C in leukocyte transmigration, but Bradfield and colleagues
140
 and 
Woodfin et al.
141
 found evidence that JAM-C rather regulates polarized 
leukocyte transmigration in such a way that it blocks leukocyte reverse 
endothelial transmigration. Further proof for a role of JAM-C in atherosclerosis 
was provided when an increase in JAM-C expression in atherosclerotic lesions 
of Apoe
–/–
 mice was shown
142
. Additionally, the authors were able to show an 
increase in JAM-C expression after oxidized as well as enzymatically modified 
LDL treatment of HUVECs together with a re-localization away from endothelial 
cell junctions to their apical site, thus increasing JAM-C’s availability for its 
leukocyte counter-receptors. This inflammatory re-localization was also shown 
in vivo after ischemia/reperfusion injury
139
. More evidence for a role of JAM-C in 
atherosclerotic lesion formation came from Shagdarsuren and colleagues 
showing that JAM-C blockade decreased neointimal hyperplasia after wire 
injury of carotid arteries
143
 and from Langer et al. presenting a MAC-1/JAM-C 
mediated platelet-dendritic cell interaction leading to dendritic cell activation and 
recruitment to the injured vessel wall as well as platelet phagocytosis
144
. In 
contrast, one study was not able to detect differences in JAM-C expression 
pattern after inflammatory stimuli nor JAM-C dependent neutrophil adhesion 
and transmigration in in vitro flow assays
145
. Only when JAM-C blockade met 
blockade of PECAM-1, ICAM-1 and CD99 an effect on neutrophil transmigration 
became evident.  
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Aim of the study 
Preceding studies identified JAM-A as a crucial mediator for leukocyte adhesion 
as well as leukocyte transmigration in different inflammatory models, 
additionally to a JAM-A overexpression in atherosclerotic lesions of 
hyperlipidemic tissue of mice and human, but direct evidence for JAM-A 
facilitated mononuclear cell transmigration in hyperlipidemia and disturbed flow 
mediated atherosclerotic lesion formation is still missing. Furthermore, 
deficiency of leukocytic JAM-A has an impact on cell motility and integrin 
expression, but information on the consequences on atherosclerotic lesion 
formation is lacking yet. On molecular level, a re-localization of JAM-A after 
inflammatory stimuli was demonstrated, but deeper knowledge of re-localization 
sites in a atherogenic context and its causal mechanism remain elusive. By 
using Apoe
–/– 
mice with a specific JAM-A deficiency in endothelial cells, 
leukocytes or platelets as well as deficiency of somatic JAM-A, we aimed to 
clarify the different roles of JAM-A originating from different cellular 
compartments on leukocyte transmigration and thus on hyperlipidemia 
mediated and flow-dependent atherosclerotic lesion formation additional to its 
net effect. As JAM-A re-localization seems to be an important prerequisite for 
leukocyte transmigration in inflammatory diseases, extensive fluorescent 
microscopy and atomic force microscopy studies shall add more information to 
JAM-A localization in inflammatory and atherogenic settings and its underlying 
mechanism. Targeting JAM-A localization might be a therapeutic strategy to 
interfere mononuclear cell transmigration in atherosclerotic vessels. The 
cholesterol-lowering lovastatin and the peroxisome proliferator activated 
receptor gamma-agonist pioglitazone are commonly used anti-atherosclerotic 
drugs, which have been shown to exert beneficial effects on oxLDL receptor 
expression and mononuclear cell recruitment
146-151
. Thus, the influence of 
lovastatin and pioglitazone on JAM-A localization and JAM-A mediated 
mononuclear cell recruitment shall be investigated. 
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and 
Results  
 
Endothelial JAM-A promotes atherosclerosis: 
Atherosclerosis is characterized by an immune cell driven narrowing and 
rupture of arterial vessel walls. Foam cell formation facilitated by excess uptake 
of modified lipids by macrophages comprises the earliest stage of lesion 
formation. Pro-inflammatory factors are massively secreted by different 
leukocyte subsets in these early stages, additionally attracting further 
leukocytes. Thus, leukocyte recruitment into the vessel wall is a crucial 
prerequisite for atherosclerotic lesion formation.  
 The underlying mechanism of leukocyte recruitment is represented by a 
multi-step cascade comprising leukocyte tethering, rolling, firm adhesion and 
transendothelial migration. Junctional adhesion molecules, especially JAM-A, 
have been shown to mediate adhesion and transmigration in various 
inflammatory models, but a comprehensive study comparing the roles of JAM-A 
in atherosclerotic lesion formation regarding their cellular context is still lacking. 
 In chapter 2, we strived to unravel the atherogenic potential of JAM-A 
expressed by endothelial cells or leukocytes as well as the atherogenic potential 
of somatic JAM-A. Additionally, we investigated recruitment rates of leukocytes 
transmigrating through endothelial cells, either with or without JAM-A deficiency 
under different inflammatory conditions in vivo and in vitro. Furthermore we 
aimed to localize endothelial JAM-A under different inflammatory and altered 
shear stress conditions in ex vivo and in vitro studies in order to elucidate the 
underlying mechanism.   
 2 
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Abstract 
Background - Junctional Adhesion Molecule (JAM)-A expressed in endothelial, 
epithelial and blood cells can regulate permeability and leukocyte extravasation. 
Atherosclerosis develops at sites of disturbed flow in large arteries but the 
mechanisms guiding inflammatory cells into these predilection sites remain 
unknown. 
Methods and Results - To characterize cell-specific functions of JAM-A in 
atherosclerosis, we employed apolipoprotein E-deficient mice with a somatic or 
endothelium-specific deficiency in JAM-A and bone marrow chimeras with 
JAM-A-deficient leukocytes. We show that impaired JAM-A expression in 
endothelial cells reduced mononuclear cell recruitment into the arterial wall and 
limited atherosclerotic lesion formation in hyperlipidemic mice. In contrast, 
JAM-A deficiency in bone marrow cells impeded monocyte de-adhesion, 
thereby increasing vascular permeability and lesion formation, whereas somatic 
JAM-A deletion revealed no significant effects. Regions with disturbed flow 
displayed a focal enrichment and luminal redistribution of endothelial JAM-A 
and were preferentially protected by its deficiency. The functional expression 
and redistribution of endothelial JAM-A was increased by oxidized low-density 
lipoprotein, but confined by athero-protective laminar flow through an up-
regulation of miR-145, which repressed JAM-A.  
Conclusions - Our data identify endothelial JAM-A as an important effector 
molecule integrating atherogenic conditions to direct inflammatory cell entry at 
predilection sites of atherosclerosis.  
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Introduction 
Junctional Adhesion Molecule-A (JAM-A, also known as F11R), a member of 
the immunoglobulin (IgG) super-family, is located in the tight junctions of 
epithelial and endothelial cells but also expressed by leukocytes and CD34
+
 
cells, and exerts a wide variety of functions in cell polarity
1
 and barrier function 
via homophilic interactions
2
, stem cell adhesion and differentiation
3
, leukocyte 
trafficking and recruitment
3-6
. In particular, JAM-A mediates leukocyte adhesion 
and transmigration via heterophilic interactions with the αLβ2 integrin LFA-1
7-10
. 
Moreover, dendritic cell trafficking to the lymph nodes was increased in 
mice with somatic but not endothelial JAM-A deficiency, indicating a specific 
role in dendritic cell migration
11
. Additional findings revealed a crucial role of 
JAM-A on leukocytes in promoting de-adhesion
12
. In the absence of JAM-A, the 
directional motility of neutrophils was impaired, leading to incomplete 
transmigration with neutrophils being stuck between the endothelial cell layer 
and the basement membrane
12
. Whereas JAM-A on neutrophils promotes 
chemotaxis by regulating integrin internalization and recycling
13
, endothelial 
JAM-A has been implicated in mediating stimulus-specific neutrophil 
transmigration
14
. Upon co-stimulation with TNF- and IFN-, endothelial JAM-A 
is redistributed to the luminal surface
15, 16
 and specifically to the site of leukocyte 
transmigration as part of lateral border recycling compartments
17
. 
Compelling evidence has emerged to indicate that JAM-A-mediated 
leukocyte transmigration plays an important role in inflammatory disease. For 
example, JAM-A-deficient mice displayed reduced leukocyte infiltration in 
models of peritonitis, hepatic and myocardial ischemia-reperfusion injury
12, 18
, 
and in acute lung injury
19
. In models of vascular disease, somatic JAM-A 
deficiency was shown to protect against neointimal hyperplasia after wire-injury 
of the carotid artery in hyperlipidemic mice
20
. Accordingly, increased levels of 
JAM-A transcripts and protein have been demonstrated in human plaque 
biopsies and in plaque-prone aortas of mice
21
. The expression of JAM-A on 
inflamed and early atherosclerotic endothelium has been implicated in the 
recruitment of mononuclear cells through an inhibition with soluble JAM-A, 
suggesting a functional involvement in atherogenesis
5
. 
Despite being strategically positioned at junctional entry ports of arterial 
endothelium, less is known about the cell-specific contributions and net effect of 
JAM-A in directing mononuclear cell migration during atherogenic recruitment 
and lesion formation. To dissect the functions of JAM-A in atherosclerosis, we 
employed apolipoprotein E-deficient (Apoe
–/–
) mice with a somatic or endothelial 
cell-specific deficiency in JAM-A and bone marrow (BM) chimeras with 
JAM-A-deficient leukocytes. Our data show that endothelial JAM-A promotes 
lesion formation by integrating effects of hyperlipidemia and disturbed flow, 
which result in its up-regulation, redistribution and subsequent function in 
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promoting mononuclear cell influx into the artery wall, while limiting reverse 
transmigration. In contrast, leukocytic JAM-A is required for monocyte de-
adhesion and complete transmigration, thereby preventing vascular damage 
and protecting against atherosclerosis.  
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Methods 
Mouse models of JAM-A–deficiency and plaque formation 
Somatic JAM-A
–/–
Apoe
–/–
 were backcrossed for >10 generations into a C57Bl/6 
background
20
. Congenic Apoe
–/–
 mice were used as controls. Chimeric mice 
with a leukocytic JAM-A deficiency were obtained by reconstituting Apoe
–/–
 
recipients with JAM-A
–/–
Apoe
–/–
 or control Apoe
–/–
 bone marrow (BM)
22
. Briefly, 
BM cells (5×10
6
 in PBS) from donor mice were administered to recipient mice 
by tail vein injection, 24 h after an ablative dose of whole-body 
irradiation (2×6.5 Gy). 
A genetic reduction of endothelial JAM-A was achieved by crossing 
Apoe
–/–
 mice with a loxP flanked (floxed) JAM-A gene (JAM-A
fl/fl
) with 
VeCad CreERT
2
 Apoe
–/–
 mice to obtain VeCad CreERT
2
 JAM-A
fl/fl
Apoe
–/–
 mice 
(C57Bl/6)
23
. At an age of 3 weeks, 5 daily intraperitoneal injections of the 
estradiol analog tamoxifen (0.04 mg per g mouse) dissolved in miglyol 810 
(Caelo, Hilden, Germany) were administered to VeCad CreERT
2
-positive or 
VeCad CreERT
2
-negative animals to obtain eJAM-A
–/–
Apoe
–/–
 or 
eJAM-A
+/+
 Apoe
–/–
 mice, respectively. After 4-6 weeks, genetic depletion of 
JAM-A was confirmed by FACS analysis, resulting in ~50% less endothelial 
JAM-A levels with no difference in leukocytic JAM-A levels compared to control 
mice. We chose a mouse model with an inducible endothelium-specific Cre-
recombinase, since constitutive expression of Cre-recombinase under the 
control of an endothelium-specific promotor (e.g. Tie2/Tek, VE-cadherin) has 
been shown to lead to a non-negligible amount of deletion of the floxed gene in 
hematopoietic cells
24, 25
. 
Plaque formation was induced in female littermates (aged 6-8 weeks, 
n=10-13) by feeding a high-fat diet (HFD, 21% fat, 0.15% cholesterol, Altromin, 
Lage, Germany) for 12 weeks or by partial ligation of the carotid artery, resulting 
in altered shear stress due to reduced and partially retrograde blood flow
26
. In 
brief, Apoe
–/–
 mice (n=5) were anesthetized with ketamine (80 mg/kg) and 
xylazine (10 mg/kg), and left external and internal carotid, and occipital artery 
were ligated with 6-0 silk sutures, leaving only superior thyroid artery open. 
Mice were left on HFD for 2-8 weeks. Animal experiments were approved by 
local authorities and complied with German animal protection law (LANUV 
NRW, Recklinghausen, Germany). 
Quantification and immunohistochemical analysis of atherosclerosis  
The extent of atherosclerosis was assessed in aortic roots and on 
thoracoabdominal aortas by Elastica van Gieson (EVG) staining and for lipid 
depositions with Oil-red-O, respectively, and was quantified by computerized 
image analysis (Diskus Software, Hilgers, Königswinter, Germany) and Leica 
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Qwin Imaging software (Leica Microsystems, Wetzlar, Germany)2. The relative 
content of macrophages and CD3
+
 T cells was determined by staining with 
antibodies against Mac-2 and CD3 (both AbD Serotec, Düsseldorf, Germany), 
and detection with FITC- and Cy3-conjugated antibodies (both Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA). Nuclei were visualized 
with DAPI. Necrotic core areas were quantified in DAPI-stained slices of aortic 
roots. Images were recorded with a Leica DMLB fluorescence microscope and 
CCD camera. Stages of atherosclerotic lesions were determined by evaluation 
of EVG-stained aortic roots, as reported by Virmani et al.
27
.  
Stimulation of endothelial cells under static or flow conditions 
Human aortic endothelial cells (HAoECs) without genetic modification, and 
JAM-A
+/+
 Apoe
–/–
 or JAM-A
–/–
Apoe
–/–
 SV40-large T antigen-immortalized mouse 
ECs were grown on collagenized glass slides or in specialized 48-well plates 
(IUL Instruments, Königswinter, Germany), respectively. HAoECs were treated 
with LDL, oxLDL (both 10 µg/ml, 16 h), TNF- and IFN- (10 ng/ml and 
20 ng/ml, 4 h, respectively) or oxLDL plus JAM-A.Fc (10 µg/ml, 15 min). Mouse 
ECs were activated for at least 4 h with TNF- (25 ng/ml). For culture under 
flow conditions, HAoECs were harvested from static cultures and transferred to 
0.4 µm µ-slides (ibidi, Martinsried, Germany). After attachment, cell culture was 
continued under static or flow (both 48 h) conditions, while shear stress was 
gradually increased to 5 or 20 dyn/cm
2
 using an ibidi pump system. 
In vitro, ex vivo and in vivo monocyte adhesion and transmigration assays 
CD14
+
 human monocytes and CD115
+
 mouse monocytes were freshly isolated 
from blood from healthy volunteers or from spleens of mice with the respective 
genetic modification, respectively, for every experimental series using the 
Monocyte Isolation Kit II or the CD115 mouse MicroBead Kit (Miltenyi, Bergisch 
Gladbach, Germany), which employ blocking reagents for the Fc-receptor. 
Human monocytes (0.7×10
6
/ml) were applied on HAoECs under shear stress 
(1.5 dyn/cm
2
) using a syringe pump (WPI, Berlin, Germany) in a laminar flow 
chamber for 5 min and flushed with assay medium for 30 min, while time-lapse 
images were recorded (CellM system, Olympus, Tokyo, Japan). Mouse 
monocytes (2×10
6
/ml) were applied on stimulated mouse ECs under shear 
stress (0.8 dyn/cm
2
, BioFlux 200, IUL Instruments) for 10 min and flushed with 
assay medium for 30 min, while time-lapse images were recorded. Monocytes 
showing complete, reverse and incomplete transmigration were counted and 
related to adherent or transmigrated monocytes. Human studies were approved 
by the institutional review board and informed consent was given by the 
subjects. 
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Carotid arteries of Apoe
–/–
 mice were explanted, mounted, pressurized at 80 
mmHg and incubated with FITC-coupled CD31 antibody (5 µg/ml, 
BD Biosciences, San Jose, CA). After staining of monocytes with Rhodamine B 
(1 µg/ml, Sigma Aldrich, Carlsbad, CA) and stimulation of carotid arteries with 
TNF- (10 ng/ml, 3 h, eBioscience, San Diego, CA), primary CD115
+
 
monocytes with and without JAM-A deficiency (3 ml of 2×10
5
 cells/ml) were 
perfused in the mounted and pressurized vessel at 0.4 ml/min, and monocytes 
were counted via 2-photon laser scanning microscopy (TPLSM). 
The right carotid arteries of eJAM-A
–/–
 and eJAM-A
+/+
 mice were 
challenged with IL-1β (2 µg/ml, BioLegend, San Diego, CA) carried by a slowly 
degrading periarterial pluronic gel for 24 h. In addition, Alexa Fluor (AF) 
568-coupled anti-CD115 antibody (5 µg/mouse, eBioscience, San Diego, CA) 
was administered intravenously. On the next day, anaesthetized mice were 
injected intravenously with anti-CD31 FITC coupled antibody (35 µg/mouse 
total, BD Biosciences, San Jose, CA) and subsequently prepared for in vivo 
TPLSM by surgically exposing the common carotid artery
28
.  
Measurement of vessel wall permeability 
Carotid arteries explanted from C57Bl/6, Apoe
–/–
 with and without HFD, 
eJAM-A
–/–
, eJAM-A
+/+
Apoe–/– and BM-chimeric mice were mounted in a 
perfusion chamber and incubated with 70 kDa dextran coupled to Rhodamine B 
(0.35 mg/ml), for 1 h at a pressure of 60 mmHg. Control carotid arteries were 
co-incubated with 50 µmol/l histamine. After subsequent washing of the vessels, 
z-stack images were taken with an Olympus FV1000MPE TPLSM system 
coupled to a BX61WI microscope.  
De-adhesion assay for mouse monocytes on SVEC monolayer or ICAM-1.Fc 
Simian Virus 40 large T antigen-transfected mouse endothelial cells (SVECs) 
were grown to confluence in µ-slides
0.4
 (ibidi, Martinsried, Germany) under low 
shear stress (<0.5 dyn/cm
2
) over night. Alternatively, µ-slides
0.4
 were coated 
with 2 µg/ml intercellular adhesion molecule (ICAM)-1.Fc (R&D Systems, 
Minneapolis, MN) or murine Fc control for 2 h at 37°C before blocking with 5% 
albumin/PBS for 2 h. After stimulation of SVECs with TNF- (10 ng/ml, 4 h, 
eBioscience, San Diego, CA), JAM-A
+/+
 and JAM-A
–/–
 CD115
+
 monocytes 
(10
6
 cells/ml) labeled with CFSE (1 µg/ml, Sigma Aldrich, Carlsbad, CA) were 
perfused through µ-slides
0.4
 and allowed to adhere at 0.75 dyn/cm
2
 for 
3 minutes. Subsequently, flow rates were gradually increased up to 
11.5 dyn/cm
2
 and monocytes remaining adherent were counted. 
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TPLSM of the carotid artery in vitro and in vivo  
TPLSM imaging was performed using a resonant scanning Leica SP5MP (in 
vivo, Mannheim, Germany) or an Olympus FV1000MP (Hamburg, Germany) 
with a pulsed Ti:Sapphire Laser tuned at 800 nm and a 20×NA1.00 (Leica) or 
25×NA1.05 (Olympus) water immersion objectives. Emitted fluorescence 
signals were detected using photo-multiplier tubes (PMTs). Image processing 
was performed using Image-Pro Analyzer 7.0 (Media Cybernetics, Rockville, 
MD) and MetaMorph (Molecular Devices, Sunnyvale, CA). 
In vivo image acquisition (Leica) was performed at 10 Hz with a field of 
view (FOV) of 435 µm
2
 (voxel: 1.09×1.09×1.00 µm
3
), including threefold line 
averaging. Directly after in vivo recording, image acquisition was continued 
in situ at 0.4 Hz with a FOV of 435 µm
2
 (voxel: 0.85×0.85×1.00 μm
3
) to examine 
the vessel without motion artefacts. Emitted fluorescence signal was detected 
using 2 non-descanned PMTs: 500-565 nm (FITC) and 565-620 nm (AF568). 
Isolated plaque-prone carotid arteries including the bifurcation were 
mounted in a perfusion chamber and imaged ex vivo
29
. Subsequently, vessels 
were flushed with directly conjugated anti-JAM-A AF488 (10 µg/ml, 
clone H202-106, AbD serotec, Düsseldorf, Germany) and anti-CD31-PE 
(2 µg/ml, clone MEC13.3, BD Pharmingen, San Diego, CA). Antibodies were 
incubated at physiological pressure (60-80 mmHg) for 1 h and arteries were 
flushed prior to imaging. Emitted fluorescence signal was detected using 
3 PMTs: 400-470 nm for second-harmonic generation (SHG); 500-565 nm 
(AF488); 565-605 nm (PI, PE). Three-dimensional datasets were acquired at 
0.1 Hz including twofold frame averaging; FOV = 500 µm
2
 (voxel: 
0.49×0.49×1.00 μm
3
).  
For ex vivo perfusion assays, a total of 6×10
5
 Rhodamine-B labeled CD115
+
 
monocytes were perfused through mounted carotids (60-80 mmHg) at a flow 
rate of 0.5 ml/min for 6 minutes at 37°C. Prior to perfusion, the endothelium was 
labeled with anti-CD31-FITC for 20 minutes. After perfusion, the number of 
leukocytes adherent to approximately 50% of the luminal surface was 
determined using TPLSM (as number of adherent leukocytes per 
500×500×250 µm
3
). The first 500 µm adjacent to the pipettes were excluded 
because of potential handling damage. Emitted fluorescence signal was 
detected in 3 PMTs: 400-510 nm for second-harmonic-generation and 
autofluorescence; 510-525 nm (FITC); 560-660 nm (Rhodamine-B). 
Quantification of immunofluorescence 
HAoECs cultured under flow conditions were stained with an anti-JAM-A 
antibody (10 µg/ml, 2 h, clone M.Ab.F11, Hycult biotech, Uden, The 
Netherlands) followed by secondary antibody staining (anti-mouse IgG 
Alexa 594, 1 µg/ml, 1 h, Invitrogen, Carlsbad, CA) and 
anti-CD31-FITC-antibodies (10 µg/ml, 2 h, clone 5.6E, Beckman Coulter, 
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Krefeld, Germany). Slides were imaged using a High-Content Imager (BD 
Pathway 855, BD Biosciences, San Jose, CA) with a 20x objective. Per slide, 
10 images were made. Using AttoVision-software (BD Biosciences, San Jose, 
CA), cells were segmented and fluorescence intensity per cell was determined.  
Fluorescent bead assay 
HAoECs were treated as above and incubated with 3.3 µl fluorescent 
microbeads (~1 µm diameter, Polysciences Inc., Warrington, PA) coupled to 
JAM-A antibodies (clone 246) for 30 min. Nuclei were stained with HOECHST 
33342 (Sigma Aldrich, Carlsbad, CA). After washing, bright field and fluorescent 
images were recorded. Bead numbers were related to nuclei count and 
normalized to binding of IgG-coupled control beads. 
MiR-145 and anti-miR-145 transfection of HAoECs 
HAoECs were grown to 80% confluence, before transfection with miR-145-3p or 
miR-145-5p mimics (75 pM, mirVana, Ambion Life Technologies, Darmstadt, 
Germany) or miR-145-3p or anti-miR-145-5p inhibitors (30 nM, mirVana, 
Ambion Life Technologies, Darmstadt, Germany) was performed using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following the supplier’s 
recommendations. Quantitative (q)PCR analysis was performed after 24 h. 
Quantitative real-time PCR 
Analysis of JAM-A mRNA and miR-145 levels in HAoECs was performed using 
established protocols
5, 30
. In brief, cDNA was synthesized from freshly isolated 
total RNA (1 µg) and mixed with TaqManTM Fast Universal PCR Master Mix 
(Applied Biosystems, Darmstadt, Germany) or SYBR Advantage qPCR Premix 
(Clontech, Mountain View, CA) and specific products were analyzed in duplicate 
by quantitative or comparative real time PCR. Primer sequences for 
JAM-A mRNA analysis after oxLDL/LDL treatment were 
5´-TCGAGAGGAAACTGTTGTGC-3` and 5´-ACCAGTTGGCAAGAAGGTCA-3` 
(huJAM-A) and 5´-GCCTCAAGATCATCAGC-3` and 
5´-ACCA CTGACACGTTGGC-3` (huGAPDH). For JAM-A mRNA analysis after 
HAoEC culture under flow or after transfection with miR-145 mimics, a 
predesigned TaqManTM assay (Hs00170991_M1:F11R) was performed using 
a 7900HT cycler (Applied Biosystems). Comparative analysis of target JAM-A 
mRNA or miR-145 copies was normalized to levels of actin or small nucleolar 
RNA RNU-44, respectively, and compared to static or transfection controls, 
respectively. For oxLDL/LDL-treated HAoECs, target JAM-A mRNA was 
quantified using a standard curve and normalized to levels of GAPDH. 
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Statistical Analysis 
Statistical analysis was performed using Prism 6.0 (GraphPad Software). 
Means were compared between 2 groups by 2-tailed, unpaired or paired 
Student’s t-test, without or with Welch correction or among more than 2 groups 
by 1-way ANOVA with Tukey's or Bonferroni post-test or Kruskal-Wallis test with 
Dunn's post-test, as indicated. Differences with P<0.05 were considered as 
statistically significant. 
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Results 
Deficiency in endothelial JAM-A protects against atherosclerosis 
The inhibition of mononuclear cell recruitment by soluble JAM-A has implicated 
JAM-A in atherogenesis
5
, however, owing to its pleiotropic functions the overall 
and cell-specific effects of JAM-A have remained elusive. Notably, somatic 
JAM-A deletion did not significantly affect atherosclerotic lesion area in the 
thoraco-abdominal aorta and the aortic root of Apoe
–/–
 mice  fed  a  high-fat  diet 
 
 
Figure 1: Cell-specific role of JAM-A deficiency in atherosclerosis.  
JAM-A
+/+
Apoe
–/–
 and JAM-A
–/–
Apoe
–/–
 mice (A,B), leuJAM-A
+/+
Apoe
–/–
 and leuJAM-A
–/–
Apoe
–/–
 mice 
(C,D), eJAM-A
+/+
Apoe
–/–
 and eJAM-A
–/–
Apoe
–/–
 mice (E,F) were fed a high-fat diet for 12 weeks. 
Atherosclerotic lesions were quantified in the thoraco-abdominal aorta after Oil-red-O staining 
(A,C,E) and in the aortic root after EVG staining (B,D,F). Representative images depict the 
thoracoabdominal aortas (G) and aortic roots of eJAM-A
+/+
Apoe
–/–
 and eJAM-A
–/–
Apoe
–/–
 mice (H). 
Scale bar = 200 µm. Data represent mean±SEM (n=10-13) and all P values were calculated by 
2-tailed t test. 
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(HFD) for 12 weeks (Fig. 1A,B). In contrast, reconstitution of Apoe
–/–
 mice with 
JAM-A
–/–
Apoe
–/–
 BM (leuJAM-A
–/–
Apoe
–/–
) enhanced diet-induced lesion area in 
the thoraco-abdominal aorta but not in the aortic root, as compared to controls 
carrying JAM-A
+/+
Apoe
–/–
 BM (leuJAM-A
+/+
Apoe
–/–
), indicating an 
atheroprotective function of JAM-A on BM-derived leukocytes (Fig. 1C,D). In 
turn, genetic deficiency in endothelial JAM-A reduced the diet-induced lesion 
area in the thoracoabdominal aorta and aortic root of tamoxifen-treated 
VeCad-CreERT
2
JAM-A
fl/fl
Apoe
–/–
 (eJAM-A
–/–
Apoe
–/–
) mice, as compared to their 
Cre- (eJAM-A
+/+
Apoe
–/–
) littermates (Fig. 1E-H), demonstrating a remarkable 
role of JAM-A on endothelial cells in promoting atherosclerosis.  
Endothelial JAM-A deficiency reduces lesional infiltration 
Immunohistochemistry in the aortic root revealed that the lesional content of 
Mac-2
+
 macrophages did not differ in somatic JAM-A
–/–
Apoe
–/–
 mice versus 
JAM-A
+/+
Apoe
–/–
 controls (Fig. 2A). As compared to control chimeras, JAM-A 
deficiency in BM-derived cells reduced macrophage content (Fig. 2B). Likewise, 
deficiency in endothelial JAM-A markedly decreased macrophage content, as 
compared to controls with intact JAM-A (Fig. 2C,D). The infiltration with 
CD3
+
 T cells characterizing early lesion stages was unaffected by somatic 
deletion of JAM-A but markedly reduced in mice with JAM-A-deficient 
leukocytes or with an endothelial deficiency in JAM-A (Fig. 2E-G). As a hallmark 
for advanced lesions, necrotic core size was unaltered by somatic deletion of 
JAM-A, higher in mice with JAM-A-deficient BM-derived cells, indicative of 
increased macrophage turnover, and considerably reduced by endothelial 
deficiency in JAM-A (Fig. 2H-J). To evaluate the rate of lesion development in 
these mice, we performed a phenotypic classification
27
. Whereas JAM-A
–/–
Apoe
–/–
 and leuJAM-A
–/– 
Apoe
–/–
 mice developed lesions that were mainly in an 
advanced stage, eJAM-A
–/–
Apoe
–/–
 mice almost exclusively bore lesions in initial 
or intermediate stages, displaying an increase in early lesion stages, as 
compared to controls (Fig. 2K). Whereas the preponderance of advanced 
lesions in chimeric mice is likely related to irradiation, a higher proportion of less 
advanced lesion stages in the eJAM-A
fl/fl
 lines could be due to tamoxifen 
treatment or residual differences in genetic background. Taken together, cell 
type-specific effects of leukocyte and endothelial JAM-A deficiency differentially 
modulate the inflammatory phenotype and stage of atherosclerotic plaques. 
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Figure 2: Phenotype of atherosclerotic lesions in JAM-A–deficient mice.  
The relative content of Mac-2
+
 macrophages (A-D) and CD3
+
 T cells (E-G) in aortic root lesions was 
analyzed by quantitative immunofluorescence. Representative images of Mac-2–stained aortic roots 
isolated from eJAM-A
+/+
Apoe
–/–
 and eJAM-A
–/–
Apoe
–/–
 mice are shown (D). Scale bar = 200 µm.  
Necrotic core size in aortic root lesions was quantified following DAPI staining (H-J). 
JAM-A
+/+ 
Apoe 
–/–
 and JAM-A
–/–
Apoe
–/–
 mice (A,E,H), leuJAM-A
+/+
Apoe
–/–
 and leuJAM-A
–/–
Apoe
–/–
 
mice (B,F,I), and eJAM-A
+/+
Apoe
–/–
 and eJAM-A
–/–
Apoe
–/–
 mice (C,D,G,J) were fed a high-fat diet for 
12 weeks. The lesions were phenotypically characterized according to the stage (K). IX: intimal 
xanthoma, PIT: pathologic intimal thickening, FCA: fibrous cap atheroma. Data represent 
mean±SEM (n=10-13) and all P values were calculated by 2-tailed t test. 
Role of endothelial JAM-A in arterial leukocyte recruitment  
We used in vivo, ex vivo and in vitro adhesion and transmigration assays to 
mechanistically evaluate the role of endothelial and leukocytic JAM-A in arterial 
monocyte recruitment. Indeed, we found a lower number of wild-type 
CD115
+ 
monocytes that had crossed the endothelial layer of carotid arteries in 
eJAM-A
–/–
 mice after treatment with IL-1, as compared to eJAM-A
+/+
 controls, 
both during in vivo recording (Fig. 3A) and in situ after sacrifice (Fig. 3B). 
Accordingly, the adhesion of wild-type monocytes to JAM-A-deficient 
endothelial monolayers stimulated with TNF-/IFN- was unaltered but their 
transmigration underneath JAM-A-deficient endothelial monolayers was 
markedly reduced, compared with JAM-A-bearing endothelial cells (Fig. 3C,D). 
The decreased transmigration of monocytes across JAM-A-deficient endothelial 
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cells might also be explained by an increase in reverse transmigration, which 
was only observed when JAM-A
+/+
 leukocytes transmigrated across 
JAM-A-deficient endothelial cells (Fig. 3E). 
Leukocytic JAM-A deficiency impairs de-adhesion and endothelial barrier 
function 
As compared to wild-type monocytes, JAM-A
–/–
 mouse monocytes showed a 
marked increase in firm adhesion to ex vivo perfused wild-type carotid arteries 
(Fig. 3G) and to JAM-A
+/+
 endothelial cells in a recruitment assay under flow 
conditions in vitro (Fig. 3C). This was accompanied by reduced transmigration 
of JAM-A
–/–
 monocytes (Fig. 3D), which may be attributable to a defect in de-
adhesion
12
. JAM-A
–/–
 monocytes showed a higher rate of incomplete 
transmigration (defined as cells that had entered endothelial junctions without 
exiting, thus being entrapped) across both JAM-A-expressing or 
JAM-A-deficient endothelial cells (Fig. 3F), explaining the overall decrease in 
complete transmigration (Fig. 3D).  
To confirm defective de-adhesion of JAM-A
–/–
 monocytes, we performed 
assays under variable flow conditions. Compared with JAM-A
+/+
 controls, 
adherent JAM-A
–/–
 monocytes were more resistant to shear stress and 
detachment induced by gradually increasing flow rates both on stimulated 
SVEC monolayers (Fig. 4A) and the 2 integrin ligand ICAM-1.Fc (Fig. 4B). This 
clearly indicates that de-adhesion was impaired in JAM-A
–/–
 monocytes and that 
this effect was likely mediated by increased activity of 2 integrins. 
Because compromised endothelial integrity is a hallmark of early 
atherosclerosis
31
, we investigated the permeability of the carotid artery wall of 
Apoe
–/–
 mice deficient in leukocytic and endothelial JAM-A fed with or without 
HFD for 6 weeks. As assessed by ex vivo TPLSM, the uptake of fluorescent 
dextran into the arterial media was not affected by HFD or endothelial JAM-A 
deficiency but increased by histamine-treatment or leukocytic JAM-A–deficiency 
(Fig. 4C). Altered vascular permeability in leuJAM-A
–/–
Apoe
–/–
 mice may reflect 
the damage inflicted by impaired de-adhesion or transmigration of leuJAM-A
–/–
leukocytes and may explain increased lesion formation. 
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Figure 3: Cell-specific effects of JAM-A on transmigration.  
(A,B) Numbers of CD115
+
 cells located in the vessel wall of common carotid arteries after 
incubation with IL-1β in a perivascular pluronic gel for 24 h were analyzed by in vivo (A) and 
post mortem in situ (B) 2-photon laser scanning microscopy (TPLSM) in eJAM-A
+/+
 (n=3) and 
eJAM-A
–/–
 mice (n=7-9). Representative images depict CD115
+
 monocytes (red; inset shows 
magnification) migrated into sub-endothelial regions, CD31
+
 endothelium and elastin 
autofluorescence in green (B, right panels). Scale bar = 40 µm. (C-F) Stable adhesion (C) 
completed (D), reverse (E) and incomplete (F) transendothelial migration of leuJAM-A
+/+
 or 
leuJAM-A
–/–
 monocytes perfused on TNF-/IFN-–treated eJAM-A
+/+
 (black bars) or eJAM-A
–/–
 
endothelial cells (grey bars) at 1.5 dyn/cm
2
 was analyzed by video microscopy (n=3-5). 
(G) Adhesion of primary JAM-A
+/+
Apoe
–/–
 (n=6) and JAM-A
–/–
Apoe
–/–
 (n=7) CD115
+
 mouse 
monocytes was determined using TPLSM after ex vivo perfusion of TNF-–activated carotid arteries 
(JAM-A
+/+
Apoe
–/–
) pressurized at 80 mmHg). Data represent mean±SEM and P values were 
calculated by one-way ANOVA with Bonferroni (Fig. 3C-F) multiple comparison test or 2-tailed t test 
(Fig. 3A,B,G). 
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Figure 4: Cell-specific effects of JAM-A on de-adhesion and permeability. 
(A,B) De-adhesion of primary JAM-A
+/+
 and JAM-A
–/–
CD115
+
 mouse monocytes was assessed by 
detachment of adherent cells at gradually increasing flow rates on TNF-–activated SVEC 
monolayers (A) or ICAM-1.Fc (B) (n=12 each). (C) Permeability was assessed by extravasation of 
70 kDa FITC-labeled dextran using TPLSM in carotid arteries ex vivo with or without (ctrl) 
histamine-treatment or after 6-weeks of HFD in Apoe
–/–
 mice (open bars), with or without deficiency 
of endothelial (n=5, grey bars) or leukocyte (n=5, black bars) JAM-A. Data represent mean±SEM 
and P values were calculated by one-way ANOVA with Tukey's multiple comparison test or 2-tailed 
t test. 
Focal redistribution of endothelial JAM-A in lesion-prone areas 
Analysis of atherosclerotic arteries and plaque tissue revealed an increase in 
JAM-A expression
5, 21
. We used ex vivo 2-photon laser scanning microscopy 
(TPLSM) in unfixed and intact carotid arteries of Apoe
–/–
 mice to label JAM-A 
and to determine its distribution in plaque-prone vessels as a potential 
mechanism underlying atherogenic leukocyte recruitment (Supplementary 
Fig. 1). The undiseased common part of the carotid artery explanted from 
1 year-old Apoe
–/–
 mice on normal chow showed an organized mesh-like 
junctional pattern of JAM-A expression in luminal endothelial cells (Fig. 5A, left 
panel, Supplementary Video online). In contrast, segments near the bifurcation, 
which are prone to lesion formation owing to disturbed flow, displayed an apico-
luminal redistribution and focal concentration of JAM-A away from endothelial  
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Figure 5: Arterial localization of JAM-A during atherogenesis.  
(A) Visualization of JAM-A (green) and collagen (blue, SHG) in an explanted carotid artery of a 
1 year-old Apoe
–/–
 mouse fed normal chow. An organized junctional pattern of JAM-A staining is 
evident in the healthy part of the carotid artery (left panel), which changes into a focally enriched 
pattern in the shoulder (middle panel) and core (right panel) regions of the plaque. Images are total 
projections of z-stacks. A schematic drawing (lower part) depicts where images were taken. Scale 
bar = 40 µm. (B) Co-staining (left and middle panels) and semi-quantitative analysis (right panel) of 
CD31 (red) and JAM-A (green) in the carotid artery of an Apoe
–/–
 mouse fed a high-fat diet for 
7 weeks revealed a decreased JAM-A/CD31 pseudo-overlap in the endothelial junctions at the 
diseased bifurcation, compared with the common part. Scale bar = 40 µm. Data represents 
mean±SEM (n=5) and P value was calculated by 2-tailed t test. 
cell junctions (Fig. 5A, middle and right panels). The middle panel shows the 
transition zone between undiseased segments with a normal junctional JAM-A 
pattern (left part) and focal enrichment of JAM-A in the shoulder region of a 
lesion (right part). To assess the propensity of JAM-A for early focal 
redistribution during lesion formation, we performed co-staining with PECAM-1 
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(CD31) as another junctional protein expressed in endothelial cells (Fig. 5B and 
Supplementary Fig. 2). In carotid arteries of Apoe
–/–
 mice fed a HFD for 
6 weeks, typical examples of co-staining for JAM-A and CD31 in the 
undiseased common part and the plaque-prone areas near the bifurcation are 
shown (Fig. 5B, left and middle panels). Using image analysis, we determined 
the pseudo-overlap of JAM-A and CD31 expression in undiseased areas for 
normalization (Fig. 5B, right panel). The bifurcation prone to nascent 
atherosclerotic  lesion  formation revealed a decrease in junctional co-
localization of JAM-A and CD31 (72.8±8.4% of control, n=5, P<0.05), implying a 
preferential redistribution of JAM-A. 
Oxidized LDL increases functional JAM-A expression  
To elucidate whether the focal accumulations of endothelial JAM-A in 
atherosclerotic lesions are caused by redistribution or increased de novo 
synthesis,  we  performed  JAM-A  antibody-coupled  fluorescent  bead  assays,  
 
Figure 6: Expression and localization of JAM-A under atherogenic conditions. 
(A,B) Human aortic endothelial cells (HAoECs) were treated with or without LDL, oxLDL (16 h), 
TNF-/IFN- (4 h) and/or cycloheximide (Chex, 1 h), before incubation with fluorescent microbeads 
coupled to JAM-A antibodies (green). After washing, representative images were taken (A), beads 
were counted (B) and normalized to the number of endothelial cells (blue). Scale bar = 40 µm. 
Counts were corrected for unspecific binding using beads carrying isotype control. (C) HAoECs 
were treated with LDL (open symbols) or oxLDL (solid symbols) for 16 h at indicated concentrations. 
Quantitative real-time PCR normalized to GAPDH (left panel, n=3) and western blot analyses 
normalized to Ponceau staining (right panel, n=5) were performed. (D) Transendothelial migration of 
CD14
+
 monocytes across HAoECs treated with or without (open bar) LDL, TNF-/IFN- or oxLDL 
and with or without blocking JAM-A.Fc fusion protein (black bars) under flow conditions. 
Transmigrated cells were counted and normalized to the total number of adherent cells. Data 
represent mean±SEM of 3 independent experiments. P values were calculated by one way ANOVA 
with Tukey's multiple comparison test (Fig. 6B,D) or 2-tailed t test (Fig. 6C).  
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real-time PCR and western blot analysis. Similar to co-stimulation with TNF- 
and IFN-, treatment with oxLDL but not with native LDL increased specific 
surface binding of anti-JAM-A microbeads to aortic endothelial cell monolayers 
(Fig. 6A,B). Blocking de novo protein synthesis with cycloheximide partially yet 
non-significantly reduced JAM-A surface levels, suggesting that both increased 
expression and redistribution contributed to the up-regulation of endothelial 
surface JAM-A. Treatment with oxLDL but not native LDL or TNF- 
dose-dependently increased JAM-A transcript and protein expression in 
HAoECs, reaching a plateau at 2.5 µg/ml of oxLDL (Fig. 6C). To link JAM-A 
expression to atherogenic recruitment, we performed a transmigration assay 
using classical CD14
+
 monocytes and HAoECs under shear flow conditions 
(Fig. 6D). Similar to co-stimulation with TNF- and IFN-, treatment with oxLDL 
but not native LDL caused an increase in monocyte transmigration. Notably, 
blocking endothelial JAM-A with soluble JAM-A.Fc reduced the oxLDL-induced 
increase in transmigration to levels seen in untreated HAoECs, indicating that 
the effect of oxLDL on transmigration is mediated by JAM-A.  
The expression and localization of JAM-A is governed by shear flow and 
miR145 
Because the increased susceptibility to lesion formation in areas near 
bifurcations or branching points is related to altered flow conditions, e.g. low or 
oscillatory flow, we tested whether such aberrant flow conditions as induced by 
partial ligation of the carotid artery of Apoe
–/–
 mice affects the localization of 
JAM-A. Indeed, co-staining for JAM-A and CD31 revealed a discontinuous 
pattern of JAM-A and redistribution from the junctions in the common part of 
partially ligated carotid arteries, as seen in the bifurcation of mice with 
established lesions (Fig. 7A and Supplementary Fig. 2). The redistribution of 
JAM-A was evident both in the common part and in the bifurcation, as early as 2 
weeks after ligation (Fig. 7A). The pseudo-overlap of JAM-A with CD31 was 
markedly reduced in carotid arteries after 2 weeks and this reduction sustained 
for at least 8 weeks after partial ligation (Fig. 7B), indicating that JAM-A is 
preferentially redistributed from its junctional expression pattern under 
conditions of disturbed flow. Conversely, the control of JAM-A might be linked to 
atheroprotective laminar flow conditions. Hence, we assessed JAM-A 
expression in HAoECs cultured under static or flow conditions, revealing an 
inverse correlation of JAM-A expression with laminar shear flow (Fig. 7C,D; 
Supplementary Fig. 3A). To correlate this effect with a JAM-A-dependent local 
predilection for atherosclerosis, in vivo analysis confirmed that the reduction of 
atherosclerotic lesion formation in the descending aorta and the aortic arch 
between eJAM-A
+/+
Apoe
–/–
 and eJAM-A
–/–
Apoe
–/–
 mice was more prominent at 
regions of low/oscillatory shear stress, e.g. in the inner curvature of the arch or 
the  descending  aorta  with  branching  points,  as  compared  to  regions  with 
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Figure 7: Expression and localization of JAM-A during altered flow conditions.  
(A) Visualization of JAM-A (green), CD31 (red) and collagen (blue) in control (left panels) and 
treated carotid arteries (right panels) at the common part and the bifurcation, 2 weeks after partial 
ligation. Images are total projections of z-stacks. Scale bar = 40µm. (B) Quantification of the 
percentage of junctions staining positive for both JAM-A and CD31 in controls and carotid arteries, 
2 and 8 weeks after partial ligation (n=4-6). (C,D) Expression of JAM-A mRNA relative to 
18S housekeeper, as analyzed by qRT-PCR (C), and expression of JAM-A protein relative to CD31, 
as quantified by immunofluorescence (D) in human aortic endothelial cells (HAoECs) cultured under 
static or flow conditions, as indicated (n=19-32). (E,F) Quantification of Oil-red-O
+
 lesion surface in 
areas of low/oscillatory shear flow (inner curvature), high/laminar shear flow (outer curvature) or the 
total aortic arch (E), and number of plaques in the descending, abdominal and total aorta (F) of 
eJAM-A
+/+
Apoe
–/–
 and eJAM-A
–/–
Apoe
–/–
 mice fed a high-fat diet for 12 weeks (n=10-13). 
(G,H) Expression of miR-145 relative to U44 housekeeper in HAoECs cultured under static or flow 
conditions (G) and expression of JAM-A mRNA relative to 18S housekeeper in HAoECs transfected 
with miR-145-3p, miR-145-5p mimics or control (H), as analyzed by qRT-PCR (n=3-4). Data 
represent mean±SEM and P values were calculated by one-way ANOVA with Tukey's multiple 
comparison (Fig. 7B,E,F,H), Kruskal-Wallis with Dunn's post-test (Fig. 7D) or 2-tailed t test 
(Fig. 7C,G). 
high/laminar shear flow, e.g. the outer curvature of the arch and the abdominal 
aorta (Fig. 7E,F). 
Recent evidence has linked the expression of microRNA (miR)-145 in 
endothelial cells under shear flow conditions to the mechanosensitive 
transcription factor Krüppel-like factor 2 (KLF2)
32, 33
. Indeed, culture of HAoECs 
under shear flow conditions increased the expression of miR-145, as compared 
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to static conditions (Fig. 7G). Notably, an analysis of miR target sequences 
revealed that the gene of JAM-A harbors at least two seed sequences for 
miR-145-3p and miR-145-5p (see Supplementary Fig. 4). To investigate 
whether JAM-A expression is regulated by a miR-145-dependent mechanism, 
we transfected HAoECs with miR-145-3p and miR-145-5p mimics. Notably, 
both the miR-145-3p and miR-145-5p strands reduced the copy number of 
JAM-A mRNA in HAoECs (Fig. 7H). Vice versa to verify those results we 
checked whether inhibition of miR-145-3p and miR-145-5p by transfection of 
appropiate miR inhibitors led to increased JAM-A mRNA copy numbers. Indeed, 
inhibitors against both miR-145-3p and miR-145-5p strands resulted in 
increased copy number of JAM-A mRNA (Supplementary Fig. 3B). These 
findings suggest that miR-145 is a flow-dependent regulator of JAM-A 
expression, which may protect against plaque formation by attenuating JAM-A 
mRNA levels under flow conditions. Taken together, endothelial JAM-A levels 
might serve to functionally integrate atherogenic risk factors, such as modified 
LDL and disturbed flow conditions.  
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Discussion 
Here we have unraveled the cell-specific effects and mechanisms exerted by 
JAM-A in diet-induced atherosclerosis, and the overall and context-dependent 
consequence of its genetic deficiency. Previous studies have reported 
differential or even contradictory effects of somatic and endothelial JAM-A 
deficiency in various models of tissue injury and inflammation
14, 17, 34, 35
. This 
apparent inconsistency may be due to the use of heterogeneous models 
affecting different vascular beds. We employed diet-induced atherosclerotic 
lesion formation and arterial inflammation in Apoe
–/–
 mice and found that 
endothelial JAM-A promoted lesion formation and mononuclear cell infiltration. 
This effect was mediated by an elevated accessibility of JAM-A (through up-
regulation and redistribution) and its function in guiding monocyte recruitment, 
which was stimulated under atherogenic conditions. The expression and luminal 
enrichment of JAM-A was exacerbated by disturbed flow conditions, e.g. 
reduced shear flow, as encountered at predilection sites, whereas laminar shear 
flow induced miR-145 to repress JAM-A expression, in a mechanism that may 
contribute to limiting the susceptibility to atherosclerosis. Targeting endothelial 
JAM-A may thus serve as a feasible option to protect against atherogenic 
inflammation. 
In contrast, we demonstrate that JAM-A deficiency in BM-derived 
leukocytes aggravates atherosclerotic lesion formation. Dendritic cells deficient 
in JAM-A display higher migratory capacity in lymphoid organs but not in blood 
vessels
11
, while JAM-A-deficient polymorphonuclear cells show reduced 
diapedesis in peritonitis and ischemia-reperfusion injury, related to impaired 
de-adhesion and polarized motility
12
. We found that JAM-A-deficient monocytes 
indeed display defects in de-adhesion and complete transendothelial migration, 
likely due to persistently increased activity of 2 integrins. Consequently, 
monocytes become entrapped between the endothelial cell layer and the 
basement membrane, and may thereby cause vascular damage. Our data thus 
indicate that the presence of leukocytic JAM-A may limit atherogenic damage 
by enabling physiological de-adhesion and migration of mononuclear cells. 
No significant alterations of atherosclerotic lesion formation were found 
in mice with somatic JAM-A deletion, pointing towards an intermediate 
phenotype between the atherogenic influence of endothelial JAM-A and the 
protective functions of leukocytic JAM-A. Notably, the reduction in Mac-2
+
 and 
CD3
+
 cell content in mice with either endothelial or leukocytic deficiency in 
JAM-A was not recapitulated in JAM-A
–/–
 mice, where no difference could be 
observed. This may be due to counteracting effects of JAM-A deficiency in cells 
other than endothelial and bone-marrow derived cells, e.g. smooth muscle cells, 
pericytes or non-BM-derived resident macrophages. The intermediate 
phenotype was also reflected in the classification of lesion stages. In general, 
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irradiation for BM reconstitution appeared to accelerate the development of 
more advanced stage plaques, whereas the deficiency in endothelial JAM-A 
delayed lesion progression and clearly favored a retention in early lesion 
stages. 
We used various assays to assess the capacity of JAM-A-deficient 
leukocytes and/or endothelial cells to support recruitment in vivo, ex vivo and 
in vitro and we provide novel in vitro evidence that a deficiency in endothelial 
JAM-A might also allow for monocytes to reappear on the monolayer by 
passively permitting reverse migration, contributing to the overall decrease in 
complete transmigration. This retentive control exerted by JAM-A complements 
a reverse “gate-keeper” function revealed for JAM-C in a study, where blocking 
JAM-C reduced the number of monocytes in inflammatory tissue by increasing 
reverse transmigration
36
. Accordingly, a 'hesitant' or 'reverse' transmigration 
behavior has been identified for neutrophils during inflammation after 
ischemia-reperfusion injury in vivo, which was characterized by lower 
expression of JAM-C at endothelial junctions, enhanced by blockade or genetic 
deletion of JAM-C
37
, and implicated in systemic dissemination of inflammation.  
Mechanistically, the exacerbation of atherosclerotic lesion formation by 
endothelial JAM-A appears to be due to its redistribution from the intercellular 
junctions to the luminal surface, and to an up-regulated expression under 
atherogenic conditions, thus increasing the availability of luminal JAM-A. 
Previous work has addressed the redistribution of endothelial JAM-A, showing 
that JAM-A is re-localized to the apical surface in a cytokine-dependent manner 
under static or flow conditions in vitro
15-17, 35
. We extend these findings by 
unveiling a focal up-regulation and redistribution of JAM-A expression in 
endothelial cells of carotid arteries under atherogenic conditions of 
hyperlipidemia. The increased luminal JAM-A availability could mediate 
enhanced recruitment and higher content of macrophages and T cells in 
atherosclerotic plaques of hyperlipidemic mice. In vitro experiments confirmed 
that oxidized LDL increased expression of JAM-A and its redistribution to the 
apical surface.  
Our data challenge the intuitive assumption that knocking-out a protein 
that is crucially involved in junctional barrier function, would cause a 
non-specific influx of leukocytes. Rather, the evidence presented in this study 
refutes a role of JAM-A in limiting transendothelial migration and points towards 
a specific role of JAM-A in leukocyte recruitment in the context of 
atherosclerosis. First, genetic deficiency in endothelial JAM-A decreased 
infiltration of plaques with macrophages and T cells and reduced luminal 
monocyte extravasation in carotid arteries in vivo. Second, redistribution of 
JAM-A induced by oxLDL facilitated the transmigration of monocytes.  
The increase in expression and focal redistribution of JAM-A in 
response to atherogenic stimulation with oxLDL reveals a striking similarity to 
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JAM-C, a related JAM family member, which displays increased expression and 
redistribution to the apical surface after oxLDL treatment
38
. Like for JAM-A, 
JAM-C predominantly localized to interendothelial contacts under quiescent 
conditions, oxLDL induced a disorganized JAM-C localization that was no 
longer restricted to interendothelial junctions, and JAM-C supported both 
adhesion and transmigration upon oxLDL stimulation
38
.  
The up-regulation and luminal redistribution of JAM-A is enhanced by 
aberrant shear flow conditions, e.g. after partial ligation or at predilection sites, 
whereas laminar shear flow appears to exert beneficial effects on JAM-A, 
limiting the susceptibility to atherogenesis. Accordingly, the reduction of 
atherosclerotic lesion formation in the aortic arch was more prominent in 
regions of low shear rather than high shear, e.g. the inner curvature of the arch 
and branching points of the descending aorta. Of note, KLF2-transduced or 
shear stress-stimulated human endothelial cells have been found to be enriched 
in miR-143/145, providing a mechanism for atheroprotective communication 
with neighboring SMCs via miR-145-containing microvesicles
33
. Our data 
confirmed that shear flow induces an increase in miR-145 expression in arterial 
endothelial cells, which is highly relevant and extends findings identifying 
JAM-A as a miR-145- target in tumor cells
39
. The overexpression or inhibition of 
miR-145 respectively suppressed or enhanced the expression of JAM-A in 
endothelial cells, which was mirrored by the flow-dependent reduction in JAM-A 
expression. Thus, miR-145 is a regulator of JAM-A in the setting of arterial 
remodeling.  
Notably, platelet endothelial adhesion molecule-1 (PECAM-1), another 
Ig family adhesion molecule expressed on platelets, leukocytes and endothelial 
cell junctions, has recently been found to regulate atherosclerotic plaque 
formation in a cell- and site-specific manner
40
. In contrast to JAM-A, PECAM-1 
on BM cells was atherogenic irrespective of the hemodynamic environment, 
whereas PECAM-1, like JAM-A, reduced lesion formation in areas of disturbed 
flow but was atheroprotective in high shear regions by mechanisms yet to be 
elucidated.  
In the context of arterial denudation injury, the neointimal content of 
macrophages was reduced in mice with a somatic JAM-A deletion. This was 
likely due to a reduced JAM-A-dependent deposition of the chemokine CCL5 by 
platelets on the luminal surface of injured arteries
20
. Moreover, the phenotype of 
regenerating endothelial cells after wire-injury may differ, benefiting from 
increased JAM-A expression and its function in endothelial cell migration and 
shear resistance
41
. 
Our study identifies the differential and cell type-specific contribution of 
JAM-A in atherosclerosis, namely a crucial involvement of endothelial JAM-A in 
atherogenic leukocyte recruitment in response to modified lipids and at 
predilection sites with disturbed flow. Increased expression and focal 
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redistribution of JAM-A controlled by miR-145 establish a novel set of 
mechanisms to explain the higher susceptibility to atherosclerosis in regions 
with disturbed shear flow. Endothelial JAM-A may serve as a suitable marker for 
molecular imaging of early stages of lesion formation and may be developed as 
a therapeutic target to treat atherosclerosis  
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Supplementary Figures 
 
Supplementary Figure 1: Ex vivo TPLSM scanning mode of murine carotid arteries. 
Scheme of TPLSM scanning mode for JAM-A (green) and CD31 (red) localization in murine carotid 
arteries under physiological pressure ex vivo. Z-stack record (1 µm optical slices) starts in the 
adventitia. Of note, CD31 is located distal to the lumen compared to JAM-A. Collagen is depicted 
blue due to Second Harmonic Generation. EEL: external elastic lamina; IMEL: intermediate elastic 
lamina; IEL: inner elastic lamina. 
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Supplementary Figure 2: TPLSM imaging of arterial JAM-A and CD31 expression 
Individual visualization of JAM-A (green, left) and CD31 (red, middle) with collagen (blue, all panels) 
in control (A), atherosclerotic (B) and ligated carotid arteries at the common part (C) or the 
bifurcation (D). Right panels show merged images. TPLSM imaging was performed after 7 weeks of 
high-fat diet feeding or 2 weeks after partial ligation in Apoe
–/–
 mice. Images are total projections of 
z-stacks. Scale bar = 40 μm. 
CHAPTER 2 
68 
2 
 
Supplementary Figure 3: Expression of JAM-A during altered flow conditions and miR 145 
inhibition 
(A) Expression of JAM-A protein relative to GAPDH housekeeper, as analyzed by western blotting 
in human aortic endothelial cells (HAoECs) cultured under static or flow conditions, as indicated 
(n=3). (B) Expression of JAM-A mRNA relative to 18S housekeeper in HAoECs transfected with 
miR-145-3p, anti-miR-145-5p inhibitors or control, as analyzed by qRT-PCR (n=4). Data represent 
mean±SEM and P values were calculated by one-way ANOVA with Tukey's multiple comparison 
post-test. 
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Supplementary Figure 4: Seed sequences for miR-145 in JAM-A gene. 
The JAM-A gene contains 2 seed sequences for hsa-miR-145-3p and 3 seed sequences for 
has-miR-145-5p, thus being a putative target for both miR-145 strands. Complementary regions of 
JAM-A gene and miR-145 that are homologous are depicted in green, heterologous base-pairs in 
these regions are marked in grey. 
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Supplementary video file 
 
Supplementary video online 
Link at: 
 
http://circ.ahajournals.org/content/suppl/2013/09/24/CIRCULATIONAHA.113.00
4149.DC1/004149_Video_1.mov 
 
Movie composed of z-stack imaging (1µm depth) of a murine carotid artery mounted. Blue depicts 
SHG of collagen, green represents JAM-A and red illustrates CD31. 
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JAM-A dispersal facilitates leukocyte recruitment: 
In chapter 2, we demonstrated a focal JAM-A re-localization away from the 
cell-cell borders to the apical site of endothelial cells after oxLDL or cytokine 
treatment, as well as in areas of disturbed flow. This re-localization increased 
recruitment rates of monocytes and thus might represent the reason for 
endothelial JAM-A exerting atherogenic effects.  
 Not much is known about the underlying molecular mechanism of 
endothelial JAM-A re-localization. Martinez-Estrada and colleagues found a 
TNF-mediated re-localization of endothelial JAM-A and hypothesized that this 
re-localization was due to decreased interaction of JAM-A with cortical actin
1
. 
As their results were rather preliminary, additional data to determine the role of 
JAM-A/actin interaction on endothelial JAM-A localization is needed. 
With the following chapter 3, we aimed to further characterize the 
influence of endothelial JAM-A re-localization on atherogenic lymphocyte 
recruitment. Additionally, a potential pharmacologic intervention of endothelial 
JAM-A re-localization and leukocyte recruitment with atheroprotective drugs like 
lovastatin or pioglitazone shall be investigated. Moreover, we strived to further 
elucidate the molecular mechanism underlying endothelial JAM-A re-localization 
by studying actin localization as well as ZO-1/JAM-A interaction under 
atherogenic conditions as well as after actin (de-) stabilizing treatment.   
 3 
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Abstract 
Background - Junctional adhesion molecule (JAM-) A is a transmembrane 
protein expressed in many cell types and maintains junctional integrity in 
endothelial cells. Upon inflammatory stimulation, JAM-A relocates to the apical 
surface and might thereby facilitate the recruitment of leukocytes.  
Objective - Although inflammatory JAM-A redistribution is an established 
process, its exact role in the transmigration of mononuclear cells has not yet 
been characterized, particularly under atherogenic conditions.  
Methods - By the use of RNA interference and genetic deletion, the role of 
JAM-A in the transmigration of T cells and monocytes through aortic endothelial 
cells was investigated. JAM-A–localization and subsequent mononuclear cell 
transmigration was explored during endothelial inflammation, induced by 
oxidized LDL or cytokines.  
Results - RNA interference or genetic deletion of JAM-A in aortic endothelial 
cells resulted in a decreased transmigration of mononuclear cells. Treatment of 
the endothelial cells with oxLDL resulted in an increase of both permeability and 
apical JAM-A presentation, as shown by bead adhesion and confocal 
microscopy experiments. Redistribution of JAM-A resulted in an increased 
leukocyte transmigration, which could be inhibited with antibodies against 
JAM-A or by lovastatin-treatment, but not with the peroxisome proliferator 
activated receptor gamma-agonist pioglitazone. 
Conclusions - This study demonstrates that redistribution of JAM-A in 
endothelial cells after stimulation with atherogenic oxidized lipoproteins results 
in increased transmigration of mononuclear cells. This inflammatory dispersal of 
JAM-A could be counteracted with statins, revealing a novel aspect of their 
mechanism of action.  
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Introduction 
Junctional Adhesion Molecule A (JAM-A, F11 receptor, JAM-1) is a member of 
the immunoglobulin superfamily (Ig-SF) transmembrane adhesion molecules 
and is expressed on a large variety of cell types, notably leukocytes, platelets 
and vascular endothelial cells
2
. In endothelial and epithelial cells, JAM-A 
maintains the integrity of the tight junctions through homophilic interactions, 
thereby controlling vascular and epithelial permeability
3
. Under inflammatory 
conditions, JAM-A has been shown to relocate to the apical surface of 
endothelial cells, where it becomes available for homophilic interactions with 
JAM-A on blood cells and for heterophilic interactions with lymphocyte 
functional antigen-1 (LFA-1)
4, 5
. Thus, it may facilitate leukocyte adhesion and 
transendothelial migration
6-9
. Alternatively, JAM-A can be shed from the cell 
surface by metalloproteases and soluble JAM-A may modulate the actions of 
leukocytes distal from the site of inflammation
10
. Accordingly, elevated plasma 
levels of soluble JAM-A have been observed in individuals with coronary artery 
disease and strongly correlated with circulating levels of tumor necrosis factor-α 
(TNF-α)
11
. In addition, increased expression of JAM-A was observed in early 
vascular lesions of hyperlipidemic mice and in specimen of human 
atherosclerotic plaques
7, 12
 and is involved in vascular remodeling after wire 
injury
13
. Interestingly, the structurally and functionally related JAM-C is both 
upregulated and redistributed in endothelial cells after treatment with oxidized 
low-density lipoprotein (oxLDL), further indicating a role for JAM family 
members in atherosclerosis
14
. In a recent study we have demonstrated that 
endothelial JAM-A promotes atherogenic leukocyte recruitment under 
conditions of disturbed arterial flow, by redistributing from the endothelial 
junctions to the luminal side of the vessel wall
15
. 
Similar to other members of the Ig-SF, JAM-A consists of 2 globular 
extracellular domains, a transmembrane region and a relatively short 
N-terminus, which contains a type II PDZ domain
5, 16
. The first VH-type 
extracellular domain mediates homophilic interactions of neighboring JAM-A 
molecules in cis, as well as homophilic interactions of JAM-A on nearby cells in 
trans
17
. The second C2-type domain, closest to the plasma membrane, binds to 
the integrin LFA-1
8
. A previous study revealed that binding of LFA-1 to domain 
2 of JAM-A caused a destabilization of the homophilic interaction through 
domain 1
18
. Thus through LFA-1 binding, the tight junction barrier of JAM-A 
might be loosened, facilitating the advancement of leukocytes through the 
cellular junctions. The PDZ domain links JAM-A to a variety of intracellular 
proteins, notably zonula occludens 1 (ZO-1), which serve as anchors to the 
cytoskeleton  and  are  components  of  the  organizational  tight  junction 
scaffold
19, 20
. Stimulation of endothelial or epithelial cells with TNF-α and/or 
interferon-γ (IFN-γ) resulted in an increase of JAM-A in the triton-X100 cell 
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fraction, which is indicative of its dissociation from the cytoskeleton
1, 21
 and 
being liberated from cytoskeletal restraints, JAM-A might be able to guide 
leukocytes to junctional transmigration sites
22
. However, it is still unclear how 
this cellular redistribution and dispersal of JAM-A influences the subsequent 
recruitment of inflammatory cells. Moreover, it is of interest to investigate 
whether a pharmacologic attenuation of endothelial inflammation would also 
have effects on endothelial distribution of JAM-A and its consequences on 
monocyte recruitment. 
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Methods 
Reagents and cell culture 
Dharmacon
®
 small interfering RNA (siRNA) pools targeting JAM-A or laminin 
and FITC-conjugated phalloidin were purchased at Thermo Scientific (Pittsburg, 
PA). Antibodies against mouse and human JAM-A were purchased at Hycult 
Biotech (Uden, Netherlands) and mAb TS1/22 against CD11a was isolated from 
hybridoma-conditioned medium. Fab fragments were generated by papain 
digestion of JAM-A antibodies (243 and 246) and of mAb TS1/22
22
. Cytokines 
and chemokines were from Peprotech (Rocky Hill, NJ). Low-density lipoprotein 
(LDL) was prepared from freshly prepared human plasma by ultracentrifugation 
in a KBr density gradient and oxidized with CuCl2 as described
23
. Fusion protein 
of human IgG Fc and JAM-A (JAM-A.Fc) was isolated from stably transfected 
CHO supernatants
7
. All other reagents were purchased at Sigma-Aldrich 
(St. Louis, MO) and were of the highest purity available. 
Peripheral blood mononuclear cells (PBMC) were isolated from fresh buffy 
coats by density gradient centrifugation. T cells were isolated using magnetic 
beads (Life Technologies, Carlsbad, CA) and were cultured up to 48 hours in 
RPMI medium containing 10% fetal bovine serum and 25 ng/ml interleukin 2. 
Mouse aortic endothelial cells (MAoECs) were isolated from JAM-A
–/–
 and 
JAM-A
+/+
 apolipoprotein E–deficient (Apoe
–/–
) mice according to Kreisel et al.
24
 
and maintained in RPMI 1640 containing 20% FCS, 0.1% 2-mercaptoethanol 
and 50 μg/mL endothelial cell growth supplement (BD Biosciences, Franklin 
Lakes, NJ). Human aortic endothelial cells (HAoEC) were purchased from 
Promocell (Heidelberg, Germany) and cultured in proprietary MV2 media. Blood 
and tissue donations by humans and animals, respectively, were approved by 
the local ethics boards of the RWTH, LMU and Maastricht universities and the 
local governments. 
Stimulation and transfection of endothelial cells 
HAoEC were untreated, treated with TNF-α (10 ng/ml), without or with CCL2 
(100 ng/mL) or CXCL12 (500 ng/mL), or transfected with siRNA using a 
nucleofector
TM
 with a reagent kit for endothelial cells (Lonza, Basel, 
Switzerland). The cells were subsequently cultured in 5 µM pore size 
Transwell
®
 filters (Corning, Tewksbury, MA) or collagenized glass slides until 
confluency. MAoECs (JAM-A
+/+
 Apoe
–/–
 or JAM-A
–/–
Apoe
–/–
) were grown on 
collagenized glass slides and were activated for at least 4 h with TNF-α 
(25 ng/ml). For some experiments, JAM-A
–/–
Apoe
–/–
 MAoECs were transfected 
with siRNA or a pcDNA3-based expression vector containing a cDNA for human 
JAM-A using a nucleofector. Cells were analyzed by flow cytometry with proper 
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gating and appropriate isotype controls on a FACSCalibur (BD Biosciences, 
Franklin Lakes, NJ).  
Transendothelial migration experiments 
Real time measurement - Human monocytes (0.7×10
6
/ml) or T cells 
(0.5×10
6
/ml) were untreated or treated with oxLDL (10 µg/ml, 16 h) and were 
applied on HAoEC or MAoECs untreated or treated with JAM-A.Fc, 
JAM-A D1.Fc, JAM-A D2.Fc (all 15 µg/mL) without or with LDL, oxLDL (both 
10 µg/ml, 16 h), TNF-α and IFN-γ (10 ng/ml and 20 ng/ml, 4 h, respectively) or 
oxLDL plus JAM-A.Fc (10 µg/ml, 15 min) under shear stress (1.5 dyn/cm
2
) 
using a syringe pump (WPI, Berlin, Germany) in a laminar flow chamber for 
5 min and flushed with assay medium for 2 min. After flushing, time-lapse 
images were recorded (Cell
M
 system, Olympus, Tokyo, Japan). Leukocytes 
showing transmigration were counted and related to adherent cells. 
Transwell
®
 assay - PBMC (1x10
5
) were added in the filter inserts containing 
confluent HAoEC and were allowed to transmigrate towards CCL2 (100 ng/mL) 
or CXCL12 (500 ng/mL) to attract monocytes or T cells, respectively, for 90 min 
at 37°C. The transmigrated leukocyte subtypes were gated and counted using 
flow cytometry. 
Fluorescent bead assay 
HAoEC were treated without or with LDL, oxLDL (both 10 µg/ml, 16 h) or TNF-α 
and IFN-γ (10 ng/ml and 20 ng/ml respectively, 4 h) in the absence or presence 
of cytochalasin D, jasplakinolide (both 50 nM, 24 h), lovastatin or pioglitazone 
(both 1 µM, 24 h preincubation) and were subsequently incubated with 
fluorescent microbeads (~1 µm diameter) coupled to JAM-A antibodies 
(clone 246) or IgG control for 30 min. Nuclei were stained with HOECHST 
33342. After washing, bright field and fluorescent images were recorded.  
Cell permeability assay 
Confluent HAoEC grown in a Transwell
®
 filter system were treated without or 
with LDL, oxLDL (both 10 µg/ml, 16 h), TNF-α and IFN-γ (10 ng/ml and 
20 ng/ml, 4 h, respectively), thrombin (1 U/ml, 4 h) or histamine (50 µM, 4 h). 
After washing, a solution of 70 kDa dextran coupled to FITC (0.5 mg/ml in 
HBSS) was subjected to the filter insert for 90 minutes at 37°C. Subsequently, 
fluorescence intensity in the bottom well was measured and normalized to 
untreated control. 
Co-Immunoprecipitation and Western blotting 
Co-Immunoprecipitation and Western blotting was performed as described
20
. 
Briefly, HAoEC were treated without or with oxLDL (10 µg/ml, 16 h) or TNF-α 
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and IFN-γ (10 ng/ml and 20 ng/ml respectively, 4 h) and subjected to lysis buffer 
on ice for 30 minutes (50 mM TrisHCl pH 8.0, 150 mM NaCl, 2% Triton-X100, 
protease inhibitor cocktail). Lysates were incubated overnight with total 2 µg 
anti-JAM-A antibody (clone mAb F11) following to antibody capture with 
magnetic beads coupled to Protein-G (Miltenyi, Bergisch Gladbach, Germany). 
Immunocomplexes were purified using MACS µ-columns (Miltenyi, Bergisch 
Gladbach, Germany) and subsequently precipitated with SDS-loading buffer. 
After Western blotting ZO-1 protein was detected using a polyclonal antibody 
against ZO-1 (Hycult Biotech, Uden, Netherlands). 
Confocal microscopy 
HAoEC were treated without or with oxLDL (10 µg/ml, 16h) or TNF-α and IFN-γ 
(10 ng/ml and 20 ng/ml, 4 h, respectively) in the absence or presence of 
cytochalasin D, jasplakinolide (both 50 nM, 24 h), lovastatin or pioglitazone 
(both 1 µM, 24 h) and stained with an anti-JAM-A antibody (10 µg/ml, 2 h, 
clone mAb F11) followed by secondary antibody staining (anti-mouse IgG 
Alexa 594, 1 µg/ml, 1 h). Subsequently, cells were permeabilized and incubated 
with FITC-coupled phalloidin (1 µg/ml, 1 h). Finally, cells were visualized using a 
Leica SP5MP microscope set in confocal mode. 
Statistical analysis 
Statistical analysis was performed using Prism 6.0 (GraphPad Software). 
Means of 2 groups were compared by 2-tailed, unpaired Student’s t-test or 
non-parametric Mann-Whitney U test. Means of more than 2 groups were tested 
by 1-way ANOVA with Tukey's or Bonferroni's post-test or non-parametric 
Kruskal-Wallis test with Dunn's post test, where applicable. Differences with 
P<0.05 were considered as statistically significant.
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Results  
Endothelial JAM-A mediates transendothelial migration of mononuclear cells 
In order to further characterize the role of endothelial JAM-A in the 
transendothelial migration of T cells and monocytes, its expression in HAoEC 
was attenuated by transfection with specific siRNA and appropriate controls. 
This resulted in an approximately 50% decrease of JAM-A surface expression, 
compared to the control siRNA (Fig. 1A). Interestingly, a decreased JAM-A 
expression also diminished T cell and monocyte transmigration towards 
CXCL12 or CCL2, respectively (Figure 1B,C). A similar, albeit slight, reduction 
in   transmigration   was   observed   when   human   T  cells   were   allowed  to  
 
Figure 1: Endothelial JAM-A mediates transendothelial migration of mononuclear cells.  
FACS histograms of JAM-A expression before (b) or after (a) transfection with siRNA and isotype 
(grey trace) and unstained (black trace) HAoEC (A). Transmigration of T cells towards CXCL12 (B) 
or of monocytes towards CCL2 (C) through HAoEC transfected with lamin or JAM-A siRNA (n=4). 
Transmigration of T cells through JAM-A
+/+
, JAM-A
–/–
 MAoEC or JAM-A
–/–
 MAoEC transfected with 
human JAM-A (n=7-14) (D). 
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transmigrate over TNF-α-activated JAM-A-deficient mouse aortic endothelial 
cells, compared to wild type endothelial cells (Fig. 1D). Reconstitution of these 
JAM-A
–/–
 endothelial cells with human JAM-A restored the transmigration of 
T cells (Fig. 1D). 
Oxidized LDL increases endothelial permeability and induces cytoskeletal 
rearrangement as well as JAM-A redistribution.   
The involvement of JAM-A in the transendothelial migration of monocytes and 
T cells through aortic endothelial cells raised the question whether JAM-A could 
play a role in the recruitment of mononuclear cells under atherogenic 
conditions. As a model, endothelial cells were treated with oxLDL. In the 
presence of oxLDL, the permeability of HAoEC monolayers was increased 
almost to the extent of that observed with potent agents e.g. histamine, 
thrombin and TNF-α/IFN-γ, while native LDL did not affect permeability 
(Fig. 2A). To investigate if treatment with oxLDL causes a redistribution of 
JAM-A on the endothelial surface, a fluorescent bead assay was used. Due to 
steric effects, junctionally located JAM-A is unavailable for binding to the 
antibody-coupled beads, making this assay specific for apically located JAM-A. 
Treatment with TNF-α/IFN-γ, an established trigger for JAM-A redistribution, 
increased the amount of surface-bound beads (Fig. 2B). Unlike native LDL, 
oxLDL also caused a notable increase in cellular bead count, indicating JAM-A 
redistribution under atherogenic conditions. Confocal microscopy of JAM-A and 
actin filaments in HAoEC under quiescent conditions revealed a predominantly 
junctional pattern of JAM-A staining and directed actin fibers without 
colocalization (Fig. 2C), while stimulation with TNF-α/IFN-γ resulted in an 
increase of apical JAM-A localization and elongated cellular actin yet no notable 
colocalization (Fig. 2D). After stimulation with oxLDL, a considerable amount of 
JAM-A was located outside of the junctions. Interestingly, focal JAM-A staining 
was also observed that robustly colocalized with accumulations of actin fibers, 
indicating that JAM-A might form clusters that facilitate leukocyte recruitment 
(Fig. 2E). Immunoprecipitation of JAM-A revealed that treatment of HAoEC with 
oxLDL increased its association with the junctionally located cytoskeletal anchor 
protein ZO-1 (Fig. 2F), indicating an increased connection of JAM-A to the 
cytoskeleton. Destabilization of filamentous actin by cytochalasin D resulted in 
an increased amount of beads bound to the surface of the HAoEC and a 
pronounced apical localization of JAM-A (Suppl. Figure 1A,B). Inhibition of actin 
depolymerization by jasplakinolide on the other hand also resulted in an 
increased bead binding, possibly due to the formation of focal JAM-A and actin 
accumulations, similar as observed after oxLDL treatment (Suppl. Figure 1A,C). 
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Figure 2: OxLDL increases endothelial permeability and causes endothelial JAM-A 
redistribution. 
Endothelial permeability expressed as percentage of untreated controls of HAoEC after treatment 
with TNF-α/IFN-γ, oxLDL, LDL, thrombin or histamine (n=8) (A). Adhesion of control IgG or 
anti-JAM-A antibody-coupled fluorescent beads to HAoEC after treatment with LDL, oxLDL or 
TNF-α/IFN-γ (n=5-12) (B). Confocal micrographs of HAoEC after staining for JAM-A (red) or actin 
(green) under control conditions (C) or after treatment with TNF-α/IFN-γ (D) or oxLDL (E). Scale 
bars: 30 µm. Co-immunoprecipitation of JAM-A with specific ZO-1–antibodies from HAoEC under 
quiescent conditions or after activation with TNF-α/IFN-γ or oxLDL (F). 
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Oxidized LDL increases transendothelial migration of mononuclear cells. 
Under conditions of flow stasis, treatment of HAoEC with oxLDL, but not with 
native LDL, significantly increased the transmigration of both monocytes and 
T cells, albeit to a lower extent as after TNF-α/IFN-γ stimulation (Fig. 3A-F). The 
oxLDL-induced increase in transendothelial migration was effectively reversed 
by treatment of endothelial cells with JAM-A.Fc, whereas this did not influence 
diapedesis after LDL-treatment (Fig. 3A,D). Incubation of the mononuclear cells 
with oxLDL did not increase transmigration, confirming the specific role of 
endothelial JAM-A in this process (Fig. 3A,D). To address the roles of the 
extracellular domains of JAM-A and to rule out any unspecific 
Fc-receptor-mediated effects, HAoEC were treated with blocking Fab fragments 
against domain 1 or domain 2 of JAM-A, or the mononuclear cells with a 
blocking Fab against CD11a prior to transmigration over oxLDL or TNF-α/IFN-γ 
stimulated HAoEC. Both extracellular domains appeared to be involved in the 
transmigration of monocytes and T cells after stimulation with either oxLDL or 
TNF-α/IFN-γ, with an over 50% reduction of transmigration events in the 
presence of blocking Fabs (Fig. 3B,C and 3E,F). 
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Figure 3: OxLDL-treatment induces transendothelial migration of mononuclear cells. 
Transendothelial migration of monocytes (A-C) or T cells (D-F) through HAoEC under the indicated 
conditions (n=3-6). 
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Anti-inflammatory treatment attenuates JAM-A redistribution and mononuclear 
cell transmigration. 
Since atherogenic conditions caused a re-localization of endothelial JAM-A with 
an accompanying increase in mononuclear cell transmigration, we were 
interested whether these effects could be counteracted by the action of 2 
classes of established therapeutics for the treatment of cardiovascular disease. 
From the class of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
inhibitors (statins), the active compound lovastatin was chosen. Pre-treatment 
of the HAoEC with lovastatin for 24 hours lowered baseline adhesion of 
anti-JAM-A–coupled beads and prevented bead adhesion after stimulation with 
oxLDL or TNF-α/IFN-γ (Fig. 4A). This observation was supported by confocal 
microscopy, where lovastatin prevented the relocalization of JAM-A after 
inflammatory stimulation, leaving the majority of JAM-A localized in the cell-cell 
contacts (Fig. 4B-D). In addition, lovastatin treatment of HAoEC almost 
completely abrogated the oxLDL-induced transmigration of both monocytes and 
T cells and strongly (>50%) reduced the transmigration of monocytes after 
TNF-α/IFN-γ–stimulation, while leaving that of T cells unaffected (Fig. 4E, F). 
This indicates that the prevention of JAM-A–mediated leukocyte recruitment 
might be one of the anti-inflammatory actions of statins. In contrast to statins, 
the peroxisome proliferator activated receptor gamma (PPAR) agonist 
pioglitazone was unable to prevent the oxLDL- and cytokine-induced 
redistribution of JAM-A (Fig. 5A-D) and prevented the transmigration of 
monocytes, but not of T cells, through HAoEC only after 
TNF-α/IFN-γ-stimulation (Fig. 5E,F). Thus, PPAR-activation does not 
counteract oxLDL-induced endothelial activation, at least at the level of JAM-A 
redistribution and leukocyte recruitment. 
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Figure 4: Lovastatin counteracts inflammatory JAM-A redistribution and diapedesis. 
Adhesion of control IgG or anti-JAM-A antibody-coupled fluorescent beads to HAoEC after 
treatment without or with oxLDL or TNF-α/IFN-γ in the absence or presence of lovastatin (n=3-4) 
(A). Confocal micrographs of HAoEC after staining for JAM-A (red) or actin (green) after treatment 
with lovastatin without (B) or with oxLDL (C) or TNF-α/IFN-γ (D). Scale bars: 30 µm. 
Transendothelial migration of monocytes (E) or T cells (F) through HAoEC after treatment without or 
with oxLDL or TNF-α/IFN-γ in the absence or presence of lovastatin (n=3-10). 
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Figure 5: Effects of pioglitazone on JAM-A localization and diapedesis. 
Adhesion of control IgG or anti-JAM-A antibody-coupled fluorescent beads to HAoEC after 
treatment without or with oxLDL or TNF-α/IFN-γ in the absence or presence of pioglitazone (n=3-4) 
(A). Confocal micrographs of HAoEC after staining for JAM-A (red) or actin (green) after treatment 
with pioglitazone without (B) or with oxLDL (C) or TNF-α/IFN-γ (D). Scale bars: 30 µm. 
Transendothelial migration of monocytes (E) or T cells (F) through HAoEC after treatment without or 
with oxLDL or TNF-α/IFN-γ in the absence or presence of pioglitazone (n=3-10). 
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Discussion 
In this study, we have demonstrated that rearrangement of endothelial JAM-A 
facilitates the transmigration of mononuclear cells under atherogenic conditions. 
It is well established that JAM-A redistributes from the endothelial junctions to 
the surface of the cells. Already in the 1990s, Ozaki and colleagues 
demonstrated that a potent inflammatory stimulus, such as a combination of 
TNF-α and IFN-γ caused junctional JAM-A to become dispersed in endothelial 
cells
4
. Through the determination of triton-X100 soluble and insoluble fractions 
in later studies, this dispersal was attributed to a disconnection of JAM-A from 
the cytoskeleton
1, 21
. However, our microscopy observations of arterial 
endothelial cells suggest that JAM-A and filamentous actin are generally not 
colocalized, neither under quiescent conditions nor after stimulation with TNF-α 
and IFN-γ, speaking against a connection of JAM-A with the cytoskeleton under 
these conditions. This might appear to conflict with the previous observations 
from Bruewer et al. and Martinez-Estrada and colleagues. Yet in both studies, a 
large pool of triton-X100–soluble JAM-A was observed also under quiescent 
conditions, which decreased further after stimulation with cytokines
1, 21
. Thus, 
JAM-A might have an alternative cytoplasmic anchorage that modulates its 
cellular localization.  
 Interestingly, treatment with oxLDL resulted in a notable colocalization 
of JAM-A with actin fibers in focal cytoplasmic arrangements and showed an 
increased association with the cytoskeletal anchor ZO-1, compared with 
quiescent and cytokine-treated cells. Thus, JAM-A might actively associate with 
the cytoskeleton under atherogenic conditions, yet might also move out of the 
junctions, causing the junctional JAM-A staining to become more diffuse. 
Interestingly, both after treatment of the endothelial cells with oxLDL or 
cytokines, the permeability rose, the junctional localization of JAM-A decreased 
and JAM-A became available to fluorescent beads coupled with a specific 
antibody. Thus, inflammatory activation of endothelial cells does lead to an 
increased availability of JAM-A. This availability was reflected by an increased 
transendothelial migration of both monocytes and T cells. Accordingly, a 
downregulation of JAM-A expression led to a decreased transmigration of 
mononuclear cells and reconstitution of JAM-A
–/–
 murine endothelial cells with 
JAM-A restored T cell diapedesis, highlighting the important role of endothelial 
JAM-A in leukocyte transmigration. A recent study revealed that stimulation of 
human umbilical endothelial cells (HUVEC) with TNF-α and IFN-γ resulted in an 
increased concentration of JAM-A near the intercellular junctions
22
. Hence, 
JAM-A might guide mononuclear cells to transmigration sites on activated 
endothelium, similar as what was shown for ICAM-1
25
.  
 In a previous study by Woodfin and colleagues, the important role of 
endothelial JAM-A in transmigration was demonstrated and the function of 
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JAM-A appeared to depend on the inflammatory stimulus
6
. This finding is 
supported by our observations that oxLDL and TNF-α and IFN-γ differentially 
influence endothelial JAM-A localization. The authors could further demonstrate 
that neutrophils showed incomplete transmigration in the absence of JAM-A
6
, a 
finding that was corroborated by our recent study, showing that this 
phenomenon specifically occurred in JAM-A–deficient leukocytes, but not in 
endothelial cells lacking JAM-A
15
. Since JAM-A can undergo both homophilic 
and heterophilic interactions
5
, the question about the counterligand for JAM-A 
remained open. By using specific Fab-fragments, an involvement of both the 
first or second extracellular domains of JAM-A in the transmigration of T cells 
and monocytes could be demonstrated. From this observation, the presently 
known counterligands for JAM-A can be inferred, since extracellular domain 1 is 
involved in interactions with JAM-A and the second domain mediates binding to 
LFA-1
8, 26
. It is conceivable that both homo- and heterophilic interactions are 
involved in the complex molecular process of transmigration, yet this notion is 
subject to future investigation and would add a further dimension to the cell- and 
stimulus-specific roles of JAM-A in transmigration.  
 Since inflammatory cell recruitment is a key driving force in 
atherogenesis, a role for JAM-A in plaque formation was hypothesized over a 
decade ago
27
. Subsequent work revealed an upregulation of JAM-A in 
atherosclerotic specimen from mice and humans
7, 12
 and levels of soluble 
JAM-A were increased in patients with atherosclerosis and hypertension, 
compared to healthy individuals
11, 28
. Recently, JAM-A was found to be 
upregulated in the brains of hypertensive rats and also in vein specimen of 
humans with hypertension
29
. Although these studies strongly hinted towards a 
role for JAM-A in cardiovascular disease, a direct causative role for JAM-A 
remained undefined. This might be explained by our recent observations in 
hyperlipidemic mice with a somatic deficiency of JAM-A, which showed no 
differences in plaque formation compared with JAM-A–positive mice
15
, 
indicating that JAM-A–deficiency might affect different cell types in a differential 
manner. This notion was supported by specific genetic deletion of endothelial 
JAM-A, which significantly delayed lesion progression due to a decreased 
diapedesis of mononuclear cells. The role of endothelial JAM-A during 
atherogenesis could thus be perceived as a guiding beacon, since conditions of 
aberrant flow, such as occurring in predilection sites for atherosclerosis led to a 
dispersal of endothelial JAM-A, in turn leading to an increased influx of 
monocytes
15
. The observation that oxLDL increases the transmigration of both 
T cells and monocytes over HAoEC in a JAM-A–dependent manner further 
supports a role of this adhesion molecule in atherosclerosis. Given the anti-
inflammatory effects of statins and PPAR-agonists and their benefit for 
cardiovascular diseases
30
, we were interested whether treatment of the 
endothelial cells with such compounds could revert the inflammatory 
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redistribution of JAM-A. Treatment with lovastatin effectively counteracted the 
oxLDL-induced dispersal of JAM-A on HAoEC and reduced transendothelial 
migration of mononuclear cells to background levels. Given the role of JAM-A in 
atherosclerotic disease, the counteraction of vascular JAM-A rearrangement 
might be a novel functional aspect of statins, besides their established 
lipid-lowering activity. Interestingly treatment with pioglitazone, which also 
exerts anti-inflammatory effects, neither reduced JAM-A redistribution nor the 
subsequent transmigration of mononuclear cells, indicating a minor involvement 
of PPAR in these JAM-A–related processes. 
In conclusion, this study demonstrates that redistribution of JAM-A in 
endothelial cells after stimulation with atherogenic oxidized lipoproteins results 
in increased transmigration of mononuclear cells. This inflammatory dispersal of 
JAM-A could be counteracted with statins, revealing a novel aspect of their 
mechanism of action. 
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Supplementary Figure 
 
Supplementary figure 1: Role of cytoskeletal integrity on the cellular localization of JAM-A. 
Adhesion of control IgG or anti-JAM-A antibody-coupled fluorescent beads to HAoEC after 
treatment with cytochalasin D or jasplakinolide (n=5-13) (A). Confocal micrographs of HAoEC after 
staining for JAM-A (red) or actin (green) after treatment with cytochalasin D (B) or jasplakinolide (C). 
Scale bars: 30 µm. 
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 Cytokines promote lymphocyte adhesion facilitating junctional TEM:  
In chapter 2 and 3, we provided evidence for endothelial JAM-A re-localization 
and its subsequent result on leukocyte recruitment under atherogenic 
conditions. In chapter 2, we showed an increase of apical JAM-A under 
atherogenic conditions as well as a focal clustering of apical JAM-A ex vivo. In 
chapter 3, we verified those results by performing in vitro immuno-fluorescence 
staining and expanded them by further mechanistical details. In order to detect 
the exact site of endothelial JAM-A re-localization and to determine its 
consequence on mononuclear cell recruitment, a follow-up study resolving 
endothelial JAM-A localization with higher accuracy is desirable. 
 Additional to the results presented in this thesis, preceding studies were 
able to provide evidence for JAM-A re-localization to the apical area of 
endothelial cells under inflammatory conditions, representing a chronic 
modality
1, 2
, as well as rapid JAM-A re-localization after transient leukocyte 
adhesion
3, 4
. 
With the following chapter 4, we further investigated the effect of 
JAM-A re-localization under inflammatory conditions observed in chapter 2 
and 3. We therefore examined the effect of cytokine-triggered JAM-A re-
localization on junctional T cell transendothelial migration. By performing single 
cell force spectroscopy and atomic force microscopy assisted homophilic JAM-
A adhesion mapping of endothelial cells we endeavored to obtain more precise 
information on JAM-A location after inflammatory stimulation.   
 3 
4 
Contribution to the manuscript (chapter 4): 
Martin Schmitt designed, conducted and evaluated transmigration assays, 
which are essential for the conclusion of this study. Additionally, Martin Schmitt 
prepared Supplemental movie 1, showing junctional transendothelial migration 
of a monocyte, which crucially contributes to authors’ assumptions. 
Furthermore, Martin Schmitt wrote part of the manuscript.  
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Abstract 
Inflammatory conditions induce redistribution of junctional adhesion receptors 
toward the apical regions of endothelial cells promoting lymphocyte 
transendothelial migration (TEM). Much of the molecular structures of TEM 
have been revealed, however, the biophysical mechanisms underlying this 
process remain to be fully elucidated. Here, we used immunofluorescence 
microscopy and atomic force microscopy (AFM) to study endothelial distribution 
of adhesion molecules upon lymphocyte activation and transmigration. Our 
immunofluorescence results revealed redistribution of both JAM-A and 
PECAM-1, but not ICAM-1 or VCAM-1, toward the apical junctional regions of 
HUVECs following a 6 hour stimulation with TNF- and IFN- Consistently, our 
single cell force spectroscopy (SCFS) studies revealed that Jurkat cell adhesion 
to stimulated HUVEC monolayers was significantly greater in junctional regions. 
Enhanced adhesion was mostly mediated by JAM-A receptors. Further AFM 
adhesion mapping of the homophilic JAM-A/JAM-A interaction on the surfaces 
of HUVECs revealed a greater number of JAM-A receptors available for binding 
along junctional regions after TNF- and IFN- stimulation. Our data reveal for 
the first time that adhesion “hot spots” of JAM-A receptors are involved in 
initiating lymphocyte TEM under inflammatory conditions. 
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Introduction 
Inflammation leads to recruitment of leukocytes from the circulation into injured 
tissues. This process involves leukocyte adhesion to the endothelium and 
subsequent transendothelial migration (TEM) into the interstitial space. Initial 
leukocyte capture by the endothelium is mediated by interaction of glycosylated 
ligands and the very-late antigen-4 (VLA-4) on the leukocyte surface with 
selectins and the vascular adhesion molecule-1 (VCAM-1), respectively, in the 
vascular wall
5, 6
. Subsequently leukocytes undergo firm adhesion mediated by 
integrin interaction with members of the immunoglobulin superfamily
7
. This is 
particularly enhanced under inflammatory conditions where interaction of L2 
or leukocyte function associated antigen-1 (LFA-1) with intercellular adhesion 
molecule-1 (ICAM-1) play a primary role during firm adhesion
8
. The arrested 
leukocyte then transmigrates through the endothelium to the underlying 
connective tissue employing paracellular or transcellular TEM
9, 10
. Paracellular 
TEM occurs between two adjacent endothelial cells, while transcellular TEM 
occurs through the endothelial cell.  
This work addresses the predominant paracellular pathway mediated by 
junctional adhesion receptors. The endothelial junctions consist of the tight 
junctions and the more permeable adherens junctions
11, 12
. The integrity of 
these junctions is maintained via homophilic interactions of adhesion receptors 
between adjacent endothelial cells. These junctional receptors are linked to 
intracellular partners that mediate cytoskeletal anchorage and stabilize the 
junction. Junctional Adhesion Molecules (JAMs) maintain the integrity of tight 
junctions. Adherens junctions are stabilized by vascular endothelial 
(VE)-cadherins, which are associated with the actin cytoskeleton via catenins, 
platelet endothelial cellular adhesion molecule-1 (PECAM-1, CD31) and CD99.  
The molecular processes associated with transmigration are complex 
as they involve binding events between leukocytes and endothelial cells. The 
migrating leukocyte encounters a number of different adhesion complexes in 
the endothelial junction that have to be disrupted. An important early event in 
transmigration is LFA-1 binding to JAM-A
13
. JAM-A is a 32kD immunoglobulin 
superfamily receptor consisting of two domains, domain 1 (D1) capable of 
binding to other JAM-A receptors and domain 2 (D2) capable of binding to 
LFA-1
13-15
. LFA-1/JAM-A interaction is essential in initiating TEM. It has been 
hypothesized that a trimeric complex forms between LFA-1 and junctional 
JAM-A/JAM-A. Indeed, the binding of lymphocyte LFA-1 to junctional 
JAM-A/JAM-A complex has been shown to weaken the JAM-A homophilic 
interaction and thus potentially facilitating cell entry into the junction
3, 13, 16-18
. 
Further migration of leukocytes through the junction involves two other adhesion 
receptors, PECAM-1 and CD99
9, 19, 20
. PECAM-1 is also member of the 
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immunoglobulin superfamily and consists of six Ig domains
21
. In vitro and in vivo 
studies have shown that homophilic PECAM-1 interaction between junctional 
endothelial cells and transmigrating leukocytes via D1 has been shown to play 
essential role in progression of TEM
9, 19, 22, 23,
 
24
.  
The next step in the transmigration process involves CD99 receptor. 
CD99 is a 32kD transmembrane protein expressed on the surface of leukocytes 
and endothelial cells resulting in homophilic binding of leukocytes to junctional 
endothelial cells 
20
. The last step allows leukocytes to migrate across the 
subendothelial basal lamina out of the junction into the interstitial space. This is 
achieved through heterophilic interaction of domain 6 of junctional PECAM-1 
with integrin v3 receptors on the leukocyte surface
25, 26
. A recent study 
confirmed that adhesion molecules do act in sequence to facilitate leukocyte 
TEM by demonstrating that neutrophil TEM following IL-1 treatment was 
mediated by ICAM-2, JAM-A and PECAM-1, respectively
27
. 
Transmigration of leukocytes is enhanced under inflammatory 
conditions induced experimentally through TNF- and IFN- injection in vivo
28
. 
TNF- and IFN- treatment leads to a number of changes in the endothelium 
that affect leukocyte binding. While endothelial surface expression of selectins, 
ICAM-1, and VCAM-1 has been shown to increase upon endothelium activation, 
PECAM-1 and JAM-A are thought to redistribute to different regions of the cells 
possibly through diffusion in the plasma membrane and/or transient 
internalization and re-expression at different sites
1, 12, 29-33
. Overall, TNF- and 
IFN- stimulation has been shown to promote leukocyte adhesion and TEM in 
various experimental models
28, 34-37
. These in vitro and in vivo studies suggested 
a modest to substantial increase in TEM, the extent of which seems to depend 
on stimulation time, with reduced effects for treatments exceeding 18 hours. 
Cytokine stimulation also was shown to promote endothelial cytoskeletal 
changes and increased endothelial permeability
29, 34, 38, 39
 . While these studies 
have provided us with insight into the molecular players of TEM and the impact 
of cytokine treatment on leukocyte trafficking, the biophysical mechanisms 
mediating TEM have not been fully elucidated. Although we know that cytokine 
treatment enhances leukocyte endothelial adhesion, the preferred regions for 
adhesion of a single leukocyte to an endothelial cell have not been identified. 
This work employed Atomic Force Microscopy (AFM) to provide a molecular 
level glimpse of lymphocyte-endothelial cell interactions. We show for the first 
time that redistribution of key adhesion receptors to junctional “hot spots” 
enhance lymphocyte interaction with junctional regions of stimulated HUVEC 
monolayers and promote their transendothelial migration
40-42
. 
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Methods 
Isolation of peripheral blood T cells 
Human venous blood was obtained from healthy volunteers according to ethical 
regulations. CD4
+
 T cells were directly purified from whole blood using 
Flowcomp
®
 Human CD4 Dynabeads (Life Technologies, Carlsbad, CA) 
according to manufacturer’s instructions. Flow cytometry analysis confirmed the 
purity of the isolated cells (>90%). For the video transmigration experiment (see 
below), the T cells were cultured up to 48 hours in RPMI medium containing 
10% fetal bovine serum and 25 ng/ml interleukin 2 in a humidified CO2 
incubator at 37 °C. 
Transmigration of primary T cells 
Human umbilical vein endothelial cells (HUVEC, PromoCell Heidelberg, 
Germany) were cultured in proprietary medium (PromoCell) until confluency in 
porous filter inserts (5 µM pore size Transwell
®
, Corning, NY) or 35 mm 
petridishes and activated for 6 h with TNF- (10 ng/ml) and INF- (20 ng/ml). 
After 6 h the cytokines were removed and the HUVECs were washed before 
isolated primary CD4
+
 T cells (1x10
6
/ml) were added in 100 µl (Transwell assay) 
or 2 ml (time lapse assay) RPMI1640 medium containing 1% human albumin 
(Baxter, Deerfield, IL). Where applicable, blocking antibodies (0.5 µg/mL) 
against JAM-A
18
, PECAM-1 (Santa Cruz Biotechnology, Santa Cruz, CA) or 
ICAM-1 (R&D Systems, Minneapolis, MN) or Fab fragments (10 µg/ml) 
generated by papain digestion of JAM-A antibodies (243-246) and anti-LFA-1 
mAb clone TS1/22 were added to the T cell suspension and T cells were 
subsequently allowed to transmigrate for 2 h in a humidified CO2 incubator at 37 
°C. The transmigrated T cells were identified and quantified by morphologic 
gating using flow cytometry (FACS Canto II, BD Biosciences, Franklin Lakes, 
NJ). Time lapse recordings were made in 30 s intervals for 60 min at 37 °C and 
at 10x magnification, using differential interference contrast (DIC) and a CCD 
camera on a TE 2000-E microscope (NIS Elements AR software, Nikon, Tokyo, 
Japan).  
Cells and cell culture 
Human T-leukemia Jurkat cell line was obtained from ATCC and maintained in 
RPMI 1640 medium supplemented with 10% FBS, 1% glutamine, 50 U/ml 
penicillin, and 50 µg/ml streptomycin in 5% CO2 at 37°C. HUVECs were 
purchased from Lonza Inc. and cultured in endothelial cell basal medium 
(EBM-2) supplemented with 2% FBS, hydrocortisone, human fibroblast growth 
factor, VEGF, IGF-1, ascorbic acid, human epidermal growth factor, 
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gentamicin-amphotericin, and heparin. HUVECs were plated on 35 mm tissue 
culture dishes (Becton-Dickinson; Franklin Lakes, NJ) coated with 25 µg/ml 
human fibronectin (overnight at 25°C). To activate the HUVECs, confluent 
monolayers were stimulated with TNF- (100 ng/ml) and IFN- (200 ng/ml) for 
6 h at 37°C, 5% CO2. 
Immunofluorescence and analysis 
Immunofluorescence images were acquired on HUVEC monolayers cultured as 
described above with and without permeabilization to exclusively visualize 
extracellular receptors. Confluent HUVEC monolayers were fixed in 4% 
paraformaldehyde, washed three times with blocking solution in PBS, incubated 
at room temperature for 1 h with primary antibodies (anti-ICAM-1, anti-JAM-A, 
or anti-PECAM-1) followed by appropriate secondary antibodies. Finally, culture 
dishes were washed extensively with PBS to remove excess unbound 
antibodies and the cells were kept submerged in PBS until imaging. 
Fluorescence confocal imaging was performed using an upright Leica DMLFSA 
microscope with long distance water-dipping lenses (Leica HXC APO 20x 0.5W, 
40x 0.8W). Z-stacks of confocal images were acquired with 0.5 µm spacing and 
different zoom factors using the same acquisition parameters (e.g., laser power, 
gain, etc). Images were shown as maximum projections unless otherwise 
stated. 
 To measure changes in the distribution patterns of extracellular 
receptors on the surface of HUVECs after stimulation, we measured the volume 
of the immunostain of the different receptors based on fluorescence intensity 
and quantified the relative co-distribution of JAM-A with ICAM-1 or PECAM-1 
receptors. The receptor co-distribution was calculated based on the “intersect” 
(i.e., overlap) values (µm
3
) of the corresponding immunostains normalized to 
the volume of the analyzed 3D images 
43, 44
. It should be noted that this analysis 
is an indirect measure of the co-distribution, not co-localization, of the surface 
receptors as the spatial resolution of our images precludes the latter. The 
images showed that ICAM-1 maintained relatively constant, diffuse distribution 
on HUVEC surface with and without stimulation. By contrast, there was evident 
change in the distribution pattern of JAM-A before and after stimulation; 
whereas, it had a diffuse distribution similar to that of ICAM-1 in unstimulated 
HUVECs, JAM-A was predominantly expressed on the periphery of stimulated 
cells. Although all images were obtained using the same acquisition 
parameters, we did not quantify expression levels of the different receptors 
based on fluorescence intensity of immunostains; instead, we opted for a 
conservative approach by using the co-distribution analysis to estimate changes 
in JAM-A and PECAM-1 distribution relative to that of ICAM-1, which remained 
relatively constant before and after stimulation. Therefore, given that JAM-A 
expression was predominantly at the periphery of stimulated HUVEC, an 
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increase in the co-distribution (i.e., intersect) of JAM-A with ICAM-1 was 
interpreted as increased presence of JAM-A in the junctional regions. The 
analysis was performed automatically in Volocity (Perkin Elmer) based on 
fluorescence intensity using built-in proprietary algorithms with user feedback. 
Detection threshold was set to 3-5 standard deviations (SD) depending on the 
channel
45
. Data were derived from 4-8 images for each condition and presented 
as mean ± standard error (SEM).  
Single cell force spectroscopy (SCFS) studies 
SCFS studies were carried out by attaching a single cell to an AFM cantilever 
(Brukernano). Cantilevers with nominal spring constant of 10 pN/nm were used 
in all experiments. Experimental spring constants were calculated using the 
method described by Hutter and Bechhoefer and ranged from 6 to 15 pN/nm
46
. 
Attaching the cell to an AFM cantilever tip was accomplished by 
Concanavalin-A (Con-A) mediated linkages as most cells have Con-A surface 
receptors
47
. To prepare the Con-A functionalized cantilever, the cantilevers 
were soaked in acetone for 5 min, UV-irradiated for 10 min and incubated in 
biotinamidocaproyl-labeled bovine serum albumin (biotin-BSA, 0.5 mg/ml in 
100 mM NaHCO3, pH 8.6; Sigma) overnight at 37 C. The cantilevers were then 
rinsed three times with PBS and incubated in streptavidin (0.5 mg/ml in PBS; 
Pierce; Rockford, IL) for 10 min at room temperature. Unbound streptavidin was 
removed by thorough rinsing in PBS. The cantilevers were then incubated in 
biotinylated Con-A (0.2 mg/ml in PBS; Sigma) and rinsed again with PBS prior 
to use. A single cell was attached to the cantilever by positioning the end of the 
Con-A-functionalized cantilever above the center of the cell and carefully 
lowering it onto the cell for approximately 1 s. When attached, the cell was 
positioned right behind the AFM tip of the cantilever
48
. Experiments were carried 
out by lowering the cantilever with the attached cell onto HUVEC monolayers. 
Measurements were acquired at a fixed rate of cantilever retraction (5 µm/s), 
applied force (200 pN) and contact time (2 s). Data was analyzed using Igor Pro 
6.0 software. Data are presented as mean ± SEM. 
AFM Adhesion Mapping 
Experiments were performed using MFP3D-Bio AFM (Asylum Research, Santa 
Barbara, CA, USA). Unstimulated and TNF-/IFN- stimulated HUVEC in 
culture media were probed with recombinant human JAM-A functionalized 
cantilevers at 37° C. Cantilevers were functionalized as described previously
18
. 
To prevent receptor redistribution during adhesion map acquisition, all HUVEC 
were fixed with 4% formaldehyde in PBS for 30 min at room temperature. 
Adhesive interactions were blocked with function blocking antibody directed 
against D1 of JAM-A (100 µg/ml, 60 min). Force-distance adhesion force scans 
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were acquired at a constant velocity (4 µm/s) and a maximum applied force of 
~200 pN. Adhesion maps were obtained over a scanning region ranging from 
40-90 µm
2 
and were composed of up to 9000 force-distance curves acquired in 
a square pattern of 32-96 curves along each side of the square scanned area. 
Statistical analysis  
For statistical comparisons we used Student’s t-test (to compare two samples) 
or one-way ANOVA (to compare multiple samples) followed by multiple 
comparison procedures with the Holm-Sidak method (SigmaStat; Systat, CA). 
Data were presented as means ± SEM. Asterisks indicate p value < 0.05. 
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Results  
Transmigration assay across HUVEC monolayer 
The effects of inflammation on transendothelial migration of lymphocytes were 
investigated. We conducted transendothelial migration assays of primary 
CD4
+
 T cells across TNF- and IFN- stimulated (6 h) and unstimulated HUVEC 
monolayers. T cell TEM across the junctions of stimulated HUVEC was 
visualized using real time video microscopy as shown in supplementary video 
file 1. The average number of migrating cells per mm
2
 increased significantly 
following HUVEC stimulation (Fig. 1AB). Blocking antibodies directed against 
JAM-A, PECAM-1, or ICAM-1 inhibited this increase down to the levels 
observed for unstimulated HUVEC (Fig.1A). Furthermore, anti-JAM-A Fab 
fragments were generated and used to block TEM. All JAM-A Fab fragments 
reduced TEM down to the level of untreated cells (Fig.1B). 
 
 
Figure 1: Transendothelial migration is enhanced following HUVEC stimulation. 
Transendothelial migration of CD4
+
 T cells was assayed across unstimulated (open bar) or 
TNF-/IFN--stimulated HUVEC (6 h, solid bars) by Transwell assay (A) or using real time video 
microscopy (B) at 37 °C and 5% CO2. Stimulation of HUVEC with TNF-/IFN- enhanced migration 
significantly. (A) Blocking antibodies (0.5 µg/ml) or (B) Fab fragments (10 µg/ml) against JAM-A 
(243-246), PECAM-1, ICAM-1 and LFA-1 (TS1/22) significantly reduced migration. Data represent 
mean ± SEM of at least 3 independent experiments. *P<0.05 vs. control. ** P<0.001 vs. stimulated 
HUVEC without antibody. 
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Extracellular JAM-A and PECAM-1 receptors redistribute toward HUVEC 
junctions following TNF- and IFN- stimulation.   
We next determined if receptor redistribution played a role in promoting 
lymphocyte TEM. We used immunofluorescence confocal imaging on HUVEC 
monolayers to determine the presence/distribution of adhesion receptors 
involved in mediating lymphocyte-endothelial adhesion. HUVEC monolayers 
were fixed with 4% PFA and immunostained for JAM-A, PECAM-1, or ICAM-1 
without permeabilization. We also performed dual immunostaining for 
ICAM-1/JAM-A or PECAM-1/JAM-A. Control experiments with isotype 
antibodies confirmed immunostaining specificity. All studies were performed 
using both unstimulated and TNF-/IFN- stimulated HUVECs. Confocal 
images spanning the monolayers showed that all receptors were present on the 
HUVEC surface in both conditions (Fig. 2A; also see Movies 2 and 3 in the 
online supplemental material). While JAM-A, ICAM-1, and PECAM-1 were 
diffusely distributed on unstimulated cells, stimulation (6 h) with TNF- and 
IFN- resulted in evident redistribution of JAM-A and PECAM-1, but not ICAM-1, 
receptors to the junctional regions. We next quantified the relative co-
distribution of JAM-A with that of ICAM-1 or PECAM-1 on unstimulated or 
stimulated dual-stained HUVEC monolayers by measuring the “intersect” 
(i.e., overlap) of the corresponding immunostains (Fig. 2B)
43, 44
. The nuclear 
stain (DAPI) was used as negative control in permeabilized monolayers. The 
intersect was used as an indirect measure of the relative co-distribution of the 
receptors to adjacent areas within the HUVEC membrane (see Methods). The 
intersect of ICAM-1 and JAM-A increased significantly following stimulation (6 h) 
(Fig.2B). Given that ICAM-1 surface expression did not appreciably change 
following stimulation (Fig. 2A) and that JAM-A appeared predominantly on the 
periphery of stimulated HUVECs, the relative increase in JAM-A distribution with 
ICAM-1 was interpreted as higher presence of JAM-A receptors in junctional 
regions. We performed similar analysis for PECAM-1 and JAM-A and found that 
PECAM-1 distribution did not differ from that of JAM-A before and after 
stimulation indicating that, similar to JAM-A, PECAM-1 expression was higher in 
junctional regions after TNF-α/IFN-γ treatment. 
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Figure 2: Adhesion receptor distribution on unstimulated and TNF-/IFN- stimulated HUVEC 
monolayers.   
(A) Unpermeabilized cells were immunostained for extracellular adhesion receptors (ICAM-1, 
JAM-A, or PECAM-1). Unstimulated and stimulated HUVECs were imaged using confocal image 
z-stacks spanning the monolayers. Images are shown as maximum projections. Scale bar = 50 µm. 
Unstimulated HUVECs exhibited diffuse staining on the cell surface for all receptors. Following 6 h 
stimulation with TNF- and IFN-, junctional staining for JAM-A and PECAM-1 receptors increased 
noticeably. (B) Intersect analysis in Volocity was used to quantify the relative co-distribution of 
JAM-A with that of ICAM-1 or PECAM-1. The results showed significantly increased co-distribution 
of JAM-A with ICAM-1 indicating increased expression of JAM-A in junctional regions on stimulated 
versus unstimulated HUVECs. No difference was observed for JAM-A/PECAM-1 indicating that 
PECAM-1 distributed in a similar pattern as JAM-A before and after HUVEC stimulation. Co-
distribution of PECAM-1 with the nuclear stain DAPI and of isotype antibody/DAPI served as 
controls. 
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SCFS reveals enhanced adhesion of Jurkat to junctional regions of stimulated 
HUVEC  
Motivated by our immunoimaging results, we performed SCFS studies between 
Jurkat cells and HUVEC monolayers cultured in Petri dishes as illustrated 
(Fig. 3 panel 1). The Jurkat cell was allowed to interact with either the HUVEC 
body or junctional region to determine if cell adhesion was enhanced at HUVEC 
junctional regions under inflammatory conditions. The Jurkat cell was attached 
to the AFM probe via Con-A-mediated linkages and lowered via the expansion 
of the piezoelectric translator onto the desired location on the HUVEC selected 
visually using the light microscope objective and camera located beneath the 
sample (Fig. 3). Following a 2 s contact with the HUVEC, the Jurkat cell was 
then retracted. This cycle was repeated up to 100 times for each cell assayed. 
Throughout the approach-retraction cycle, the AFM probe undergoes bending, 
leading to the deflection of a laser signal off the probe which is detected by the 
photodiode (Fig. 3). The result is a force-displacement record, or force scan.  
A typical AFM force-displacement record of the interaction between a 
Jurkat cell and activated HUVEC monolayer is presented (Fig. 4A. top trace). 
This represents one adhesion-detachment cycle of the Jurkat from the HUVEC 
as it is moved in the X-Y plane via the expansion and contraction of the 
piezoelectric translator (Fig. 3). The straight line represents zero force. Initially, 
as the Jurkat cell is lowered onto the HUVEC there is a slight increase in force 
(upward deflection along Y-axis), contact is achieved between the 2 cells and 
then the Jurkat cell is detached from the HUVEC. This typically results in 
stepwise rupture of adhesive contacts formed between the two cells as clearly 
seen in the second force-displacement record acquired on stimulated HUVEC 
depicted in Fig.4A. Each of these rupture events resulted in a rapid jump in 
force which correspond to the unbinding of one or more adhesive 
ligand-receptor bonds. The magnitudes of the force transitions are between 30 
and 80 pN and are consistent with the reported unbinding forces of individual 
selectin and integrin bonds
47, 49, 50.  
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Figure 3: Experimental system to study cell-cell or protein-cell interactions.   
A lymphocyte (Jurkat cell) was attached to the AFM silicon nitride probe via con-A linkages and 
lowered onto the HUVEC monolayer (panel 1). Alternately, JAM-A was cross-linked to the cantilever 
via 3-aminopropyl-triethoxysilane (panel 2). Cells were visualized via the objective and camera 
beneath the sample. The lymphocyte or JAM-A were lowered onto the HUVEC via the expansion of 
the piezoelectric translator (approach), allowed to make contact, and then the probe was retracted, 
breaking all contacts. A laser light was reflected off the probe onto a photodiode detector. The 
bending of the probe during the approach-retraction cycle resulted in laser deflection. These 
changes are detected by the photodiode and translated into a digital signal from which the force 
traces are derived. 
The extent of the adhesive interaction was measured by calculating the work of 
de-adhesion, or the work required to pull and stretch the cell and disrupt all 
receptor-ligand interactions. This parameter is represented by the shaded 
region of the top two traces shown in Fig. 4. Our measurements revealed that 
Jurkat cell adhesion was equivalent to both HUVEC regions under unstimulated 
conditions (Fig. 4B). The work of de-adhesion required to detach a Jurkat cell 
from an unstimulated HUVEC was 1.38 x 10
-16
  ±  0.42 J at the HUVEC center 
and 1.60 x 10
-16
  ±  0.45 J at the HUVEC junction (Fig. 4B). Following a 6 h 
stimulation of HUVEC with TNF- and IFN-, there was a significant increase in 
the measured work of de-adhesion at both the HUVEC center and junction as 
compared to that measured on unstimulated HUVEC (Fig. 4B) (p<0.002 for 
center, p<0.001 for junction). Interestingly, the most pronounced increase was 
observed at the junction, as evidenced by a significantly greater work of de-
adhesion represented by the filled gray region (Fig. 4A). The average measured 
work of de-adhesion required to detach a Jurkat cell from a stimulated HUVEC 
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center was 3.09 x 10
-16
 ± 0.55 J and 7.03 x 10
-16
 ± 0.58 J at the HUVEC junction 
(Fig. 4B) (p<0.001). This corresponds to a greater than 4-fold increase in overall 
adhesion at junctional regions, suggesting greater number of receptors 
available for binding following stimulation (Fig. 2). 
To determine the contribution of the various adhesion receptors toward 
mediating enhanced adhesion of Jurkat to TNF-/IFN--stimulated HUVEC, we 
carried out a series of experiments in the absence and presence of 
adhesion-blocking antibodies. We focused on the main receptors responsible 
for mediating firm adhesion of leukocytes to the endothelium, namely ICAM-1, 
and compared their contribution to that of JAM-A and PECAM-1 which are 
primarily responsible for leukocyte TEM (Fig. 4B). An antibody against ICAM-1 
was used to block the LFA-1/ICAM-1 interaction as Jurkat cells express LFA-1. 
ICAM-1 blockade reduced adhesion by ~25% at the HUVEC center 
(2.32 ± 0.41 x 10
-16
 J) and ~17% at the junction (5.87 ± 0.59 x 10
-16
 J) as 
compared to untreated stimulated HUVEC (p=<0.005 and <0.003, respectively). 
Thus, blocking key adhesion receptors for firm lymphocyte adhesion to the 
endothelium had a modest effect, particularly, at junctional regions. It is 
important to point out that this decrease in adhesion did not reveal large 
differences between the junction and the cell center. Two antibodies were used 
in conjunction to block all JAM-A interactions. One was directed against the 
second domain of JAM-A, thus blocking LFA-1/JAM-A heterophilic interactions, 
and the other directed against the first domain of JAM-A, blocking JAM-A 
homophilic interactions. Following the addition of both JAM-A antibodies, the 
measured work of de-adhesion was 1.92  ±  0.87 x 10
-16
 J at the HUVEC center 
and 0.82 ±  0.06 x 10
-16
 J at the junction. This is a ~38% decrease in adhesion 
at the center and ~88% at the HUVEC junction (p=<0.003 and <0.001, 
respectively). These results clearly indicate an important role for JAM-A 
interactions in lymphocyte adhesion to the endothelium and their recruitment 
into the endothelial junction under inflammatory conditions. Specifically, this 
indicates that JAM-A plays a more important role in mediating adhesion of 
lymphocytes in the junctional region than at the center of endothelial cells where 
ICAM-1 is more likely to be involved. 
Finally, an antibody directed against PECAM-1 was then used to block 
the v3/PECAM-1 interaction. PECAM-1 blockade reduced adhesion by 23% at 
the center (2.38 ± 0.34 x 10
-16
 J) and 33% at the junction (4.7 ± 0.40 x 10
-16
 J) 
as compared to untreated stimulated HUVEC (p=<0.005 and <0.002, 
respectively). The decrease in adhesion was slightly larger at the junction as 
expected. However, the role of this interaction was not as pronounced 
compared to JAM-A consistent with the notion that PECAM-1 homophilic and 
heterophilic interactions are more significant in other cell types such as 
neutrophils. 
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Figure 4: Measuring Jurkat-HUVEC 
interaction.   
(A) Representative AFM force scans showing 
de-adhesion forces under different conditions. 
The work of de-adhesion required to disrupt 
adhesion of Jurkat to TNF-/IFN--stimulated 
HUVEC is shaded (top two traces). Force scans 
measured at the HUVEC center, junction, and in 
the presence of JAM-A-function-blocking 
antibodies directed D1 and D2 to block 
JAM-A/JAM-A and JAM-A/LFA-1 interactions 
are shown. Measurements were acquired with a 
compression force of 200 pN, 2 s contact time 
and 5 µm/s cantilever retraction speed. Arrows 
in the second trace point to rupture events. 
Dashed line indicates zero force. Hundred force 
scans were acquired for each Jurkat cell 
measured. (B) Average work of de-adhesion of 
Jurkat cells measured on unstimulated or 
stimulated HUVEC monolayers. Measurements 
were conducted at the HUVEC junction (black 
bars) and center (gray bars). Blocking 
antibodies particularly against JAM-A reduced 
Jurkat adhesion to stimulated HUVEC 
(p=<0.001 for junction and P=<0.003 for center). 
Results for each condition represent over 
500 AFM force scans acquired from at least five 
independent experiments and are presented as 
means ± SEM. *P<0.005. 
 
AFM adhesion maps of JAM-A reveal adhesion “hot spots” following HUVEC 
stimulation 
Since JAM-A was chiefly responsible for Jurkat cell adhesion to the endothelial 
junctional region, we postulated that JAM-A may form adhesion “hot spots” that 
facilitate recruitment of lymphocytes into junctional regions (Figs. 1, 2, 4). We 
therefore conducted detailed AFM adhesion mapping of JAM-A adhesion 
distribution on the HUVEC surface. This requires systematic acquisition of 
adhesion force scans on the HUVEC surface as illustrated in Fig. 5A. Each 
recorded force scan provides information regarding the magnitude of the 
measured JAM-A adhesive interaction and its specific location on the HUVEC 
surface in the X-Y-Z planes (Fig. 5A). Measurements were acquired using 
purified JAM-A cross-linked to the cantilever tip as described in Methods (also 
see Fig. 4, panel 2). JAM-A was allowed to interact with the HUVEC surface 
with 1 µm intervals along each line scan. At each point the functionalized probe 
was lowered onto the HUVEC to make contact with the HUVEC before it was 
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subsequently withdrawn. This cycle is represented by the approach-retract 
traces shown in force scan 1 depicted in Fig. 5B. If an adhesive interaction is 
formed and disrupted a single rupture event is observed (Fig. 5B force scans 1 
and 2) where a force jump of ~60 pN in the retraction traces was observed. If no 
adhesive interaction occurs, there is no jump in force (Fig 5B force scans 3 and 
4). To generate adhesion maps, we repeated force measurements along line 
scans in predefined areas where each interaction was represented by a pixel 
per square (Fig. 5C, lower panel). Lighter pixels correspond to larger adhesive 
forces where as dark pixels represent no adhesion.  
In addition to adhesion force measurements, these experiments 
simultaneously allow for the acquisition of topographical information about the 
probed cells. Topographical information is derived from the extent of expansion 
of the piezoelectric transducer which is used to lower the probe onto the 
substrate. Therefore, the piezoelectric transducer has to expand to a greater 
extent in order for the probe to reach lower regions of the cell edge as 
compared to higher regions located at the center of the cell. For example, force 
scan 4 is located at ~1.8 µm, a lower position compared to force scan 1 
(~3.8 µm) (Fig. 5B); the higher the point of contact, the lighter the region in the 
height map (Fig. 5C, top panel). Both maps shown in Fig. 5C are a magnified 
12x12 µm region of the larger adhesion map shown in Fig. 6B. 
Figure 5: AFM adhesion map acquisition. 
(A) Adhesion mapping entails systematically scanning the cell surface with a coated AFM cantilever 
tip. This allows height mapping of the cell in conjunction with adhesion measurement acquisition for 
specific points on the cell. (B) Representative force-displacement traces acquired with a JAM-A 
coated AFM probe at specific heights on a TNF- and IFN--stimulated HUVEC. (C) Detailed height 
and corresponding adhesion maps for a 12x12 µm region of TNF- and IFN- -stimulated HUVEC. 
Locations and adhesion forces of the force scans shown in B are numbered 1-5 on both maps. 
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Only adhesion maps acquired on stimulated HUVEC revealed JAM-A adhesion 
patterns. A height map image of a HUVEC monolayer and its corresponding 
adhesion map for unstimulated HUVECs acquired for a 60 µm
2
 region is shown 
in Fig. 6A. Although a few white pixels indicating stronger JAM-A adhesive 
interactions in the 80-100 pN range appeared sporadically, most of the map 
consisted of gray or black regions representing little or no JAM-A adhesive 
interactions. A 40 µm
2
 height map of a HUVEC and the corresponding adhesion 
map for TNF-/IFN--stimulated HUVEC is depicted in Fig. 6B. The adhesion 
map of the stimulated HUVEC revealed greatly enhanced JAM-A adhesion as 
compared to unstimulated cells (Fig. 6A). In specific, JAM-A adhesive contacts 
were measured in the range of 80-100 pN, arranged in a semicircular pattern 
along the edge of the stimulated HUVEC. This “hot spot” is located 
between ~15-25 µm on the horizontal axis of the map and 10-35 µm on the 
vertical axis and is large enough to accommodate T cell adhesion as the 
average T cell diameter is 7 µm. Blockade of domains 1 and 2 of JAM-A 
eliminated all JAM-A interactions, and the adhesion map acquired on a 90 µm
2
 
region of the HUVEC monolayer was composed mostly of dark pixels (Fig. 6C). 
 
 
Figure 6: AFM adhesion maps of JAM-A-mediated adhesion to HUVEC.   
Adhesion maps were acquired by scanning the HUVEC surface with a JAM-A coated AFM probe. 
Each adhesion map (bottom) is shown with the corresponding height map image (top) where the 
cells are outlined with dotted lines. White regions represent the greatest height and the highest 
force as shown. (A) Adhesion map of an unstimulated HUVEC monolayer. Note the lack of white 
pixels indicative of few strong adhesive contacts. (B) Adhesion map of a HUVEC monolayer 
stimulated for 6 h with TNF- and IFN-. Note strong JAM-A adhesive contacts of >80 pN (white 
pixels) along the HUVEC junction (dashed lines). (C) Map of the same stimulated HUVEC 
monolayer acquired in B after addition of JAM-A function-blocking antibodies against D1 and D2. 
Note loss of adhesive contacts along the HUVEC junction. 
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Discussion 
Our results showed that a 6 hour TNF- and IFN--treatment promoted TEM of 
T cells across HUVEC monolayers. Moreover, our work shows, for the first time, 
that the underlying molecular mechanism for enhanced lymphocyte paracellular 
TEM is the development of JAM-A “hot spots” located near the HUVEC 
junctions that enhance lymphocyte junctional adhesion and facilitate their 
junctional recruitment.   
Function-blocking antibodies directed against ICAM-1, JAM-A or 
PECAM-1 significantly diminished lymphocyte TEM after stimulation as assayed 
by transwell assays and real time video microscopy (Fig.1 and Supplementary 
movie 1). Furthermore, we observed a redistribution of JAM-A and PECAM-1, 
but not ICAM-1, following a 6 hour TNF- and IFN- stimulation. The diffuse 
staining at the HUVEC center of both receptors was reduced and only junctional 
staining was observed following stimulation (Fig.2). 
Our findings prompted us to investigate the potential role of receptor 
redistribution in lymphocyte junctional recruitment at the single cell level. In 
order for cells to be recruited into endothelial junctions they must first adhere 
more strongly to the endothelium as had been shown by others
28, 34-37
. Our 
study is the first of its kind to determine the specific region on a single HUVEC 
cell where leukocyte binding is most likely to take place. We conducted SCFS 
measurements that revealed that lymphocyte adhesion was enhanced near 
HUVEC junctions following 6 h stimulation. A key feature of SCFS is that the 
adhesion of a single living cell is measured under applied force (~200 pN) 
simulating in vivo conditions where shear forces in the blood stream act on 
migrating leukocytes as they interact with the endothelium. During each force 
measurement, the lymphocyte is subjected to both pushing (approach toward 
substrate) and pulling (retraction) forces. The rate of probe retraction was kept 
constant (~5 µm/s) as was the applied force and contact time based on our 
previous studies of leukocyte adhesion to HUVEC showing the impact of these 
parameters on the adhesion strength measured by detachment force and work 
of de-adhesion
51, 52
. SCFS revealed that Jurkat cell adhesion to HUVEC 
junctional regions increased by >4 fold after a 6 h TNF- and IFN- stimulation. 
Blocking experiments also showed that JAM-A played the most significant role 
in enhancing adhesion at junctions of stimulated HUVEC. PECAM-1 blockade 
also had a significant yet lesser effect than JAM-A blockade on Jurkat cell 
adhesion likely due to low levels of integrin v3, the binding partner of 
PECAM-1, on HUVECs. ICAM-1 was more prominent at mediating cell 
adhesion at the cell center as revealed by greater blockade in that HUVEC 
region. These findings are consistent with previous studies showing the 
important role of ICAM-1 in transcellular TEM
10, 53
.   
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It has been suggested by numerous studies that an adhesion receptor gradient 
is responsible for guiding lymphocytes to the junction. We further determined if 
such a JAM-A gradient was present on stimulated HUVEC by conducting AFM 
adhesion mapping to determine the availability of functional JAM-A adhesive 
contacts on the HUVEC surface with 1 micron resolution. Systematic adhesion 
mapping of the interaction of purified JAM-A with the surface of stimulated 
HUVEC monolayers following a 6 h TNF- and IFN--treatment revealed a large 
increase and markedly altered distribution profile of adhesive forces. The 
measured forces of the interaction of JAM-A with HUVEC surface ranged from 
50 pN to 100 pN, which is in the range of previously measured single bond 
forces of JAM-A/JAM-A interaction
18
. JAM-A can also form heterophilic 
interactions with LFA-1. However, the JAM-A/LFA-1 interaction is unlikely to 
have been involved as JAM-A/LFA-1 single bond forces are >150 pN. The 
regions of functional JAM-A receptors were arranged in ~10 µm
2
 regions, an 
area sufficient in size to accommodate lymphocyte binding
54
. We term these 
regions of increased JAM-A receptors as adhesion “hot spots.” Lymphocyte 
binding to a “hot spot” likely plays a key role in guiding it toward the junction. 
Indeed, our video microscopy observations suggest that such a process occurs, 
showing lymphocytes preferentially transmigrating at the endothelial cell 
contacts.  
This is consistent with previous studies where effects of combined 
TNF- and IFN- treatment on leukocyte paracellular TEM were investigated 
under both static or flow conditions in vitro and in vivo. An in vivo study by 
Munro and colleagues conducted in the baboon reported that TNF- and IFN- 
treatment resulted in the upregulation of E-selectin and ICAM-1 and led to 
leukocyte accumulation at endothelial junctions as early as 6 h after combined 
TNF- and IFN- treatment
28
. Interestingly, E-selectin levels decreased at 24 
hours. In addition, the Munro et al. study also revealed that the level of 
polymorphonuclear cells (PMN) accumulation peaked at 6-9 h following 
combined treatment and later decreased to lower levels. A later in vitro study by 
Shaw et al. revealed an increase in leukocyte adhesion and TEM under flow 
following TNF- and IFN- treatment with an observed increase in endothelial 
permeability
34
. These findings are consistent with a number of subsequent 
studies. For example, two studies by Mohan et al. described a notable increase 
in adhesion of T cells to HUVEC stimulated with TNF- and IFN- and an 
increase in migration and a study by Ancuta et al. revealed increased migration 
for CD16
-
 monocytes
36
. 
Our immunofluorescence images revealed a more diffuse staining of 
JAM-A and PECAM-1 on the HUVEC surface with receptors localizing toward 
the junctions. This is consistent with the adhesion receptor movement reported 
in other studies where receptors disappear after 24 hours. It is likely that 
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receptors begin their movement toward the junctional regions and significant 
changes occur at the 6 h mark following TNF- and IFN- stimulation. Longer 
stimulation times allow the receptors to move into the junction and seemingly 
disappear from the confocal images
1, 55
. Response to inflammation is a very 
dynamic process. We believe that receptor movement is never halted but rather 
likely continues in vivo. Perhaps adhesion “hot spots” first form to recruit cells to 
junctional regions. Subsequently, receptors continue their movement, potentially 
helping to drag the leukocytes into the junction. This idea is supported by 
numerous studies highlighting cytoskeletal alterations in stimulated endothelial 
cells. For example, Munro and coworkers compared TNF- stimulation to 
cytochalasin-D treatment (a known disruptor of f-actin)
28
. Such disruption or 
rearrangement occuring in the actin cytoskeleton likely leads to the release of 
adhesion receptors anchoring to the cytoskeleton and allows for their greater 
mobility. Since confocal microscopy techniques continue to improve in 
resolution, future studies illustrating adhesion receptor distribution over a 
continuous time course in the context of lymphocyte TEM would greatly improve 
our understanding of this process. 
We believe that TNF- and IFN- stimulation for 24 h or longer leads to 
different outcomes as compared to stimulation times less than 18 h. At these 
longer stimulation times, lymphocytes may not adhere preferentially to the 
junctional region as receptors are no longer present there at greater levels as 
revealed by previous studies
1, 34
. Shaw et al. do report enhanced adhesion to 
the endothelium but the results show the number of cells bound
34
. No 
information about preferential binding is available. However, the cytoskeletal 
changes that likely facilitate receptor rearrangement likely also promote 
increased endothelial permeability as observed by these authors where 
significant increases were seen. So, although receptor distribution at longer 
time points may not favor TEM, the increased junctional permeability does. 
Therefore, TEM is not reduced. Other studies employed an 18 h treatment with 
TNF- and IFN-. All report an increase in leukocyte adhesion and TEM at this 
time point
35, 36, 37
.   
In order for the body to effectively defend against pathogens, there has 
to be a significant enhancement in immune cell interactions with the 
endothelium. This is, for example, highlighted in the ICAM-1 and ICAM-2 
receptors, where ICAM-2 is constitutively expressed on the endothelial surface 
and participates in immune surveillance. Meanwhile, ICAM-1 is greatly up-
regulated under inflammatory conditions to facilitate firm lymphocyte adhesion 
to the endothelium. It then makes sense, for TEM to be significantly increased 
in response to stimulation and for the process to be attenuated with time. As 
previously shown by Munro et al., receptor redistribution in response to 
cytokines is reversible and likely also varies for different cell types
28
. The 
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receptors likely return to their original location and await a subsequent signal, 
the release of more cytokines. We propose that this process is cyclical.  
Together, our findings suggest that inflammation of the vascular wall 
leads to redistribution of JAM-A receptors toward endothelial junctions creating 
“hot spots” that promote lymphocyte binding and facilitate initiation of TEM. 
Further lymphocyte entry into the endothelial junction requires disrupting tight 
junctions which are maintained by homophilic JAM-A/JAM-A interactions on 
adjacent endothelial cells. LFA-1 is likely to play a critical role in this step
13
. We 
have shown previously that lymphocyte LFA-1 is capable of competing out 
JAM-A homodimers in the tight junctions leading to disruption of junctional 
integrity and, thus, facilitating lymphocyte egress further into the junction 
18
. In 
summary, our findings indicate that JAM-A plays an important role in mediating 
lymphocyte recruitment to the endothelium and subsequent TEM under 
inflammatory conditions. 
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Supplemetary video files 
 
Supplementary videos online 
Linked at: 
 
http://www.jleukbio.org/content/early/2013/09/25/jlb.0412205/suppl/DC1 
 
 
Movie 1: Transendothelial migration of T cells through stimulated HUVEC. 
Transendothelial migration of CD4
+
 T cells over TNF-/IFN--stimulated HUVEC (6 h) was recorded 
using real time video microscopy in 30 s intervals at 37 °C and 5% CO2. Two contiguous image 
sequences show a transmigrating T cell (marked with x) at the intercellular junction of a HUVEC 
cell. 
Movie 2:  Movie of serial confocal z-sections of a HUVEC monolayer immunostained without 
permeabilization for ICAM-1 (green) and JAM-A (red) after 6 hour treatment with TNF-/IFN-.   
The movie loops from top to bottom (0.5 µm steps) of the monolayer showing individual ICAM-1 and 
JAM-A as well as merged immunostains. ICAM-1 appears diffusely expressed through the HUVEC 
surface (center and junction), whereas JAM-A is predominantly evident along the junctional regions 
visible in the lower equatorial z-sections. Notice the change in overlap (yellow) between the ICAM-1 
and JAM-A immunostains in the lower z-sections at the junctional regions. 
Movie 3:  Movie of serial confocal z-sections of a HUVEC monolayer immunostained without 
permeabilization for ICAM-1 (green) and JAM-A (red) without TNF-/IFN- stimulation.   
The movie loops from top to bottom (0.5 µm steps) of the monolayer showing individual ICAM-1 and 
JAM-A as well as merged immunostains. Both ICAM-1 and JAM-A appear diffusely distributed on 
the HUVEC surface from the center (top) to the junctional regions (lower z-sections).  
  
CYTOKINES PROMOTE LYMPHOCYTE ADHESION FACILITATING 
JUNCTIONAL TEM 
123 
4 
References 
1. Ozaki H, Ishii K, Horiuchi H, Arai H, Kawamoto T, Okawa K, Iwamatsu A, Kita T. Cutting 
edge: Combined treatment of tnf-alpha and ifn-gamma causes redistribution of junctional 
adhesion molecule in human endothelial cells. J Immunol. 1999;163:553-557 
2. Martinez-Estrada OM, Manzi L, Tonetti P, Dejana E, Bazzoni G. Opposite effects of tumor 
necrosis factor and soluble fibronectin on junctional adhesion molecule-a in endothelial 
cells. American journal of physiology. Lung cellular and molecular physiology. 
2005;288:L1081-1088 
3. Shaw SK, Ma S, Kim MB, Rao RM, Hartman CU, Froio RM, Yang L, Jones T, Liu Y, 
Nusrat A, Parkos CA, Luscinskas FW. Coordinated redistribution of leukocyte lfa-1 and 
endothelial cell icam-1 accompany neutrophil transmigration. The Journal of experimental 
medicine. 2004;200:1571-1580 
4. Mamdouh Z, Mikhailov A, Muller WA. Transcellular migration of leukocytes is mediated by 
the endothelial lateral border recycling compartment. The Journal of experimental 
medicine. 2009;206:2795-2808 
5. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-434 
6. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The 
multistep paradigm. Cell. 1994;76:301-314 
7. Schenkel AR, Mamdouh Z, Muller WA. Locomotion of monocytes on endothelium is a 
critical step during extravasation. Nature immunology. 2004;5:393-400 
8. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (lfa-1) interaction with 
intercellular adhesion molecule-1 (icam-1) is one of at least three mechanisms for 
lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 1988;107:321-331 
9. Muller WA, Weigl SA, Deng X, Phillips DM. Pecam-1 is required for transendothelial 
migration of leukocytes. The Journal of experimental medicine. 1993;178:449-460 
10. Carman CV, Springer TA. A transmigratory cup in leukocyte diapedesis both through 
individual vascular endothelial cells and between them. The Journal of cell biology. 
2004;167:377-388 
11. Dejana E, Corada M, Lampugnani MG. Endothelial cell-to-cell junctions. Faseb J. 
1995;9:910-918 
12. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: Molecular organization and role in 
vascular homeostasis. Physiological reviews. 2004;84:869-901 
13. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. Jam-1 is a ligand of the 
beta(2) integrin lfa-1 involved in transendothelial migration of leukocytes. Nat Immunol. 
2002;3:151-158 
14. Bazzoni G, Martinez-Estrada OM, Mueller F, Nelboeck P, Schmid G, Bartfai T, Dejana E, 
Brockhaus M. Homophilic interaction of junctional adhesion molecule. J Biol Chem. 
2000;275:30970-30976 
15. Naik UP, Naik MU, Eckfeld K, Martin-DeLeon P, Spychala J. Characterization and 
chromosomal localization of jam-1, a platelet receptor for a stimulatory monoclonal 
antibody. Journal of cell science. 2001;114:539-547 
16. Weber C, Lu CF, Casasnovas JM, Springer TA. Role of alpha l beta 2 integrin avidity in 
transendothelial chemotaxis of mononuclear cells. J Immunol. 1997;159:3968-3975 
17. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular 
inflammation. Nat Rev Immunol. 2007;7:467-477 
18. Wojcikiewicz EP, Koenen RR, Fraemohs L, Minkiewicz J, Azad H, Weber C, Moy VT. Lfa-
1 binding destabilizes the jam-a homophilic interaction during leukocyte transmigration. 
Biophysical journal. 2009;96:285-293 
19. Zocchi MR, Ferrero E, Leone BE, Rovere P, Bianchi E, Toninelli E, Pardi R. Cd31/pecam-
1-driven chemokine-independent transmigration of human t lymphocytes. European 
journal of immunology. 1996;26:759-767 
20. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. Cd99 plays a major role in 
the migration of monocytes through endothelial junctions. Nature immunology. 
2002;3:143-150 
21. Sun J, Paddock C, Shubert J, Zhang HB, Amin K, Newman PJ, Albelda SM. Contributions 
of the extracellular and cytoplasmic domains of platelet-endothelial cell adhesion 
molecule-1 (pecam-1/cd31) in regulating cell-cell localization. Journal of cell science. 
2000;113 ( Pt 8):1459-1469 
CHAPTER 4 
124 
4 
22. Berman ME, Xie Y, Muller WA. Roles of platelet/endothelial cell adhesion molecule-1 
(pecam-1, cd31) in natural killer cell transendothelial migration and beta 2 integrin 
activation. J Immunol. 1996;156:1515-1524 
23. Thompson RD, Noble KE, Larbi KY, Dewar A, Duncan GS, Mak TW, Nourshargh S. 
Platelet-endothelial cell adhesion molecule-1 (pecam-1)-deficient mice demonstrate a 
transient and cytokine-specific role for pecam-1 in leukocyte migration through the 
perivascular basement membrane. Blood. 2001;97:1854-1860 
24. Vaporciyan AA, DeLisser HM, Yan HC, Mendiguren, II, Thom SR, Jones ML, Ward PA, 
Albelda SM. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil 
recruitment in vivo. Science. 1993;262:1580-1582 
25. Buckley CD, Doyonnas R, Newton JP, Blystone SD, Brown EJ, Watt SM, Simmons DL. 
Identification of alpha v beta 3 as a heterotypic ligand for cd31/pecam-1. Journal of cell 
science. 1996;109 ( Pt 2):437-445 
26. Dangerfield J, Larbi KY, Huang MT, Dewar A, Nourshargh S. Pecam-1 (cd31) homophilic 
interaction up-regulates alpha6beta1 on transmigrated neutrophils in vivo and plays a 
functional role in the ability of alpha6 integrins to mediate leukocyte migration through the 
perivascular basement membrane. The Journal of experimental medicine. 
2002;196:1201-1211 
27. Woodfin A, Voisin MB, Imhof BA, Dejana E, Engelhardt B, Nourshargh S. Endothelial cell 
activation leads to neutrophil transmigration as supported by the sequential roles of icam-
2, jam-a, and pecam-1. Blood. 2009;113:6246-6257 
28. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-gamma induce 
distinct patterns of endothelial activation and associated leukocyte accumulation in skin of 
papio anubis. The American journal of pathology. 1989;135:121-133 
29. Romer LH, McLean NV, Yan HC, Daise M, Sun J, DeLisser HM. Ifn-gamma and tnf-alpha 
induce redistribution of pecam-1 (cd31) on human endothelial cells. J Immunol. 
1995;154:6582-6592 
30. Mamdouh Z, Chen X, Pierini LM, Maxfield FR, Muller WA. Targeted recycling of pecam 
from endothelial surface-connected compartments during diapedesis. Nature. 
2003;421:748-753 
31. Dejana E. Endothelial cell-cell junctions: Happy together. Nature reviews. 2004;5:261-270 
32. Iurlaro M, Demontis F, Corada M, Zanetta L, Drake C, Gariboldi M, Peiro S, Cano A, 
Navarro P, Cattelino A, Tognin S, Marchisio PC, Dejana E. Ve-cadherin expression and 
clustering maintain low levels of survivin in endothelial cells. The American journal of 
pathology. 2004;165:181-189 
33. Thomas FC, Sheth B, Eckert JJ, Bazzoni G, Dejana E, Fleming TP. Contribution of jam-1 
to epithelial differentiation and tight-junction biogenesis in the mouse preimplantation 
embryo. Journal of cell science. 2004;117:5599-5608 
34. Shaw SK, Perkins BN, Lim YC, Liu Y, Nusrat A, Schnell FJ, Parkos CA, Luscinskas FW. 
Reduced expression of junctional adhesion molecule and platelet/endothelial cell 
adhesion molecule-1 (cd31) at human vascular endothelial junctions by cytokines tumor 
necrosis factor-alpha plus interferon-gamma does not reduce leukocyte transmigration 
under flow. Am J Pathol. 2001;159:2281-2291 
35. Ancuta P, Moses A, Gabuzda D. Transendothelial migration of cd16+ monocytes in 
response to fractalkine under constitutive and inflammatory conditions. Immunobiology. 
2004;209:11-20 
36. Mohan K, Ding Z, Hanly J, Issekutz TB. Ifn-gamma-inducible t cell alpha chemoattractant 
is a potent stimulator of normal human blood t lymphocyte transendothelial migration: 
Differential regulation by ifn-gamma and tnf-alpha. J Immunol. 2002;168:6420-6428 
37. Mohan K, Pinto D, Issekutz TB. Identification of tissue transglutaminase as a novel 
molecule involved in human cd8+ t cell transendothelial migration. J Immunol. 
2003;171:3179-3186 
38. Szczygiel AM, Brzezinka G, Targosz-Korecka M, Chlopicki S, Szymonski M. Elasticity 
changes anti-correlate with no production for human endothelial cells stimulated with tnf-
alpha. Pflugers Arch.463:487-496 
39. Targosz-Korecka M, Biedron R, Szczygiel AM, Brzezinka G, Szczerbinski J, Zuk A. 
Stiffness changes of tumor hep2 cells correlates with the inhibition and release of trail-
induced apoptosis pathways. J Mol Recognit.25:299-308 
40. Benoit M. Cell adhesion measured by force spectroscopy on living cells. Methods Cell 
Biol. 2002;68:91-114 
CYTOKINES PROMOTE LYMPHOCYTE ADHESION FACILITATING 
JUNCTIONAL TEM 
125 
4 
41. Benoit M, Gabriel D, Gerisch G, Gaub HE. Discrete interactions in cell adhesion 
measured by single-molecule force spectroscopy. Nat Cell Biol. 2000;2:313-317 
42. Wojcikiewicz EP, Zhang X, Chen A, Moy VT. Contributions of molecular binding events 
and cellular compliance to the modulation of leukocyte adhesion. Journal of cell science. 
2003;116:2531-2539 
43. Abdulreda MH, Faleo G, Molano RD, Lopez-Cabezas M, Molina J, Tan Y, Echeverria OA, 
Zahr-Akrawi E, Rodriguez-Diaz R, Edlund PK, Leibiger I, Bayer AL, Perez V, Ricordi C, 
Caicedo A, Pileggi A, Berggren PO. High-resolution, noninvasive longitudinal live imaging 
of immune responses. Proceedings of the National Academy of Sciences of the United 
States of America. 2011;108:12863-12868 
44. Rodriguez-Diaz R, Abdulreda MH, Formoso AL, Gans I, Ricordi C, Berggren PO, Caicedo 
A. Innervation patterns of autonomic axons in the human endocrine pancreas. Cell 
metabolism. 2011;14:45-54 
45. Barlow AL, Macleod A, Noppen S, Sanderson J, Guerin CJ. Colocalization analysis in 
fluorescence micrographs: Verification of a more accurate calculation of pearson's 
correlation coefficient. Microsc Microanal.16:710-724 
46. Hutter J, Bechhoefer J. Calibration of atomic force microscope tips. Rev.Sci. Instrum. 
1993;64:1868-1873 
47. Zhang X, Wojcikiewicz E, Moy VT. Force spectroscopy of the leukocyte function-
associated antigen-1/intercellular adhesion molecule-1 interaction. Biophysical journal. 
2002;83:2270-2279 
48. Zhang X, Chen A., Wojcikiewicz EP, Moy VT. Probing ligand-receptor interactions with 
atomic force microscopy. Protein-Protein Interactions: A Molecular Cloning Manual, Cold 
Spring Harbor Laboratory Press. 2002:241-254 
49. Evans E. Probing the relation between force--lifetime--and chemistry in single molecular 
bonds. Annu Rev Biophys Biomol Struct. 2001;30:105-128 
50. Tees DF, Waugh RE, Hammer DA. A microcantilever device to assess the effect of force 
on the lifetime of selectin-carbohydrate bonds. Biophysical journal. 2001;80:668-682 
51. Zhang X, Chen A, De Leon D, Li H, Noiri E, Moy VT, Goligorsky MS. Atomic force 
microscopy measurement of leukocyte-endothelial interaction. Am J Physiol Heart Circ 
Physiol. 2004;286:H359-367 
52. Zhang X, Wojcikiewicz EP, Moy VT. Dynamic adhesion of t lymphocytes to endothelial 
cells revealed by atomic force microscopy. Exp Biol Med (Maywood). 2006;231:1306-
1312 
53. Carman CV, Sage PT, Sciuto TE, de la Fuente MA, Geha RS, Ochs HD, Dvorak HF, 
Dvorak AM, Springer TA. Transcellular diapedesis is initiated by invasive podosomes. 
Immunity. 2007;26:784-797 
54. Szczygiel AM, Brzezinka G, Targosz-Korecka M, Chlopicki S, Szymonski M. Elasticity 
changes anti-correlate with no production for human endothelial cells stimulated with tnf-
alpha. Pflugers Archiv : European journal of physiology. 2012;463:487-496 
55. Rival Y, Del Maschio A, Rabiet MJ, Dejana E, Duperray A. Inhibition of platelet 
endothelial cell adhesion molecule-1 synthesis and leukocyte transmigration in 
endothelial cells by the combined action of tnf-alpha and ifn-gamma. J Immunol. 
1996;157:1233-1241 
 
 
 Increased atherosclerosis in platelet-JAM-A ko-mice: 
In the preceding chapter 2 we were able to demonstrate different, even 
opposing, roles of JAM-A on atherosclerotic lesion formation in mice specifically 
deficient for endothelial and leukocytic JAM-A. Thus we showed that endothelial 
JAM-A displays atherogenic properties by increased availability at the luminal 
site of endothelial cells under hyperlipidemic and altered shear stress 
conditions, thereby increasing leukocyte adhesion and transmigration which 
aggravates atherosclerotic lesion formation. Leukocytic JAM-A played an 
atheroprotective role, likely by facilitating 2-integrin internalization. Leukocytes 
lacking JAM-A showed a defect in de-adhesion expectedly mediated by 
enhanced integrin activity and availability. This defect in de-adhesion most likely 
inflicts damage on the endothelial cell lining, which finally led to enhanced 
atherosclerotic lesion formation. A JAM-A deficiency in all cell-types resulted in 
no significant changes in plaque formation and composition, leading to the 
assumption that also other JAM-A expressing cell-types like smooth muscle 
cells or mast cells also play a role in atherosclerotic lesion formation. 
Another important cell-type carrying JAM-A are platelets. Besides their 
central role in hemostasis, it has been shown that platelets play a key-role in 
inflammation and atherosclerotic lesion formation. Platelets adhere at early 
atherosclerotic lesions
1
 and presumably deposit inflammatory chemokines like 
PF4 and RANTES at the glycosaminoglycans of endothelial cells
2
, thereby 
triggering leukocyte transmigration and atherosclerotic lesion formation
3
. 
Recently, it has been demonstrated that platelets lacking JAM-A showed 
enhanced reactivity as well as inhibited integrin 2b3-mediated outside-in 
signaling
4
. 
In chapter 5, we aimed to further expand our findings regarding a cell-
specific role for JAM-A in atherosclerotic lesion formation. We generated a Bl6 
mouse with ApoE background specifically deficient for platelet JAM-A. As 
performed in chapter 2, we analyzed lesion formation, composition and stage, 
also at different time-points of high-fat diet, and we were able to propose 
molecular mechanisms underlying the observed results. As such, activity and 
adhesion assays as well as measurement of inflammatory parameter pointed 
towards a hyperreactive phenotype of platelets deficient for JAM-A.  
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Abstract 
Background - Besides their essential role in hemostasis, platelets also have 
functions in inflammation. On platelets, junctional adhesion molecule (JAM-)A, 
is abundantly expressed. Recently, platelet-JAM-A was identified as an inhibitor 
of integrin 2b3-mediated outside-in signaling and its absence in platelets 
resulted in hyperreactivity. In this study, this gain-of-function was specifically 
exploited to investigate the role of platelet hyperreactivity in plaque 
development. 
Methods and Results - Mice with or without platelet-specific (tr)JAM-A-
deficiency were crossed in an apolipoprotein e (Apoe
–/–
) background and fed a 
high-fat diet (HFD) for 2, 6, and 12 weeks. During flow, trJAM-A
–/–
 apoe
–/–
 
platelets showed increased collagen adhesion and 2b3-integrin expression. 
After 12 weeks of diet at most, trJAM-A
–/–
 Apoe
–/–
 mice showed increased 
plaque formation in the aorta compared with trJAM-A
+/+
 Apoe
–/– 
controls and 
these differences were most evident at early time points. After 2 weeks of HFD, 
the plaques of the trJAM-A
–/–
 Apoe
–/– 
animals showed increased macrophage, T 
cell and smooth muscle cell content. Interestingly, the plasma levels of 
chemokines CCL5 and CXCL4 were increased in the trJAM-A
–/– 
Apoe
–/–
 mice 
and JAM-A–deficient platelets showed increased binding to monocytes and 
leukocytes. Finally, whole-blood perfusion experiments in vitro and intravital 
microscopy in vivo revealed increased adhesion of monocytes to the 
endothelium in blood of trJAM-A
–/–
 Apoe
–/–
 mice compared to controls.  
Conclusions - Deletion of JAM-A causes a gain-of-function in platelets, with 
lower activation thresholds and increased inflammatory activities. This leads to 
an increase of plaque formation, particularly in early stages of the disease. 
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Introduction 
Blood platelets have an essential function in hemostasis, but also play an 
important role in immune and inflammatory processes
5, 6
. Recent studies have 
highlighted platelets as key effectors in e.g. sepsis
7
, rheumatoid arthritis
8
, 
experimental autoimmune encephalomyelitis
9
 and host defense during bacterial 
infection
10
. In addition, platelets spark vascular inflammatory processes and 
adhere to atherosclerotic predilection sites preceding plaque formation
1
. 
Platelets may also form a bridge between leukocytes and the injured or 
inflamed vessel wall
11
, promoting the extravasation of monocytes and 
neutrophils
12
 and the response to vascular injury
13
. Accordingly, infusion of 
activated platelets into hyperlipidemic mice accelerated atherosclerosis in a P-
selectin- and CD40 ligand (CD40L)-dependent manner
14, 15
. 
 Junctional adhesion molecule A (JAM-A, F11R) is a member of the 
immunoglobulin superfamily adhesion molecules and expressed on a large 
variety of cell types, including platelets, leukocytes and endothelial cells
16
. On 
leukocytes, it mediates cell migration by regulating integrin recycling and de-
adhesion
17, 18
. On epi- and endothelial cells, JAM-A is a component of the tight 
junctions and regulates cell layer permeability through homophilic interactions
19, 
20
. Upon inflammatory stimulation of endothelial cells, JAM-A moves out of the 
intercellular contacts and is exposed on the apical surface, thereby becoming 
available for the interaction with blood cells
21
. Recently, we demonstrated that 
JAM-A plays a cell type-specific role in atherosclerotic plaque formation
22
. 
Whereas JAM-A on leukocytes protected against atherosclerosis, endothelial 
JAM-A promoted plaque formation by enhanced luminal availability under pro-
atherosclerotic conditions, thus guiding monocytes to sites of plaque 
development
22
. 
 Although JAM-A was first identified in platelets
23, 24
, its influence on 
platelet function remained poorly characterized. Earlier studies demonstrated 
phosphorylation of JAM-A upon platelet activation
25
 and its association with 
2b3-integrin
26
, yet no functional consequences for platelet function were 
reported. Recent work however identified JAM-A as an endogenous inhibitor of 
platelet function by attenuating c-Src–dependent outside-in signal transduction 
through 2b3-integrin
4, 27
. Deficiency of JAM-A in platelets resulted in increased 
aggregation in response to some platelet agonists and led to a prothrombotic 
phenotype in mice
4
. 
 The importance of platelets in the pathogenesis of atherosclerosis and 
the gain-of-function phenotype of JAM-A–deficient platelets prompted us to 
investigate the role of platelet hyperreactivity in the progression of 
atherosclerosis. Using mice with a platelet-specific deletion of the JAM-A gene, 
we demonstrate that loss of JAM-A on platelets leads to hyperreactivity and an 
acceleration of early-phase plaque formation. 
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Methods 
Mouse models  
Mice carrying cre-recombinase under the control of the platelet factor 4 (PF4)-
promoter were a kind gift from Dr. R.C. Skoda, University Hospital Basel
28
 and 
were backcrossed in an apolipoprotein e (Apoe)-deficient background 
(C57Bl/6). These mice were crossed with JAM-A
flox/flox
 Apoe
–/–
 mice
22
 to obtain 
platelet-specific (tr)JAM-A
–/–
 Apoe
–/–
 mice. Littermates not containing the PF4-
cre transgene were used as trJAM-A
+/+
 Apoe
–/–
 controls. Specific gene deletion 
of JAM-A was confirmed by FACS and western blot analysis demonstrating 
nearly complete absence of JAM-A in platelets in trJAM-A
–/–
 mice compared to 
controls.  
Blood collection and analysis 
Mice were anesthetized with ketamine (80 mg/kg) and medetomidine (0.3 
mg/kg) and blood was retro-orbitally collected into citrate-, EDTA- or hirudin-
coated tubes for flow cytometry-, cell counts and platelet function assessment 
(see below). Cell counts and mean platelet volume (MPV) were determined 
using an automated hematology analyzer (scil Animal Care, Viernheim, 
Germany).  
Plaque formation, quantification and histological analysis of atherosclerosis 
Plaque formation was induced in male/female 6-8–week old mice (n=7-14) by 
feeding a high-fat diet (HFD, 21% fat, 19.5 % casein, 0.15% cholesterol, ssniff, 
Soest, Germany) for 2, 6 and 12 weeks. Mice were anesthetized as described 
above and the heart and the whole aorta were excised after whole body in situ 
perfusion with 4% buffered formaldehyde (Carl Roth, Karlsruhe, Germany). 
After overnight fixation and adventitia removal, the aorta was longitudinally 
opened and stained en face with Oil-Red-O to visualize the lipid deposition. The 
plaque area was calculated as percentage of the Oil-Red-O
+
 stained area by 
dividing the whole aortic area. After paraffin-embedding and cutting into 4-µm 
transverse sections, aortic root samples were assessed for atherosclerotic 
plaque size after staining with Elastica van Gieson (EVG) (Baacklab, Schwerin, 
Germany). The plaque area was quantified as percentage of plaque area of all 
three aortic valves divided to the area of the internal lumen. Adjacent sections 
were used for evaluating plaque cellular content by immunofluorescence 
staining for macrophages, CD3
+
 T cells and smooth muscle cells (SMCs). 
Briefly, after heat-induced antigen retrieval (Dako, Hamburg, Germany) and 
blocking of unspecific protein binding (goat- and sheep sera, Sigma Aldrich, St. 
Louis, MO) aortic root samples were reacted with anti-MAC-2 (Cedarlane Labs, 
Burlington, Canada), anti-CD3 and anti-αSMA antibodies (both Dako), 
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respectively. Nuclei were counterstained with DAPI (Vector Laboratories, 
Burlingame, CA). For immunofluorescence staining on platelets, cells were 
isolated as described
15
, fixed with 4% formaldehyde, permeabilized with 
saponin (BD Biosciences, Franklin Lakes, NJ) and incubated with anti-CXCL4 
and anti-CCL5 antibodies (both R&D Systems, Minneapolis, MN). Finally, the 
primary antibodies were detected (visualized) after incubation with DyLight®-
488, -550 and -650–conjugated secondary antibodies (all Abcam, Cambridge, 
UK). Images were recorded with a DM 6000B fluorescence microscope (Leica, 
Solms, Germany), connected to a monochrome digital camera (DFC 365FX) for 
the fluorescent images and DFC425C camera for the EVG-stained aortic root 
pictures. MAC-2-, CD3- and αSMA cells were manually quantified as positive 
cells per plaque area. Stages of atherosclerotic lesions were determined by 
evaluation of EVG-stained aortic roots
29
. All animal experiments were approved 
by local authorities (Regierung von Oberbayern, Munich, Germany) to comply 
with German animal protection law. 
Platelet isolation and activity measurement 
Platelets were isolated and washed by centrifugation as described
15
. Platelet 
aggregation in response to adenosine diphosphate (ADP), thrombin, or collagen 
(Loxo GmbH, Dossenheim, Germany) was assessed in mouse whole blood 
within 2 hours after isolation by multiple electrode aggregometry technology 
using a Multiplate® platelet analyzer according to manufacturer's instructions 
(Roche Diagnostics, Mannheim, Germany)
30
. 
Thrombus formation on collagen under flow   
Platelet adhesion onto fibrillar collagen under shear flow was performed 
essentially as described
15, 31
. Briefly, mouse blood collected into D-phenylalanyl-
L-prolyl-L-arginine chloromethylketone (PPACK) was perfused over collagen 
type I-coated coverslips in a transparent parallel-plate perfusion chamber at a 
shear rate of 1000 s
-1
 for 4 minutes. To assess 2b3-integrin activation, 
phosphatidyl serine binding and platelet granule secretion, thrombi formed on 
the collagen surface were post-stained with fluorescently labeled anti-JON/A 
PE-conjugated (Emfret, Würzburg, Germany), anti-annexin A5 Alexa Fluor® 
647-conjugated (Life Technologies, Carlsbad, CA) and anti-CD62P (P-Selectin) 
FITC-conjugated (Emfret) antibodies, respectively. Phase contrast and 
fluorescence images were recorded using an EVOS-FL digital microscope (Life 
Technologies). Finally, surface area coverage of adherent platelets and 
fluorescence over multiple microscopic fields was analyzed using Metamorph 
5.0.0 software (MDS Analytical Technologies).  
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Western blotting 
For immunoblotting, isolated platelets and harvested arteries after whole body 
perfusion with ice-cold phosphate-buffered saline solution (PBS, Sigma Aldrich) 
were homogenized as described
32
. Briefly, protein extracts were obtained from 
homogenates after incubation in lysis buffer containing protease inhibitors and 
detergents
32
, following centrifugation at 8,000g for 1 min. Supernatants were 
analyzed for immunoblotting. Protein concentrations were determined (Bio-Rad 
protein assay, Bio-Rad). Equal amounts of protein (10 to 30 µg) were separated 
by 10% SDS-PAGE and transferred to nitrocellulose membranes. Ponceau S 
staining served as loading control. The membranes were reacted with anti-
mouse JAM-A antibody (AbSerotec, Düsseldorf, Germany) followed by 
incubation with peroxidase-conjugated secondary antibody (Santa Cruz 
Biotech, Santa Cruz, CA) and detected with chemiluminescence reagent 
(Thermo Fischer Scientific, Waltham, MA). 
Plasma lipid and chemokine determination 
Concentrations of chemokines CXCL4 and CCL5 were measured in plasma 
from mice fed a HFD for 2, 6 and 12 weeks using Enzyme-linked 
immunosorbent assays (ELISA) kits (both R&D Systems, Minneapolis). Total 
cholesterol and triglycerides concentrations were analyzed using the enzymatic 
colorimetric method (Cholesterol-CHOD-PAP kit and Triglycerides-GPO-PAP 
kit, both Roche Diagnostics) according to the manufacturer’s instructions. 
Flow cytometry 
Platelets were isolated and washed by centrifugation as described
15
 followed by 
labeling with anti-JAM-A AlexaFluor®488-conjugated (AbSerotec) and anti-
CD41 PE-conjugated (BD Pharmingen) antibodies. 
For platelet-leukocyte interactions, platelets were isolated as described 
above and activated with 0.5U/ml thrombin. Leukocytes were obtained from the 
sediments (pellets) after platelet centrifugation and lysis of erythrocytes and 
added to the activated platelets for 20 min at 37°C. Finally, cells were stained 
with anti-CD41 PE-conjugated (BD Pharmingen), anti-CD11b FITC-conjugated 
(eBioscience, San Diego, CA) and anti-Ly6G APC-conjugated (eBioscience) 
antibodies. JAM-A expression on platelets and platelet-leukocytes interactions 
were measured by flow cytometry (FACSCantoII, BD Biosciences) and 
analyzed by FlowJo v.10 software (Tree Star Inc., Ashland, OR). 
Quantitative real-time PCR 
For RNA analysis, total RNA was isolated from mouse aortae after 2 and 12 
weeks after HFD and reverse transcribed into cDNA using Mo-MLV RT (Life 
Technologies). q-PCR was performed using TaqMan Gene Expression Master 
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Mix and real time specific primers (Life Technologies). All reactions were run on 
a 7900HT thermocycler (Life Technologies). The expression levels of the target 
CXCR3 (Mm99999054_s1); IFNγ (Mm99999071_m1); TNFα 
(Mm00443260_g1) were quantified by the ratio to 18S RNA (4319413E) levels.  
Platelet and leukocyte adhesion assays 
In vitro adhesion assay 
SV-40-large T antigen-immortalized mouse endothelial cell (mECs) monolayers 
were challenged with TNFα (10 ng/ml) for 4 hours. Freshly isolated leukocytes 
and platelets were suspended in HBSS containing 0.5% human albumin and 10 
mM HEPES at 1×10
6
 leukocytes/ml and 1×10
8
 platelets/ml. The blood cells 
were then labeled with CD45 Alexa Fluor® 488-conjugated (Bio-Rad, Hercules, 
CA) and CD41 PE-conjugated (BD Pharmingen). Immediately prior to perfusion, 
0.5U/ml thrombin and 1 mM CaCl2 and MgCl2
 
was added to the platelets and 
leukocytes at 37°C. The endothelial cells were assembled as a lower wall into a 
custom-made flow chamber and platelets were perfused for 20 min, followed by 
leukocytes for 5 min and additional washing of non-adherent cells (all at wall 
shear stress of 1.5 dyne/cm
2
). Digital pictures were recorded with Leica DM 
6000B fluorescence microscope, connected to a digital camera (Leica DFC 
365FX) and quantified as percentage surface coverage of all cells or 
platelets/leukocytes over multiple microscopic fields using ImageJ software. 
In vivo adhesion assay 
Intravital microscopy was performed to visualize leukocyte-endothelium 
interactions along the atherosclerotic carotid artery. Mice were fed a HFD for 4 
weeks, anesthetized as described above and the right jugular vein was 
cannulated with polyethylene tubing for intravenous administration of anti-
CD11b eFluor®650NC-conjugated and anti-Ly6G PE-conjugated antibodies 
(both eBioscience). The left carotid artery was exposed and the firm arrest of 
the labeled leukocytes was captured by epifluorescence microscopy (Olympus 
BX51 10x saline-immersion objective) and recorded using a digital camera 
(Hamamatsu EM-CCD, C9100) as described
33
. Olympus cell
R
 software 
(Olympus, Shinjuku, Japan) was used for image acquisition and quantification. 
Leukocytes were considered adherent when no rolling was observed for more 
than 30 sec.  
Two-photon laser scanning microscopy 
For two-photon laser scanning microscopy (TPLSM) mice were fed a HFD for 2 
weeks and carotid arteries were carefully harvested, mounted in custom-made 
perfusion chambers and incubated at physiological pressure of 60 mmHg. To 
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detect endothelial JAM-A (eJAM-A), vessels were intraluminally incubated with 
anti-JAM-A AlexaFluor®488-conjugated (AbSerotec) and anti-CD31 
eFluor®450 (eBioscience) antibodies for 1 hour
22
. TPLSM imaging was 
performed using a Leica SP5MP system with a pulsed Ti:Sapphire laser tuned 
at 800 nm and a 20×NA1.00 water immersion objectives. Fluorescent signals 
were captured using 3 photo-multiplier tubes: 400-440 nm for second-harmonic 
generation (SHG); 460-490 nm (eFluor® 450) and 510-560 nm (Alexa 
Fluor®488). Z-stacks were acquired at 0.1 Hz over time including two-fold line 
averaging; FOV = 240 µm
2
 (voxel: 0.24×0.24×1.00 μm
3
). All pictures were 
processed using LAS software (Leica) and Image Pro v7.0 software (Media 
Cybernetics, Rockville, MD)
22
. 
Statistical Analysis 
Statistical analysis was performed using Prism 6.0 (GraphPad Software, La 
Jolla, CA). Means were compared between 2 groups by 2-tailed, unpaired or 
paired Student’s t-test, without or with Welch correction or among more than 2 
groups by 1-way ANOVA with Tukey's post-test or Kruskal-Wallis test with 
Dunn's post-test, as indicated. Differences with P<0.05 were considered as 
statistically significant. Each experiment was independently repeated at least 3 
times. 
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Results  
Deficiency in platelet-JAM-A results in hyperreactivity 
Previous studies have shown that genetic deletion of JAM-A results in platelet 
hyperreactivity
4, 27
, yet the functional consequences for the progression of 
atherosclerosis have not been investigated. For this, we implemented platelet-
specific JAM-A knock out (trJAM-A
–/–
) mice and compared them to their control 
littermates (trJAM-A
+/+
). Genetic deletion of JAM-A in platelets of trJAM-A
–/–
 
mice was confirmed by western blotting (Fig. 1A), immunofluorescence staining 
(Suppl. Fig. 1A) and flow cytometry (Suppl. Fig. 1B). Importantly, JAM-A 
expression on leukocytes (Suppl. Fig. 1C), endothelial JAM-A (eJAM-A) (Suppl. 
Fig. 2) and JAM-A in smooth muscle cells (SMCs) (data not shown) was not 
affected. This was additionally confirmed by whole vessel homogenates from 
aorta and A. carotis (Suppl. Fig. 1D). In addition, JAM-A deficiency did neither 
affect the platelet count, nor the volume or the counts of other blood cell 
populations (Suppl. Table 1). 
 To recapitulate the previous observations
4, 27
, we examined in vitro 
platelet aggregation upon activation. JAM-A–deletion resulted in enhanced 
responsiveness to different agonists such as ADP, thrombin and collagen, (Fig. 
1B-F), supporting the role of JAM-A as an endogenous platelet function 
inhibitor. 
 
 
Figure 1: Hyperreactivity of platelets in trJAM-A
-/-
 mice.  
Absence of JAM-A on platelets was confirmed by western blotting. Ponceau S served as a loading 
control (A).  Representative images of thrombin activation  (0.5 U/mL)  in  trJAM-A
+/+
 (B)  and  
trJAM-A
–/– 
(C) platelets are shown. Aggregation of trJAM-A
+/+
 and trJAM-A
–/–
 platelets by ADP (D), 
thrombin (E) and collagen (F) are depicted in aggregation units (AU). Data represent mean ±SEM 
(n=8-15) and all P values were calculated by ANOVA with Bonferroni's post test. 
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Absence of JAM-A promotes thrombus formation 
As JAM-A–deficient mice showed a prothrombotic phenotype
4
, blood from 
trJAM-A
–/–
 Apoe
–/–
 and trJAM-A
+/+
 Apoe
–/–
 mice was compared to determine the 
specific role of JAM-A on platelet in flow-dependent thrombus formation on a 
thrombogenic surface. Perfusion at high shear rates over fibrillar collagen 
induced the formation of platelet aggregates, which was markedly enhanced for 
trJAM-A
–/–
 Apoe
–/–
 platelets (Fig. 2A,D,G). In addition, post-staining with the 
JON/A antibody, specific for the activated conformation of 2b3-integrin, 
showed increased coverage of activated 2b3-integrin-carrying platelets from 
trJAM-A
–/–
 Apoe
–/–
 mice (Fig. 2B,E,H). Remarkably, JAM-A
–/–
 platelets revealed 
constant JON/A signal throughout the cell-aggregates, whereas JAM-A
+/+
 
platelets only showed JON/A staining at the aggregates’ border. Under the 
same conditions, little procoagulant surface (annexin A5 binding) was observed 
and no differences were present between platelets from trJAM-A
–/–
 Apoe
–/–
 mice 
and controls (Fig. 2C,F,I). Taken together, these results suggest that genetic 
ablation of JAM-A on platelets results in increased platelet reactivity 
accompanied with enhanced integrin activation. 
Platelet-specific JAM-A–deficiency accelerates early-stage atherosclerosis 
To investigate the role of JAM-A on platelets during the progression of 
atherosclerosis, trJAM-A
+/+
 Apoe
–/–
 and trJAM-A
–/–
 Apoe
–/–
 mice were fed a HFD 
for 2, 6 and 12 weeks. Of note, in early stages of atherosclerosis (2 weeks 
HFD) platelet JAM-A deficiency resulted in a significantly increased lesion area 
in the aortic root and in the whole aorta (Fig. 3A,B,C,F). At an intermediate time 
point (6 weeks HFD), whole-aortic plaque area was still significantly increased 
in trJAM-A
–/–
 Apoe
–/– 
mice compared with controls (Fig. 3D), whereas an 
increased plaque area was no longer observed in the aortic roots (Fig. 3G). 
Similar results were obtained after 12 weeks HFD, where a lack of JAM-A on 
platelets led to in increased lesional area only in the whole aorta (Fig. 3A,E), but 
not in the aortic root (Fig. 3B,H). No differences were detected in the platelet 
count, the size, or in other blood cell populations at any time point during HFD 
(Suppl. Table 1). In addition, no significant changes were detected in plasma 
levels of cholesterol or triglycerides in absence of JAM-A on platelets during 
atherosclerosis development (Suppl. Table 2). These observations strongly 
suggest an atheroprotective role of platelet JAM-A, particularly in early stages of 
atherosclerosis. The vascular expression of JAM-A was unaffected at this time 
point (Suppl. Fig. 2). 
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Figure 2: Platelet aggregation on collagen under flow conditions.  
Whole blood from trJAM-A
+/+ 
Apoe
–/–
 (A–C) and trJAM-A
–/– 
Apoe
–/–
 (D–F) mice was perfused over 
collagen type I and platelet aggregation or fluorescence was quantified as % surface area coverage 
per analyzed field (G-I). Expression of activated 2b3-integrin or negatively charged phospholipids 
was quantified after staining with JON/A (B,E) or anti-annexin A5 antibodies (C,F). Scale bar= 20 
µm. Data represent mean ±SEM (n=6-8) and all P values were calculated by Student's t-test. 
Absence of JAM-A on platelets accelerates lesional infiltration of mononuclear 
cells 
Quantification of plaque composition in the aortic root revealed that the lesional 
MAC-2
+
 macrophage content in early stages (2 weeks HFD) was significantly 
increased in trJAM-A
-/-
 Apoe
–/–
 mice, compared with control littermates (Fig. 
4A,D). In contrast, at intermediate (6 weeks HFD) (data not shown) or advanced 
time points (12 weeks HFD), the macrophage content did not differ in trJAM-A
–/–
 
Apoe
–/–
 mice versus trJAM-A
+/+
 Apoe
–/–
 controls (Fig. 4A,G). Of note, absence of 
platelet JAM-A markedly augmented infiltration of the CD3
+
 T-cells in early 
stages (Fig. 4B,E), whereas trJAM-A–deletion did not influence T cell content at 
intermediate (data not shown) and in late time points (Fig. 4B,H). Moreover, as  
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Figure 3: Specific role of JAM-A on platelets during atherogenesis.  
trJAM-A
+/+
 Apoe
–/–
 and trJAM-A
–/–
 Apoe
–/–
 mice were fed a high-fat diet (HFD) for 2 weeks (A-C, F), 
6 weeks (D,G) and 12 weeks (A,B,E,H), as indicated. Representative pictures display the 
atherosclerotic areas in aortic roots (A) and in whole aortae (B) of trJAM-A
+/+
 Apoe
–/–
 and trJAM-A
–/–
 
Apoe
–/–
 mice after 2 weeks and 12 weeks HFD, as indicated. Scale bar=500µm. Lesional areas 
were quantified in the whole aorta after Oil-Red-O staining (B-E) and in the aortic roots after EVG-
staining (A,F-H). Data represent mean ±SEM (n=7-12) and all P values were calculated by 
Student's t-test. 
compared to control mice, platelet JAM-A–deficiency strongly increased α-SMA
+
 
smooth muscle cell (SMC) content at the early time point (Fig. 4C,F) and neither 
had effect on SMC at intermediate (data not shown) nor at late time points (Fig. 
4C,I). In line with these findings, an evaluation of the plaque phenotype in aortic 
roots revealed that JAM-A deficiency on platelets resulted in more advanced 
plaque phenotypes, compared to controls (Fig. 4M). 
 In addition, investigations on mRNA level in atherosclerotic aortae in 
mice fed for 2 and 12 weeks HFD showed that deletion of JAM-A on platelets 
significantly increased the aortic expression of chemokine receptor CXCR3 (Fig. 
4J), a marker for helper and effector T cells and of the inflammatory cytokines 
IFNγ (Fig. 4K) and TNFα (Fig. 4L), after 2 weeks but not after 12 weeks of HFD. 
Thus, platelets may differentially modulate the inflammatory lesion phenotype 
and the atherosclerotic plaque stage.  
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Figure 4: Atherosclerotic lesion phenotype in trJAM-A
–/–
 Apoe
–/–
 mice.  
Representative pictures of MAC-2 (A, green), CD3 (B, red) and αSMA (C, red) -stained aortic roots, 
2 weeks (upper panel) and 12 weeks (lower panel) from trJAM-A
+/+
 Apoe
–/–
 and trJAM-A
–/–
 Apoe
–/–
 
mice, as indicated. Nuclei were stained with DAPI (blue). Scale bar=200µm (A,C), scale bar=100µm 
(B). The plaque content of MAC-2
+
 macrophages (D,G), CD3
+
 T cells (E,H) and SMCs (F,I) in aortic 
root lesions was quantified after 2 weeks (D-F) and 12 weeks HFD (G-I). cDNA expression of 
CXCR3 (J), IFN- (K) and TNF- (L) in whole aorta from trJAM-A
+/+ 
Apoe
–/–
 mice and trJAM-A
-/-
 
Apoe
–/–
 
 
mice after 2 weeks and 12 weeks HFD is expressed as ratio between target gene 
expression and 18S RNA. The lesions were phenotypically characterized according to stage (M). IX: 
intimal xanthoma, PIT: pathologic intimal thickening, FCA: fibrous cap atheroma. Data represent 
mean±SEM (n=7-12) and P values were calculated by Student's t-test (D-I) or ANOVA with Tukey's 
post test (J-L). 
Deficiency of JAM-A leads to increased release of chemokines from platelets  
Platelets store many inflammatory proteins in their α-granules and they can 
release chemokines e.g. platelet factor-4 (PF4, CXCL4) and RANTES (CCL5) 
upon activation, leading to increased recruitment of mononuclear cells to the 
inflamed vessel wall
3, 34
. Therefore, we investigated whether the deletion of 
platelet JAM-A might have an influence on the secretion of chemokines during 
the course of atherosclerosis. Interestingly, CXCL4 and CCL5 
immunofluorescence intensities were reduced in platelets isolated from trJAM-
A
–/–
 Apoe
–/–
 mice compared with those from trJAM-A
+/+
 Apoe
–/–
 mice after 12 
weeks and 2 weeks HFD, respectively (Fig. 5A,B). In addition, absence of JAM-
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A on platelets incrementally increased the levels of circulating CXCL4 after 2, 6 
and 12 weeks of HFD (Fig. 5C). Similarly, CCL5 levels were markedly.  
 
Figure 5: Role of trJAM-A in platelet release and platelet-leukocyte interactions. 
Representative images of CXCL4 (A) and CCL5 (B) staining in platelets after 12 weeks (A) and 2 
weeks HFD (B). Scale bar=20 µm. Chemokine levels of CXCL4 (C) and CCL5 (D) in plasma from 
trJAM-A
+/+
 Apoe
–/–
 and trJAM-A
–/–
 Apoe
–/–
 mice fed a HFD for 2 weeks, 6 weeks and 12 weeks and 
without HFD (w/o HFD). Thrombin-activated platelets and leukocytes were incubated and platelet-
monocytes aggregates (CD41
+
/CD11b
+
) (E,F) and platelet-neutrophil (CD41
+
/Ly6G
+
) (G,H) 
complexes were analyzed by flow cytometry as a percentage of all CD45+ cells. Data represent 
mean ±SEM (n=7-14) and all P values were calculated by by ANOVA with Bonferroni's post test 
(B,D) or Student's t-test (F,H). 
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enhanced in plasma from trJAM-A
–/–
 Apoe
–/–
 mice compared to controls in the 
early and intermediate time points of the HFD (Fig.5D), indicative of increased 
chemokine release by JAM-A-deficient platelets. 
JAM-A–deficient platelets show an increased interaction with leukocytes 
Activated platelets have been described to form complexes with leukocytes
14, 35
, 
which might be relevant during acute coronary events
36, 37
. To investigate 
whether JAM-A–deficiency might lead to increased interactions with leukocytes, 
activated platelets isolated from trJAM-A
–/–
 Apoe
–/–
 mice were incubated with 
leukocytes. Indeed, JAM-A–deficient platelets formed significantly more platelet-
monocyte (Fig.5E,F) and platelet-neutrophil (Fig. 5G,H) aggregation than 
platelets from trJAM-A
+/+
 Apoe
–/–
 mice, suggesting that JAM-A-deficient platelets 
might more effectively augment monocyte recruitment to sites of endothelial 
inflammation. 
Leukocyte adhesion is enhanced in the absence of JAM-A on platelets 
 Platelets are able to form a bridge between monocytes and endothelial 
cells during inflammation
11
. To assess the contribution of JAM-A to platelet and 
leukocyte adhesion to endothelial cells, we performed both in vitro and in vivo 
assays. Thrombin-activated platelets from trJAM-A
–/–
 Apoe
–/–
 mice were 
perfused over mouse endothelial monolayers challenged with TNF-α, followed 
by perfusion of activated leukocytes from the same mouse genotype. A 
significantly increased cell surface coverage with both platelets and leukocytes 
(Fig. 6A,B left), only platelets (Fig. 6A,B middle) or leukocytes adherent on the 
platelets (Fig. 6A,B right) was observed in trJAM-A
–/–
 Apoe
–/–
 mice compared 
with the control group.  
 In addition, intravital microscopy performed along the atherosclerotic A. 
carotis supported these observations. Flow-resistant monocyte–endothelium 
interactions in trJAM-A
–/–
 Apoe
–/–
 mice were significantly more pronounced than 
in trJAM-A
+/+
 Apoe
–/–
 mice (Fig. 6C,D left), whereas neutrophil adhesion in 
trJAM-A
-/-
 mice showed a non-significant tendency to an increase (Fig. 6D 
right). These results indicate that platelet hyperreactivity due to JAM-A–
deficiency might result in increased platelet-monocyte interactions which in turn 
facilitates monocyte recruitment to the vessel wall during atherogenesis.  
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Figure 6: Role of JAM-A on platelets in leukocyte recruitment.  
Representative images displaying adherent platelets (green) and leukocytes (red) in vitro (A) and of 
adherent monocytes (red) in vivo (C) are shown. Scale bar=100 µm (A,C) . Adherent CD45
+
 
leukocytes (B, right), CD41
+
 platelets (B, middle) or platelets and leukocytes aggregates (B, left 
panel) were analyzed on TNFα-activated mECs as cell surface coverage (%) in the presence or 
absence of JAM-A on platelets. Firm arrest of CD11b
+
 monocytes (D, left) and Ly6G
+
 neutrophils (D, 
right) was assessed in atherosclerotic A. carotis in vivo using intravital microscopy and presented as 
number of adherent cells per visual field. Data represent mean ±SEM (n=6) and all P values were 
calculated by Student's t-test. 
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Discussion 
It is well established that platelets play a decisive role in the clinical precipitation 
and recurrence of cardiovascular disease (CVD), and antiplatelet drugs are 
widely used in the after-care and prevention of individuals who suffered, or are 
at risk of, a cardiovascular event
38
. However, it is less known that platelets can 
also initiate and propagate vascular inflammation, which may ultimately lead to 
the development of atherosclerotic plaques
5, 6
. In both cases, platelet 
hyperreactivity might contribute to an increased risk of CVD, by initiating 
endothelial dysfunction and propagating vascular inflammation, and through 
lower aggregation thresholds, aiding to the occurrence or recurrence of 
ischemic events due to vascular occlusion. Increased platelet reactivity in 
combination with resistance to antiplatelet therapy is known to pose an 
enhanced risk for CVD in patients with e.g. diabetes or hypertension
39, 40
. In this 
respect, an increase of both the inflammatory as well as the hemostatic 
functions of platelets might play an underlying role, but experimental evidence 
for this notion is scarce. 
 Deficiency of JAM-A was shown to increase the response of platelets to 
various agonists in recent studies by Naik and coworkers
4, 27
. Additionally, lack 
of trJAM-A led to shortened bleeding times and increased platelet aggregation 
in response to collagen, ADP and PAR-4 agonists, without leading to increased 
activation of 2b3-integrin. Our findings support these observations and we 
have also demonstrated increased adhesiveness and aggregation of JAM-A–
deficient platelets to immobilized collagen under flow. In addition, unlike 
negatively charged phospholipids, active 2b3-integrin was abundantly 
expressed on these shear-resistant platelet aggregates from both trJAM-A
–/–
 
Apoe
–/–
 and trJAM-A
+/+
 Apoe
–/–
 mice, although platelets from trJAM-A
–/–
 Apoe
–/–
 
mice did show more active 2b3-integrin staining, rather due to a higher surface 
coverage than to higher integrin activity on an individual platelet. This appears 
to be in concordance with the previously postulated notion that JAM-A–
deficiency does not influence 2b3-integrin activation
27
.  
 The current mechanistic model of how JAM-A regulates platelet 
activation is that tyrosine-phosphorylated JAM-A is associated with 2b3-
integrin in resting platelets
27
. In this state, 2b3-integrin is bound to inactive, 
tyrosine-phosphorylated c-Src. Phosphorylated JAM-A was found to recruit 
CSK, an inhibitor of c-Src to the 2b3-integrin–c-Src complex, thereby 
maintaining c-Src (and 2b3) in an inactive state. Upon platelet activation, JAM-
A is rapidly dephosphorylated causing CSK and JAM-A to dissociate from 2b3, 
enabling c-Src–mediated 2b3-integrin activation. Because JAM-dissociation 
from 2b3 was observed both after agonist-induced inside-out signaling as well 
as ligand-induced outside-in signaling, it is unclear whether the regulatory 
function of JAM-A is restricted to the attenuation of outside-in signaling. Since 
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platelet activation involves an intricate sequence of instantaneous enzymatic 
steps along with autocrine communication, the resulting cascade of events 
ultimately leads to a variety of responses e.g. aggregation, shape change, 
integrin activation and vesicle release. Thus, it is challenging to pinpoint the 
regulatory effects of JAM-A solely on outside-in signaling. As a whole, the 
findings by Naik et al., combined with those in our study highlight JAM-A as an 
2b3 integrin-associated negative regulator of platelet activation and 
aggregation.  
 In trJAM-A
–/–
 Apoe
–/–
 mice, we found decreased granular staining of the 
chemokines CCL5 and CXCL4 in platelets and increased plasma levels of these 
chemokines during the course of a high-fat diet. Thus, we postulate that the 
decreased activation threshold of JAM-A–deficient platelets results in a 
continuous low-level release of -granule contents, leading to increased 
circulating chemokine concentrations. These chemokines might also be more 
effectively deposited onto the vessel walls of the trJAM-A
–/–
 Apoe
–/–
 mice, 
resulting in increased recruitment of mononuclear cells to developing plaques. 
This might explain the increased content of T cells, macrophages and the 
elevated pro-inflammatory cytokine expression levels, particularly in the lesions 
of trJAM-A
–/–
 Apoe
–/–
 mice at early time-points. Previous studies have 
highlighted a role for platelets and their secretion products particularly in early 
phases of plaque development
1, 41
. In this respect, it is interesting that the 
effects of platelet-specific JAM-A–deficiency declined at later time points during 
the high-fat diet, particularly in the aortic root. This also supports the notion that 
platelets mainly propel early-phase plaque development, which preferentially 
occurs under conditions of disturbed flow, as occurring in the aorta near the 
heart valves. As plaque progression occurs, other determinants might dominate 
and platelet-specific effects become secondary. 
 Activated platelets avidly bind to leukocytes and uncontrolled platelet 
activation might lead to increased levels of circulating platelet–leukocyte 
complexes e.g. during acute cardiovascular events
36, 37
. Since platelets have 
been shown to actively recruit mononuclear cells to the vessel wall
11, 42, 43
, it is 
conceivable that increased platelet-leukocyte aggregation in trJAM-A
–/–
 Apoe
–/–
 
mice might also contribute to plaque development. 
Taken together, JAM-A plays a crucial role in controlling platelet reactivity. 
Uncontrolled platelet reactivity might lead to continuous low-level activation of 
circulating platelets, due to a decreased stimulation threshold. Since activated 
platelets exacerbate atherosclerosis, hyperreactive JAM-A–deficient platelets 
might both initiate and accelerate early plaque formation. This study thus 
highlights the detrimental role of activated platelets in preclinical phases of CVD 
and adds another fundamental facet to the role of JAM-A in vascular disease. 
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Supplementary Figures 
 
Supplementary Figure 1: JAM-A deletion on platelets and cell-specific JAM-A expression in 
trJAM-A
–/–
 Apoe
–/–
 mice  
JAM-A was stained on isolated platelets (A, JAM-A: green, CD41: red). Scale bar=20µm. JAM-A 
expression on platelets (B) and leukocytes (C) was measured by flow cytometry. Upper right 
quadrants depict the percentage of platelet (B) and leukocyte (C) JAM-A expression in trJAM-A
+/+
 
Apoe
–/–
 and trJAM-A
–/–
 Apoe
–/–
 mice, as indicated. Western blot experiments in homogenates from 
aortae and A. carotis from trJAM-A
–/–
 Apoe
–/–
 and trJAM-A
+/+
 mice Apoe
–/–
 (D). Ponceau S staining 
served as a loading control. Representative picture express 3 independent experiments.  
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Supplementary Figure 2: Endothelial JAM-A expression in platelet-deficient JAM-A mice 
Endothelial JAM-A (A,B, merged, right) was stained in A. carotis from trJAM-A
+/+ 
Apoe
–/–
 (A) and 
trJAM-A
–/– 
Apoe
–/– 
 (B) mice fed a HFD for 2 weeks. JAM-A: green (A, B left), CD31: red (A,B, 
middle), collagen: blue (autofluorescence). Scale bar= 20µm. 
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Supplementary Table 2: Plasma cholesterol- and triglyceride levels in mice receiving HFD for 
2 weeks (2w), 6 weeks (6w) and 12 weeks (12 w) HFD 
Values are expressed as mg/dl. Data represent mean ±SEM (n=7-13) and all P values were 
calculated by Student's t-test. 
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Presently, atherosclerosis constitutes one of the leading causes for patients 
suffering morbidity and death around the world with no expected changes in 
frequency the next decades
1, 2
. A lot of efforts to find powerful therapeutic 
targets had been taken already, but the range of useful drugs is still comparably 
limited regarding the broad causalities of this multifaceted disease. Still plenty of 
crucial cellular and molecular mechanisms facilitating atherosclerosis are not 
understood completely. As atherosclerosis is a chronic inflammation of the 
vessel wall, leukocyte – endothelial cell interaction is one of the determining 
factors for atherosclerotic lesion formation. Thus, investigating mechanisms 
underlying leukocyte recruitment is important for development of novel 
therapeutic strategies as they still are not explored to a satisfying degree. One 
of the involved adhesion molecules, at which attention had be drawn to already 
years ago, is JAM-A. Over the years a rag rug of roles for JAM-A expressed by 
differing cell types in different inflammatory setups was generated. For example 
the role of JAM-A in injury models of liver
3
, carotid artery
4
 and heart
5
 had been 
investigated, sometimes with contrary results
6-9
, but a conclusive study directly 
comparing the role of JAM-A from differing cellular origin on atherogenesis is 
still missing.  
With this study, we aimed to unravel the influence of the adhesion 
molecule JAM-A expressed from different cell types on atherosclerotic lesion 
formation and progression. Meanwhile, identified new concepts of leukocyte 
extravasation and were able to verify established ones. In detail, we found that: 
1. JAM-A from differing cellular origin exerts diverse effects on 
atherogenesis 
 
2. Whereas somatic deficiency has no effect, endothelial JAM-A deficiency 
reduces plaque formation via decreasing leukocyte recruitment 
 
3. Leukocytes deficient for JAM-A lack active transmigratory capacity and 
damage the vessel wall, thus enhancing plaque formation  
 
4. Endothelial JAM-A is more abundant on the cell surface under 
hyperlipidemic and altered shear stress conditions 
 
5. Normal flow conditions exert atheroprotective function by reducing 
JAM-A expression via increased miR-145 levels 
 
6. Lovastatin completely abolishes oxidized LDL-mediated JAM-A 
re-localization and increase in leukocyte infiltration 
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7. Adhesion “hot spots” of JAM-A molecules are involved in initiating 
leukocyte infiltration under inflammatory conditions 
 
8. Platelets deficient for JAM-A show a hyperreactive phenotype 
enhancing secondary adhesion of leukocytes, thus aggravating lesion 
formation 
 
 
Cell-specific function of JAM-A in atherosclerosis 
For the first time, we were able to demonstrate opposing functions of JAM-A 
from different cellular origins in one comprehensive study (chapter 2, chapter 
5). Precisely, endothelial JAM-A facilitates leukocyte recruitment and thus 
atherosclerotic lesion formation via its increased accessibility to bypassing 
leukocytes under inflammatory and altered shear stress conditions. In contrast, 
JAM-A on leukocytes and platelets display atheroprotective properties, mainly 
because deficiency of JAM-A leads to extension of integrin activity with 
increased leukocyte adhesion or defective de-adhesion as consequence. 
Not many molecular players orchestrating the adhesion cascade are 
known to be expressed by several cell types like leukocytes, endothelial cells 
and platelets. Another adhesion molecule being closely related to JAM-A and 
expressed by diverse cell types is JAM-C. A comprehensive study regarding 
possible alternating functions of JAM-C from differing cellular origin in 
atherosclerotic lesion formation is missing, making a comparative discussion to 
JAM-A difficult, but single studies performed in different inflammatory models 
provide initial evidence. Thus, endothelial JAM-C had been discovered to act 
rather as a “gate-keeper” than facilitating transendothelial migration like JAM-A 
does. JAM-C tightly seals junctions of big vessels for already transmigrated 
leukocytes, thereby inhibiting re-transmigrated leukocytes from inflicting 
secondary organ damage by increased reactive oxygen species production
10, 11
. 
Recently, Donate and colleagues were able to show a reduction of lymphocyte 
infiltration into secondary lymphatic organs subsequent to leukocytic JAM-C 
antibody-facilitated blockade. In detail, treatment of B cells with anti-JAM-C 
antibodies reduced migration of JAM-C-expressing B cells into spleen and 
lymph nodes
12
. Comparable to genetic deletion of JAM-A in mice, a systemic 
blockade of JAM-C using antibodies resulted in decreased neo-intima formation 
after wire-injury experiments of the murine carotid artery
4, 13
 and in reduced 
accumulation of leukocytes in alveoli during acute pulmonary inflammation in 
mice
14, 15
. Additionally comparable to JAM-A deficiency, inhibition of systemic 
JAM-C using soluble JAM-C resulted in a reduction of transmigrated neutrophils 
in a model of acute thioglycollate-induced peritonitis
5, 16
. 
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Endothelial JAM-A facilitates leukocyte infiltration through re-
localization under inflammatory or altered shear stress conditions 
Some debate with contrary results regarding endothelial JAM-A as a mediator 
for leukocyte  infiltration  under inflammatory  conditions  was held  in  the  
past
3, 4, 7, 9
. Here we provide definite evidence for endothelial JAM-A–mediated 
leukocyte recruitment by using mice deficient for endothelial JAM-A, blocking 
antibodies and rescue experiments (chapter 2, chapter 3). The main reason 
why endothelial JAM-A exerts atherogenic properties is its re-localization 
triggered by cytokines, oxidized LDL or low/oscillatory shear stress (chapter 2, 
chapter 4). In an inflammatory setting, leukocytes adhere at endothelial cells of 
post-capillary venules under rather low shear forces compared to high shear in 
the arterial system. It is highly likely that, additional to selectins, further 
molecular interactions are needed to overcome the higher shear rates found in 
the artery and to facilitate adhesion of leukocytes to endothelial cells, e.g. 
hetero- and homophilic interactions of luminal JAM-A. Thus, JAM-A re-
localization enables additional leukocyte adhesion to the endothelium. In detail, 
we were able to show a clustered re-localization of JAM-A on the apical 
endothelial cell site (chapter 2) together with an accumulation of JAM-A not in 
but near the junctions to build “hot-spots” of transmigration (chapter 4). 
Concomitant to those results another study showed a chemokine triggered and 
macropinocytosis driven functional JAM-A re-localization in brain endothelial 
cells
17
. Intriguingly, further work demonstrated no observable rapid 
re-localization of JAM-A compared to LFA-1 and ICAM-1 re-localization on 
TNF-–stimulated HUVECs after neutrophil adherence
7
. This might point to 
another mechanism for JAM-A re-localization, which occurs soon after 
leukocyte adhesion compared to the mechanism triggered by prolonged 
inflammatory setups like hyperlipidemia and altered shear stress described by 
us. In another work by Mamdouh and colleagues, JAM-A was identified as part 
of the so-called “lateral border recycling compartments”, a patch of junctional 
membrane also consistent of CD31 and CD99, which tends to re-localize to 
“invest” adherent leukocytes
9
. Comparable to the former study, this mechanism 
of re-localization again should be accounted to a more rapid, cell adhesion– 
triggered phenomenon and might explain the observed differences to our 
chronic model basing on comparably long-term exposure to atherogenic factors. 
Additionally, the authors claimed that JAM-A blocking antibodies do not change 
transmigration capacities neither on the para- nor on the transcellular route. 
Observed differences to our results might originate in their aim to discriminate 
between para- and transcellular leukocyte transmigration, which demanded an 
experimental setup far from physiologic conditions and thus not necessarily 
representing the physiological role of JAM-A in leukocyte transmigration. 
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Atheroprotective function of high and laminar shear stress via 
shear receptive miR-145 
Many preceding studies were able to indicate an atheroprotective function for 
high and laminar shear stress, also regarding shear stress regulated miR 
levels
18-23
. Recently, another adhesion molecule named PECAM-1 was found to 
regulate atherosclerotic plaque formation in a cell- and site-specific manner
24
. 
PECAM-1 on bone marrow cells displayed pro-atherogenic properties 
regardless of the hemodynamic situation, whereas endothelial PECAM-1 
increased macrophage infiltration in areas of low and oscillatory shear stress 
but was atheroprotective in regions of high and laminar shear stress. Here, we 
were able to extend those results with findings for JAM-A, as a correlative 
decrease of miR-145 with shear stress enhanced JAM-A expression. Therefore, 
comparable to increased JAM-A expression under hyperlipidemic conditions, 
more functional JAM-A was available in predilection sites under conditions of 
low and oscillatory shear stress for proatherogenic facilitation of leukocyte 
transmigration (chapter 2). 
Enhanced integrin activity on leukocytes or platelets with JAM-A 
deficiency 
An initially surprising increase in adhesion of JAM-A deficient leukocytes to 
endothelial cells paved the way in understanding the increased lesion formation 
in leukocytic JAM-A deficient mice (chapter 2). A recent study found a 
co-distribution of JAM-A with 1 integrins in neutrophils causing their 
collaborative internalization, which was inhibited when JAM-A was lacking
25
. 
This decreased the transmigratory capacity of leukocytes. We found that a 
JAM-A deficiency-mediated prolonged activity of 2 integrins caused a defect in 
de-adhesion from their receptor ICAM-1 (chapter 2). Likely, JAM-A deficient 
leukocytes displaying defective de-adhesion and being captured at the 
endothelium or in between endothelium and basement membrane might inflict 
enough damage to endothelial cell integrity to facilitate secondary influx of 
atherogenic cells or compounds. In platelets JAM-A is a negative regulator of 
2b3 integrin
26, 27
. The 2b3 integrin is known to facilitate platelet/endothelial 
cell interactions
28
 and a 2b3 integrin-antagonist treatment of whole blood 
resulted in decreased platelet/monocyte and platelet/neutrophil interactions
29
. 
Concomitantly, we were able to show that deficiency of platelet JAM-A 
introduced platelet hyperreactivity with lower activation thresholds and 
increased platelet/leukocyte interaction via enhanced 2b3 integrin activity. 
Besides the increase plasma-levels of atherogenic chemokines like CCL5 and 
CXCL4, these enhanced platelet/leukocyte interactions likely aggravated the 
atherosclerotic lesion formation observed (chapter 5). 
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Lovastatin, but not pioglitazone treatment abolishes oxidized LDL– 
induced JAM-A re-localization and leukocyte infiltration 
With this study we were able to expand the knowledge on the atheroprotective 
effects of the HMG-CoA-reductase inhibitor lovastatin with another aspect. Here 
we demonstrate the complete reduction of oxidized LDL as well as TNF-/IFN-
induced functional re-localization of endothelial JAM-A by lovastatin 
treatment. Moreover, leukocyte transmigration rates enhanced by oxidized LDL 
as well as TNF-/IFN- treatment were completely abolished after co-treatment 
with lovastatin (chapter 3). Parallel to an enhanced junctional localization of 
JAM-A after lovastatin treatment, immunofluorescence analysis of actin 
organization revealed a reduction of stress fibers in endothelial cells incubated 
with lovastatin. (chapter 3). Concomitant to that, a previous study demonstrated 
lovastatin-mediated alterations in cytoskeleton organization with consequences 
on adhesion, motility and proteolysis of mammary carcinoma cells
30
. Besides a 
steric hindrance of JAM-A re-localization facilitated by actin reorganization and 
tight JAM-A/actin interactions, which might likely be the cause for the lovastatin-
mediated inhibition of TNF-/IFN-–facilitated JAM-A re-localization and 
leukocyte infiltration, statins also exerts important effects on lectin-like oxidized 
low density lipoprotein receptor (LOX)-1. As shown recently, statins protect 
vascular endothelium against effects of oxidized LDL through impairment of 
LOX-1 receptor function
31
. Together with findings that LOX-1 activation plays an 
important role in oxidized LDL-induced expression of adhesion molecules
32
 one 
could easily conclude that statins also inhibit leukocyte infiltration via reducing 
oxidized LDL mediated adhesion molecule expression. Finally, statins were 
shown to be capable of inhibiting lymphocyte homing to murine peripheral 
lymph nodes in vivo
33
.  
The peroxisome proliferator-activated receptor- agonist pioglitazone 
did not establish any effects on oxidized LDL as well as TNF-/IFN-induced 
JAM-A re-localization and leukocyte infiltration, although previous studies 
provided reliable evidence for that. For example, pioglitazone reduced 
neutrophil infiltration in a model of LPS induced acute lung injury
34
. Moreover, 
pioglitazone reduced intracellular super-oxide radical generation and 
subsequently the expression of LOX-1 and monocyte adhesion in human 
endothelial cells
35
. Additionally, pioglitazone had been shown to inhibit 
TNF--induced LOX-1 expression in bovine endothelial cells
36
. Why 
pioglitazone did not affect oxidized LDL and TNF-/IFN-induced JAM-A 
re-localization and leukocyte infiltration in our model is still to be elucidated. 
  
GENERAL DISCUSSION  
161 
6 
Concluding remarks and future perspectives 
With this thesis, for the first time we unraveled opposing contributions of JAM-A 
harbored by differing cell types to atherosclerotic lesion formation. 
 We could prove that endothelial JAM-A propagates atherogenic 
conditions in Apoe-deficient mice by regulating leukocyte infiltration, in contrast 
to leukocytic and platelet JAM-A, which mediate regular integrin internalization 
and contribute thus to normal leukocyte and platelet (de)-adhesion. 
 Another main novelty also adds more details to the atheroprotective 
function of high and laminar shear stress, namely the regulation of JAM-A 
expression by shear-receptive miR-145. 
 Last but not least, our results pointed out a novel atheroprotective effect 
of lovastatin by completely blocking oxidized LDL- and cytokine-induced 
increase of JAM-A re-localization and leukocyte infiltration. 
 Having deciphered the different engagements of JAM-A, specifically 
targeting endothelial JAM-A likely by miR-145 intervention could present a 
promising and valuable therapy for preventing atherosclerotic lesion formation 
in early and late stages. Additionally, re-localized endothelial JAM-A might be 
useful in order to identify upcoming atherosclerotic lesions, likely via JAM-A 
antibody coupled microbubbles detected by non-invasive ultrasound.  
 In general we believe that this work thoroughly illustrates the necessity 
for investigating crucial proteins in different context e.g. cellular, circadian or 
trigger-based. Deeper understanding of those issues would lead to better and 
safer drug development. 
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Worldwide, cardiovascular diseases are the leading source of patients suffering 
tremendous reduction in life quality until premature death. Fighting those widely 
spread diseases is one of the most challenging tasks of our generation. Their 
multi-factorial nature allows on the one hand a broad spectrum of potential 
therapeutics, but on the other hand being tightly linked to the body’s immune 
system, therapeutic drugs need to be highly specific without causing 
undesirable side-effects. 
The most abundant cardiovascular diseases are acute myocardial 
infarction and stroke, which are typically instigated by stenosis of arteries as a 
result of rupture of advanced atherosclerotic lesions.  
Atherosclerosis is a progressive and chronic disease, induced by 
constituents of the immune system. It is characterized by accumulation of lipids, 
immune cells and fibrous components in the arterial wall at predilection sites 
comprising altered shear stress conditions. At these sites, hyperlipidemia-
triggered excess uptake of LDL-cholesterol into the vessel wall occurs and 
oxidation as well as acetylation of those lipids take place with subsequent 
activation of endothelial cells. Enhanced monocyte influx enabled by endothelial 
cell activation finally leads to greater prevalence of highly lipid-laden foam cells, 
which were macrophages differentiated from monocytes taking up oxidized LDL 
(oxLDL). Foam cells secrete factors contributing to a persistent inflammatory 
response in the vessel wall, augmenting the influx of additional monocytes and 
other inflammatory cell types like T cells and granulocytes. Chronic occurrence 
of inflammation finally leads to development of advanced atherosclerotic lesions 
with a necrotic core being covered by a fibrous cap. Destabilization of the 
fibrous cap through proteases, but also erosion and cell death will advance the 
plaque stage to an instable plaque phenotype. Upon plaque rupture, pro-
thrombotic factors of the necrotic core will trigger coagulation and thrombus 
formation causing acute myocardial infarction or stroke.  
 Recruitment of leukocytes is an important prerequisite for athero-
sclerotic lesion formation. A lot of efforts had been taken to elucidate the 
mechanisms and molecular effectors playing a role in leukocyte recruitment. 
From a plurality of studies a multi-step cascade evolved, called the Leukocyte 
Adhesion Cascade, which however is still not studied completely.  
The beginning of the Leukocyte Adhesion Cascade comprises selectin 
and PSGL-1–mediated leukocyte tethering to and rolling on the endothelial cell 
layer, followed by integrin and adhesion molecule interaction-mediated firm 
adhesion and transmigration along a chemokine gradient. One of those 
molecular players orchestrating leukocyte adhesion and transmigration is 
Junctional Adhesion Molecule (JAM)-A. Several studies demonstrated 
(sometimes even contrary) roles for JAM-A in various inflammatory disease 
models, but a comprehensive study identifying the roles of JAM-A harbored by 
different cell types regarding atherosclerotic lesion formation is still missing 
(chapter 1).  
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Therefore, the hypothesis of this thesis is that JAM-A from differing 
cellular origin might exert different effects on leukocyte recruitment and thus on 
atherogenesis, a phenomenon being of fundamental interest not only in basic 
science but also in drug development. Additionally, exact localization of 
endothelial JAM-A under inflammatory conditions would add key information to 
the underlying mechanisms. 
In chapter 2, we were able to demonstrate atherogenic functions of 
endothelial JAM-A by showing decreased atherosclerotic lesion formation in 
mice deficient for endothelial JAM-A. In contrast, an increased lesion formation 
was observed in mice with leukocytic JAM-A deficiency, suggesting an 
atheroprotective role of leukocytic JAM-A. In transmigration assays in vitro and 
in vivo, deficiency of endothelial JAM-A resulted in decreased leukocyte 
transmigration rates contrary to deficiency of leukocytic JAM-A, which induced 
defect de-adhesion likely due to prolonged 2-integrin activity caused by 
absence of JAM-A–mediated integrin internalization, thereby damaging 
endothelial cell lining. Moreover we provided evidence that endothelial JAM-A 
re-localizes to apical cell site in a focal manner after treatment with cytokines or 
oxLDL as well as in areas of disturbed flow, thereby increasing leukocyte 
adhesion and transmigration. Additionally we could demonstrate an 
atheroprotective role of high and laminar shear stress via robust miR-145 copy 
synthesis, inhibiting endothelial JAM-A expression.  
In order to explore the mechanisms of endothelial JAM-A re-localization 
more deeply (chapter 3), immuno-fluorescence based detection of JAM-A and 
actin revealed an increase of actin expression additional to actin re-localization 
and increased JAM-A/actin co-localization likely facilitated by enhanced 
ZO-1/JAM-A interaction after oxLDL treatment. Moreover, additional 
transmigration assays expanded preceding results by ruling out any Fc-based 
artifacts while blocking JAM-A with antibodies. Thus using anti-JAM-A Fab 
fragments resulted in decreased leukocyte recruitment after cytokine or oxLDL 
treatment. Furthermore, we were able to expand the knowledge of 
atheroprotective properties of the cholesterol-lowering drug lovastatin by 
abolishment of functional JAM-A re-localization after cytokine as well as oxLDL 
treatment of endothelial cells likely via junctional actin stabilization and oxLDL 
receptor LOX-1 expression reduction. 
In a subsequent study described in chapter 4, we sought to further 
elucidate re-localization of JAM-A and its effect on leukocyte recruitment. By 
applying atomic force microscopy, we were able to show for the first time that 
the underlying molecular mechanism for enhanced T cell paracellular 
recruitment is the development of JAM-A “hot spots”, comparable to JAM-A 
re-localization shown in chapter 2 and 3. Those focal accumulations located 
near the endothelial cell-cell contacts enhance T cell junctional adhesion and 
facilitate their junctional recruitment. 
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Finally in chapter 5, we provide significant findings regarding JAM-A 
deficiency in thrombocytes and its outcome on atherosclerotic lesion formation. 
In detail, thrombotic JAM-A (trJAM-A) deficiency led to hyperreactivity and 
lowered activation thresholds for activators like ADP, thrombin and collagen, 
resulting in increased adherence and aggregation. More important, a rise of 
inflammatory cytokine (TNF-α and IFN-γ) levels was present and chemokine 
levels (CXCL4 and CCL5) were enhanced in mice specifically lacking trJAM-A. 
Additionally, we found higher platelet-leukocyte interaction triggered by trJAM-A 
deficiency. Those factors finally resulted in enhanced atherosclerotic lesion 
formation, which was most pronounced in the early phase. 
In chapter 6, the results described in this thesis and their potential use 
in drug and diagnostic marker development were discussed and put into 
perspective. In conclusion, this thesis provides novel insights into JAM-A’s 
contribution in atherosclerotic lesion formation regarding cellular origin, 
leukocyte infiltration mechanism and potential interference. 
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Herz- und Gefäßkrankheiten sind der häufigste Grund für starke 
Einschränkungen in der Lebensqualität bis hin zum Tod von Patienten weltweit. 
Der Kampf gegen diese weit verbreiteten Krankheiten ist eine der größten 
Herausforderungen unserer Zeit. Zwar erlauben Herz- und Gefäßkrankheiten 
auf Grund ihrer mannigfaltigen Kausalitäten auch ein großes Repertoire an 
verschiedenen Wirkstoffen, doch die enge Verbindung vom Immunsystem zu 
Herz- und Gefäßkrankheiten erlauben nur Therapien, die absolut frei von 
Nebenwirkung sind.  
Die wichtigsten Herz- und Gefäßkrankheiten stellen akutes 
Herzversagen und Schlaganfall dar, welche typischer Weise durch Stenose von 
arteriellen Gefäßen als Resultat eines Aufbruchs  fortgeschrittener 
atherosklerotischer Läsionen ausgelöst werden. 
Atherosklerose ist eine chronisch progressive Krankheit, ausgelöst von 
Bestandteilen des Immunsystems. Sie wird durch die Anhäufung von Lipiden, 
Immunzellen und fibrotischem Material in der Gefäßwand von sogenannten 
„predilection sites”, welche veränderte Scherflussraten aufweisen, 
charakterisiert. An diesen „predilection sites“ kommt es, ausgelöst durch eine 
Hyperlipidämie, zur erhöhten Aufnahme von LDL-Cholesterin in die Gefäßwand. 
Eine oxidative Veränderung des LDLs hat weiterhin eine von oxidierten LDL 
(oxLDL) induzierte Aktivierung von Endothelzellen zur Folge. Eine durch 
Aktivierung der Endothelzellschicht ermöglichte erhöhte Rekrutierung von 
Monozyten wiederum führt zu einem gesteigerten Vorkommen von 
Schaumzellen, deren Inhalt hauptsächlich oxidierte Lipide darstellen. Eine 
langanhaltende Entzündung der Gefäßwand wird von Schaumzellen 
sezernierten Faktoren ausgelöst, was eine erhöhte Rekrutierung von weiteren 
Immunzellen wie T Zellen und Granulozyten bewirkt. Die chronische 
Entzündung der Gefäßwand führt letztendlich zur Entwicklung von 
fortgeschrittenen atherosklerotischen Läsionen, charakterisiert durch einen 
Kern nekrotischer Zellen überlagert von einer Kappe aus fibrotischem Material. 
Durch Protease-vermittelter Destabilisierung der fibrotischen Kappe, sowie 
durch zusätzlicher Nekrose und Erosion der Läsion wird diese instabil. Nach 
Aufbruch der instabilen Läsion gelangen prothrombotische Faktoren aus dem 
nekrotischen Kern in die Blutzirkulation, was eine Koagulation des Blutes 
bewirkt. Dies hat einen Verschluss und damit einen akuten Herzinfarkt oder 
Hirnschlag zur Folge.  
 Für das Entstehen atherosklerotischer Läsionen ist die Rekrutierung 
von Leukozyten eminent wichtig. Viele Anstrengungen wurden bis jetzt 
unternommen, um Mechanismen und molekulare Effektoren der Leukozyten-
Rekrutierung zu identifizieren. Daraus konnte ein heutzutage allgemeingültiger 
Mechanismus abgeleitet werden, die sogenannte Leukozyten Adhäsions 
Kaskade, deren Gesamtbild trotz aller Bemühungen noch nicht vollständig ist. 
Der Anfang der Leukozyten Adhäsions Kaskade stellt ein Selektin und 
PSGL-1 vermitteltes loses Anheften und Rollen von Leukozyten an und über die 
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Endothelzellschicht dar, gefolgt von der festen Adhäsion und transendothelialen 
Migration der Leukozyten durch Integrin und Adhäsionsmolekül vermittelter 
Interaktion entlang eines Chemokingradienten. Ein wichtiges Molekül, welches 
Leukozyten-Adhäsion und -Transmigration vermittelt, ist das Junktionale 
Adhäsionsmolekül (JAM)-A. Mehrere Studien zeigen einen (teilweise sogar 
entgegengesetzten) Einfluss von JAM-A auf verschiedene Modelle 
entzündlicher Krankheiten, doch eine Studie bezüglich der Identifikation der 
einzelnen zellspezifischen Rollen von JAM-A auf atherosklerotischer 
Läsionsbildung fehlt bis heute (Kapitel 1).  
Deswegen lautet die Hypothese dieser Arbeit, dass JAM-A exprimiert 
durch unterschiedliche Zelltypen diverse Effekte auf die Leukozyten-
Rekrutierung und damit auf die Entstehung atherosklerotischer Läsionen 
ausübt. Das Wissen um unterschiedliche Funktionen ist nicht nur von 
fundamentalem Interesse für die Grundlagenforschung, sondern auch für die 
Wirkstoffentwicklung. Zusätzlich trägt eine exakte Lokalisierung von 
endothelialen JAM-A unter entzündlichen Bedingungen zum Verständnis des 
zugrundeliegenden Mechanismus der Leukozyten-Rekrutierung bei. 
In Kapitel 2 beschreiben wir eine atherogene Funktion von 
endothelialen JAM-A durch verminderte Läsionsbildung und Leukozyten-
Rekrutierung bei Abwesenheit dieses Proteins im Kontrast zu der 
atheroprotektiven Funktion von leukozytärem JAM-A beschrieben durch erhöhte 
Läsionsbildung und Leukozyten-Rekrutierung in Mäusen mit JAM-A
-/-
 
Leukozyten. In vitro und in vivo Transmigrations-Versuche mit Endothelzellen 
defizient für JAM-A bestätigten die verminderte Rekrutierung gegensätzlich zur 
Defizienz von leukozytärem JAM-A, was zu einer gestörten -Integrin 
vermittelten De-Adhäsion und damit zur Verletzung der endothelialen Integrität 
führt. Darüber hinaus konnten wir zeigen, dass eine erhöhte Leukozyten-
Rekrutierung in Zuge von Behandlungen mit oxLDL oder Zytokinen oder in 
Bereichen mit veränderten Scherflussraten durch eine lokale Umverteilung von 
endothelialen JAM-A zur apikalen Endothelzelloberfläche vermittelt wird. 
Weiterhin erforschten wir einen weiteren atheroprotektiven Mechanismus von 
hohen und laminaren Scherflussraten. Diese bewirken eine starke Erhöhung 
der miR-145 Synthese, welche wiederum die Expression von endothelialen 
JAM-A inhibiert.  
Um den zugrundeliegenden Mechanismus der endothelialen JAM-A 
Umverteilung weiter zu erforschen konnten wir durch Immunfluoreszenz-
basierte Detektion von JAM-A und Aktin belegen, dass eine Behandlung mit 
oxLDL erstens eine Erhöhung der Aktin-Expression, zweitens eine 
Aktin-Umverteilung und drittens eine erhöhte JAM-A/Aktin Ko-Lokalisation, 
vermittelt durch stärkere ZO-1/JAM-A Interaktion, bewirkt (Kapitel 3). Darüber 
hinaus erweitern wir die vorherigen Ergebnisse der Leukozyten-
Transmigrationsversuche nach Antikörper-vermittelter JAM-A Blockade um eine 
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Erniedrigung der oxLDL und Zytokin getriggerten Leukozyten-Rekrutierung 
nach Blockade mit anti-JAM-A Fab-Fragmenten. Dies zeigt, dass eventuelle 
Fc-basierte Artefakte während einer Antikörper-vermittelten Blockade von 
JAM-A hier keine Rolle spielen. Um Informationen über eine pharmakologische 
Beeinflussbarkeit der JAM-A Funktionen zu erhalten wurde mitunter Lovastatin 
in Lokalisations- und Transmigrations-Studien eingesetzt. Hierbei konnten wir 
zeigen, dass Lovastatin als atheroprotektiven Effekt nicht nur Einfluss auf den 
Cholesterinspiegel hat, sondern auch die oxLDL und Zytokine getriggerte 
endotheliale JAM-A Umverteilung sowie die Leukozyten-Rekrutierung hemmt.  
In einer weiterführenden Studie betrachteten wir genauer die JAM-A 
Umverteilung und ihren Einfluss auf die Leukozyten-Rekrutierung (Kapitel 4). 
Mit Hilfe der „atomic force“ Mikroskopie konnten wir zum ersten Mal beweisen, 
dass der zugrundeliegende Mechanismus für erhöhte T Zell Rekrutierung die 
Entwicklung von endothelialen JAM-A “hot-spots” darstellt. Diese lokalen 
Akkumulationen von JAM-A Molekülen nahe aber nicht in den 
Zell-Zellkontakten zeigen eine vergleichbare Struktur wie die JAM-A 
Umverteilung aus Kapitel 2 und 3 und sind für eine erhöhte T Zell Adhäsion und 
Rekrutierung entlang der Zell-Zellkontakte eminent wichtig.  
Die in Kapitel 5 dargestellten Ergebnisse verweisen auf eine wichtige 
Rolle von thrombozytärem JAM-A (trJAM-A) in der atherosklerotischen 
Läsionsbildung. So konnten wir zeigen, dass trJAM-A-Defizienz für eine 
Hyperreaktivität der Thrombozyten mit erniedrigter Aktivierungsschwelle für 
ADP, Thrombin und Kollagen verantwortlich war, was folglich zu erhöhter 
Thrombozyten-Adhärenz und Aggregation führte. Weiterhin waren höhere Level 
inflammatorischer Zytokine (TNF-α und IFN-γ) und Chemokine (CXCL4 und 
CCL5) in Mäusen mit spezifischer trJAM-A Defizienz detektierbar. Darüber 
hinaus fanden wir eine erhöhte Thrombozyten-Leukozyten-Interaktion. Diese 
Faktoren resultierten letztendlich in einer Erhöhung der atherosklerotischen 
Läsionsbildung, die besonders im frühen Stadion ausgeprägt war. 
Mit Kapitel 6 diskutieren wir die in Kapitel 2 bis 5 dargestellten 
Ergebnisse und nehmen Bezug zu einer potenziellen Nutzung von JAM-A in der 
Entwicklung von diagnostischen Markern und neuen Wirkstoffklassen. 
Zusammenfassend bietet diese Arbeit neuartige Erkenntnisse zur Rolle von 
JAM-A exprimiert von verschiedenen Zelltypen in der atherosklerotischen 
Läsionsbildung einhergehend mit Leukozyten-Rekrutierung sowie deren 
Mechanismus und Intervention.  
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Wereldwijd zijn hart- en vaatziekten de oorzaak van een sterk verminderde 
levenskwaliteit en vroegtijdig overlijden. Het bestrijden van deze ziekten is dan 
ook een van de grootste uitdaging van deze tijd. De multifactoriële aard van 
deze ziekten biedt vele mogelijkheden voor therapeutische interventie, maar 
tegelijker zullen, gezien de sterke link met het immuunsysteem, potentiële 
geneesmiddelen erg specifiek moeten zijn, om het veroorzaken van 
onwenselijke bijwerkingen te voorkomen.  
De meest voorkomende hart- en vaatzieken zijn hart- en 
herseninfarcten, die voornamelijk veroorzaakt worden door vernauwing van 
slagaders als gevolg van ruptuur van vergevorderde atherosclerotische laesies.  
Atherosclerose, ook wel bekend als aderverkalking, is een progressieve 
chronische ziekte, die wordt gekarakteriseerd door een opeenhoping van 
vetten, ontstekingscellen en vezelachtig materiaal in de bloedvatwand van 
slagaders. Atherosclerose ontstaat op plekken van veranderde 
bloedstroomprofielen, waar LDL-cholesterol de vaatwand kan binnendringen, 
geoxideerd of geacetyleerd kan worden en vervolgens leidt tot activatie van 
endotheelcellen. Ten gevolge hiervan zullen monocyten de vaatwand 
binnengaan, differentiëren tot macrofagen onder invloed van het geoxideerde 
LDL (oxLDL), en verder ontwikkelen tot met vet gevulde schuimcellen. Deze 
schuimcellen scheiden stoffen uit die zorgen voor een aanhoudende 
ontstekingsreactie, gekenmerkt door influx van meer monocyten, maar ook 
ontstekingscellen als T-cellen en granulocyten. De chronische inflammatoire 
reactie zorgt op termijn voor de ontwikkeling van een vergevorderde 
atherosclerotische laesie met een necrotische kern omgeven door een fibreus 
kapsel. Destabilisatie van dit kapsel door proteolytische enzymen, erosie en 
celdood leiden tot een instabiele laesie. Wanneer een dergelijke instabiele 
laesie scheurt, komen pro-thrombotische factoren van de necrotische kern in 
contact met het bloed, hetgeen leidt tot vorming van een bloedstolsel met een 
hart- of herseninfarct tot gevolg. 
Rekrutering van leukocyten is een vereiste in de ontwikkeling van 
atherosclerose. Er is reeds veel onderzoek gedaan om de onderliggende 
moleculaire mechanismen die hierbij een rol spelen te ontrafelen. Uit voorgaand 
onderzoek is gebleken dat een meerstaps proces gekomen dat bekend staat 
als de leukocyt adhesie cascade een belangrijke rol speelt, hoewel dit proces 
nog niet volledig begrepen is. 
De leukocyt adhesie cascade start met selectine- en PSGL-1-
afhankelijke binding van leukocyten aan en het rollen van deze leukocyten over 
het endotheel. Vervolgens zorgt interactie van integrines en adhesiemoleculen 
voor binding van leukocyten aan het endotheel, hetgeen gevolgd wordt 
transmigratie van de leukocyt over de endotheelcellaag naar een chemokine-
gradiënt. Een belangrijke factor die betrokken is bij de adhesie en transmigratie 
van leukocyten is Junctional Adhesion Molecule (JAM)-A. Voorgaand 
onderzoek heeft aangetoond dat JAM-A een rol heeft in modellen van 
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verschillende inflammatoire ziektes, alhoewel de resultaten van deze studies 
soms tegenovergestelde resultaten laten zien, en er nog geen duidelijkheid over 
is over de rol van JAM-A in de verschillende celtypes die een rol spelen in 
atherosclerose (hoofdstuk 1).  
Daarom is de hypothese van dit proefschrift dat JAM-A in verschillende 
celtypes verschillende effecten heeft op rekrutering van leukocyten en de 
ontwikkeling van atherosclerose, hetgeen ook van belang is voor de 
ontwikkeling van therapeutische interventies. Bovendien zal het bepalen van de 
lokalisatie van endotheliaal JAM-A tijdens inflammatoire condities belangrijke 
informatie verschaffen over de onderliggende moleculaire mechanismen. 
In hoofdstuk 2 konden we aantonen dat JAM-A op het endotheel een 
pro-atherogene functie heeft. Door gebruik te maken van muizen die geen 
endotheliaal JAM-A hebben, kon een verminderde atherosclerotische laesie-
vorming worden gedemonstreerd. Muizen met een deficiëntie voor JAM-A op 
leukocyten, lieten het tegenovergestelde zien, hetgeen wijst op een 
beschermende rol van JAM-A op leukocyten in de ontwikkeling van 
atherosclerose. Hierbij lieten in vitro en in vivo transmigratie-studies zien dat 
deficiëntie voor JAM-A op het endotheel resulteerde in een verminderde 
transmigratie van leukocyten. Daarentegen leidde het ontbreken van JAM-A op 
leukocyten tot een verstoorde de-adhesie van de leukocyten en beschadiging 
van het endotheel, waarschijnlijk veroorzaakt door versterkte β2-integrine 
activatie als gevolg van de afwezigheid van JAM-A afhankelijke internalisatie 
van integrines. Verder konden we aantonen dat endotheliaal JAM-A focaal 
geherdistribueerd wordt naar het apicale membraan, zowel na stimulatie met 
cytokines of oxLDL, als ook op plaatsen van verstoorde flow. Hierdoor wordt 
adhesie en transmigratie van leukocyten versterkt. Ook kon worden aangetoond 
dat hoge en laminaire flow tegen de vorming van atherosclerose beschermt 
door middel van verhoogde aanmaak van miR-145 die de expressie van 
endotheliaal JAM-A vermindert. 
In hoofdstuk 3 hebben we bestudeerd welke mechanismen betrokken 
zijn bij herdistributie van endotheliaal JAM-A na stimulatie met oxLDL. Op basis 
van immunofluorescente detectie van JAM-A en actine hebben we aangetoond 
dat na oxLDL-stimulatie niet alleen actine-herdistributie plaatsvindt, maar dat 
ook de expressie van actine werd verhoogd. Ook was er een sterkere co-
lokalisatie van JAM-A/actine, waarschijnlijk ten gevolge van de sterkere 
interactie tussen JAM-A en ZO-1 na behandeling met oxLDL. Bovendien 
konden we aantonen dat de effecten van behandeling met anti-JAM-A 
antilichamen op leukocyte-transmigratie die we voorheen beschreven hadden 
specifiek het gevolg waren van het anti-JAM-A Fab fragment van het 
antilichaam. Gebruik van enkel deze fragmenten, in plaats van het volledige 
antilichaam, resulteerde ook in verminderde rekrutering van leukocyten na 
behandeling met cytokines en oxLDL. Verder hebben we ook meer inzichten 
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verkregen in de beschermende werking van het cholesterol-verlagende middel 
lovastatine, en zagen we dat lovastatine de herdistributie van JAM-A na oxLDL- 
of cytokine-stimulatie verhinderde. Dit was waarschijnlijk het gevolg van 
stabilisatie van actine in de celjuncties en een verminderde expressie van de 
oxLDL-receptor LOX-1. 
Vervolgens hebben we ook getracht meer inzicht te krijgen in het effect 
van herdistributie van JAM-A op rekrutering van leukocyten (hoofdstuk 4). Door 
middel van atomic force microscopie konden we aantonen dat voor 
paracellulaire rekrutering van T-cellen de vorming van JAM-A hotspots 
noodzakelijk was, vergelijkbaar met de herdistributie van JAM-A die we reeds 
beschreven hadden in hoofdstuk 2 en 3. Deze hotspots waren met name 
gelokaliseerd bij de endotheliale cel-cel-contacten, en versterkten de adhesie 
van de T-cellen, die nodig is om rekrutering te bewerkstelligen.  
Aansluitend hebben we in hoofdstuk 5 de rol onderzocht van deficiëntie 
van JAM-A op bloedplaatjes en de invloed hiervan op de vorming van 
atherosclerotische laesies. Hier bleek dat deficiëntie van JAM-A op 
bloedplaatjes (trJAM-A) leidde tot hyperreactiviteit van bloedplaatjes en een 
verlaagde activatiedrempel voor ADP, thrombine en collageen, hetgeen 
resulteerde in een versterkte adhesie en aggregatie van de bloedplaatjes. 
Bovendien toonden trJAM-A-deficiënte muizen een verhoogde expressie van 
pro-inflammatoire cytokines (TNF-α en IFN-γ) en chemokines (CXCL4 en 
CCL5), en waren er meer interacties tussen bloedplaatjes en leukocyten. 
Samen zorgden deze factoren voor een versterkte vorming van 
atherosclerotische laesies, met name in de vroege fase van de laesie-
ontwikkeling. 
In hoofdstuk 6 werden tot slot de resultaten beschreven in dit 
proefschrift en de implicaties hiervan bediscussieerd en in perspectief geplaatst 
en werden de mogelijkheden voor het gebruik van JAM-A als diagnostische of 
therapeutische target besproken. In conclusie geeft dit proefschrift nieuwe 
inzichten in de rol van JAM-A in de ontwikkeling van atherosclerose, met name 
met betrekking tot de cel-type specifieke rol van JAM-A, de mechanismen de 
betrokken zijn bij rekrutering van leukocyten en potentiële interventies. 
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bedanken, und ich hoffe, dass wir noch weiterhin einige Projekte zusammen 
bearbeiten können. 
Geschätzter Prof. Dr. Christian Weber, lieber Christian. Am gleichen Tag als ich 
zum Bewerbungsgespräch bei Rory war kamst du zur Begrüßung kurz vorbei, wobei 
wohl die brennendste Frage war, ob ich Fußball spiele. Seitdem haben wir schon 
einige Duell gegeneinander auf dem Platz ausgefochten, aber auch zusammen Titel 
geholt (z.B. den RWTH-Hallen Cup 2010). Ebenso abseits des Platzes waren wir 
zusammen erfolgreich, so gabst du dem JAM-A Projekt nochmal den letzten push 
und hast es damit nochmal einen wichtigen Schritt nach vorne gebracht. Als erster 
EuCAR-Chef hattest du immer ein offenes Ohr für mich und ich wusste, dass so 
wichtige Dinge wie zum Beispiel Finanzierungen bei dir nie ein Thema waren. Wie 
von Rory konnte ich auch von dir viele für Wissenschaftler unverzichtbare Dinge 
lernen. Nicht nur dein Engagement auf dem Platz, sondern auch in 
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wissenschaftlichen Dingen weiß ich sehr zu schätzen. Vielen herzlichen Dank für 
die gute Zusammenarbeit und auf die nächsten Tore und Paper!  
Honored Prof. Dr. Tilman Hackeng, dear Tilman. You were my Maastricht supervisor 
of the EuCAR project and later on together with Jürgen head of the program. As 
such, you struggled a lot to launch the Aachen-Maastricht Joint Degree. Additionally, 
you also took lots of efforts for my personal promotion. For all that and much more I 
am very grateful. We often had a good laugh and good exchange of thoughts. I 
guess you get that a lot but I think you are a splendid fellow, never reluctant to slap 
my back. So, Tilman, thanks a lot for everything you helped me with.  
Geschätzter Prof. Dr. Jürgen Bernhagen, lieber Jürgen. Nach einiger Zeit hattest du 
den Vorsitz des deutschen Zweigs des EuCARs übernommen, und spätestens dann 
durfte ich als Studentensprecher deine Hilfsbereitschaft und deinen Optimismus 
kennen lernen. Du warst auch immer offen für neue Ideen, auch wenn sie leider in 
der angedachten Form nicht zustande kamen, wie zum Beispiel die EuCAR special 
edition. Darüber hinaus hast du mich und meine EuCAR Kollegen ständig 
unterstützt, auch auf dem Weg zum Aachen-Maastricht Joint Degree, der anfänglich 
ein wenig holprig zu sein schien. Besten Dank dafür. 
Geschätzter Prof. Dr. Marc Spehr, lieber Marc. Auch wenn wir uns in etwa nur jedes 
halbe Jahr gesehen haben fand ich trotzdem die Atmosphäre und die flachen 
Hierarchien bei euch immer sehr entspannend. Gerne bin ich auch, nach kurzer 
Einweisung von dir, zur Auswertung von TPLSM Bildern zu euch gekommen. Wenn 
es für mich nicht das IMCAR geworden wäre, hätte ich mich bestimmt auch bei euch 
beworben. Auch standen wir vor langer Zeit einmal zusammen mit Prof. Wagner, 
Philipp, Lutz und Julius auf dem Fußballplatz. Auf jeden Fall danke ich dir herzlich 
für deine Betreuung meiner Arbeit und für deine Hilfe und die wertvollen 
Kommentaren zu meinem Projekt. 
Honored Prof. Dr. Marc van Zandvoort, dear Marc. For me being (or wanting to be) 
a two-photon guy talking to you about the whole topic was always very precious, or 
even by just listening to you I did learn a lot for example about Mister Manders. 
Moreover I think you are one of those persons with indestructible optimism, which 
was also quite inspiring for me. Your humor, as part of your positive character, was 
often very compelling but also sometimes rather sobering. For your valuable advice, 
the nice conversations and cheering me up, Grazie tante! 
Dear Mr. Mullet, dear Remco. If it wasn’t for Rory I guess you would be the person 
from whom I learn the most practical thinks, and for sure you are regarding TPLSM 
and the flow-chamber model. I guess this peculiar thing made the difference for my 
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former and maybe for my future work. Just for this I am deeply indebted to you. But I 
am also very grateful for all the hours we spent sitting and waiting for the next scan. 
I really liked the talks, not only the scientific ones, for me they are quiet 
rememberable. So, I really owe you some, maybe a nice german Schnitzel?  
Lieber Michael. An dieser Stelle auch vielen Dank für deine Unterstützung am 
Aachener two-photon, für die netten Unterhaltungen und für deine spontane Hilfe 
und Rückendeckung als ich als Neu-Münchener trotzdem euer Mikroskop eine 
ganze Woche belegt habe. Natürlich war dies alles nichts im Vergleich zu dem 
einen riesigen Gefallen, den du mir sogar ohne Nachfrage erwiesen hast. Ich glaube 
nicht nur ich bin dir dafür und deine direkte Art sehr sehr dankbar. 
Liebe Frau Mayer. Auch Ihnen gebührt ein wirklich großes und herzliches 
Dankeschön. Nicht nur Ihre Arbeit haben Sie mit einer Raffinesse und Umsichtigkeit 
erledigt, die Ihres gleichen sucht, auch Ihre herzliche und zuvorkommende Art war 
stets ein Anker für mich. Christian prägte einmal den respektvollen Begriff „Autopilot 
Mayer“, ich würde so weit gehen und sagen, dass dies nicht ganz der Realität 
entspricht. Einen Autopilot muss man vorher noch aktivieren, doch meist hatten Sie 
schon Lösungen bei der Hand ohne das Problem vollständig gehört zu haben. 
Nochmals vielen lieben Dank, ich bin wirklich froh meine ersten Schritte in der 
wissenschaftlichen Welt mit Ihnen gemacht zu haben. 
Liebe AG Koenen, lieber Ali, liebe Birgit, liebe Sabine, liebe Delia. Ich kann mich 
noch gut an meinen ersten Schreibplatz erinnern, der genau zwischen Alis und 
Birgits lag. Ich fühlte mich ein wenig wie am London Heathrow Airport, weil mir die 
ganze Zeit Worte um die Ohren flogen ;-). Aber nachdem ich meine erste 
Schüchternheit abgelegt hatte merkte ich schnell, dass es ja doch ganz witzig an 
diesem Flughafen ist. Bei euch allen muss ich mich für die lustigen Gespräche im 
Labor bedanken, die einen die Inkubations- und Zentrifugations-Zeiten versüßt 
haben. Auch vielen Dank für die anfängliche Geduld, die ihr mit mir hattet, wenn ich 
mal wieder kleine Fragen zu WB, PCR oder cloning hatte. 
Wo ich gerade bei Geduld bin; liebe Aachener TA crew, liebe Sabine, liebe Roya, 
liebe Melanie, liebe Steffi, liebe Sandra, liebe Susanne, lieber Leon. Bei euch allen 
muss ich mich sehr für eure Unterstützung und für die tolle Arbeit bedanken, die ihr 
die Jahre über für mich oder mit mir erledigt habt. Sabine, vielen Dank für deine 
Einweisungen in Zellkultur, WB und PCR, vor allem auch für die netten Gespräche 
und Abende mit guten Essen bei dir in Aachen. Roya, man sagt die Lauteste hat 
nicht immer gleich recht, vielleicht bist du da die Ausnahme ;-). Vielen Dank für 
deine Hilfe mit den Färbungen und für deine gute Laune. Mel und Steffi, euch 
gebührt auch ein großes Dankeschön für eure Hilfe bei den Präparationen und 
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Schnitten. Sandra, vielen Dank für deine Unterstützung bei der Tierhaltung und den 
Bestellungen. TVs sind, aus gutem Grund, in vielen Dingen nicht trivial, doch mit 
deiner Hilfe hat alles gut geklappt. Susanne, wenn es Fragen zum FACSen gab 
konnte ich damit immer zu dir, vielen Dank für deine Hilfe. Und last but not least 
Leon, der auch jederzeit hilfsbereit war und mir mit seinen Anekdoten aus dem 
Leben den Alltag verschönert hat. Ohne euch alle hätte es wohl nicht so gut 
funktioniert, Herzlichen Dank!!!  
Liebe 3 Engel für Martin, liebe Patti, liebe Sakine, liebe Wendy. Schon zu meinen 
Aachener Zeiten ward ihr stets für mich da und habt mir geholfen, wenn es um die 
Tierzucht ging. Alleine dafür bin ich schon sehr dankbar. Eine Herausforderung 
wurde es aber, als ich nach München ging und ihr dann fast alleine die Geschicke 
von 1-2 Linien gelenkt habt. Durch eure Unterstützung aber war dies gar nicht mehr 
so chaotisch, was ich sehr zu schätzen weiß. Vielen Dank für eure Hilfe! 
Liebe Ela. Wir lernten uns als AG Koenen Mitglieder erst in München kennen. Was 
ich sah war eine tatkräftige und energische Frau, die auch ein JAM-A Projekt 
bearbeitete. Glücklicherweise kamen dann auch Kooperationen zu Stande. Auch 
der Austausch mit dir war immer belebend. Vielen lieben Dank für die gute 
Zusammenarbeit. 
Was wäre die Doktorandenzeit ohne gute und mitunter trinkfeste Kollegen? Lieber 
Ali, liebe Biggi, liebe Helene, lieber Holgor, lieber Maik, liebe Patti, lieber Santosh, 
liebe Svenja, liebe Yve. Ich denke ohne euch wäre die Zeit bedeutend weniger 
schön gewesen. So erinnere ich mich noch heute gerne an den Pizza Battle (und 
andere Koch-Events) und den Casino Besuch zurück und an all die Abende, an 
denen wir unser karges Gehalt der Kiste oder dem Domkeller kampflos überlassen 
haben. Ali und Helene, The Aachener wird immer einen Platz bei mir finden. Patti, 
vielen Dank für deine herzliche und positiv verrückte Art, auch für deine seelische 
und moralische Unterstützung. Witzig waren auch die letzten Karnevalsfeiern 
zusammen mit Mr. Croc, hoffe nächstes Mal feiern wir dann „Fassenacht“ 
zusammen. Holgor, auch unvergesslich: HSV gegen Bremen, Oktoberfestzeit, 
Schweden, Iren und der „Scherbentanz“. Es war eine wirklich schöne Zeit mit euch, 
und wenn sich die meisten in alle Himmelsrichtungen verstreut haben und man sich 
nicht mehr so häufig sieht, werde ich euch umso lieber dort besuchen. Mahalo, 
Bedankt und Dankscheen. 
Liebe Maastrichter Bande, lieber Timo, lieber David, liebe Anette. Ich bin sehr froh 
euch kennen gelernt zu haben und die Partys und Fußball-Abende fand ich echt 
klasse. Timo, ich hatte bis dato noch nie einen Holländer mit so viel Würde aus 
einer Aachener Kneipe voll mit Deutschlandfans nach einem 1:2 der Holländer 
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gegen Deutschland (EM 2012) schreiten sehen ;-). Auch deine Anteilnahme nach 
dem deutschen 1:2 im Halbfinale gegen Italien war echt, oder? Anette, vielen lieben 
Dank für deine Hilfe beim Zurechtfinden im Aachen/Maastrichter 
Promotionsregularien-Dschungel. David, vielen Dank, dass du mich in die 
Sonntags-Kick Gruppe aufgenommen hast. Es machte immer sehr viel Spaß. Doch 
das unbestrittene Highlight: RaR, Metallica, Tribüne, Gänsehaut.  
Lieber Timo, zum zweiten. Man kann mit dir nicht nur hervorragend feiern, auch 
über das Imagen haben wir schnell einen Draht zueinander gefunden. Die daraus 
resultierende Coop hat ja auch uns beiden was gebracht ;-). Doch nicht nur dafür, 
auch für deine Hilfe bei formalen Dingen dieser Arbeit bin ich dir sehr dankbar. 
La Familia Gerdes, lieber Norbert, lieber Holgor, lieber Tobi, liebe Geli, liebe Sigrid, 
lieber Dirk, lieber Karl Otto, liebe Chrissy. In München angekommen fühlte ich mich 
eher heimatlos, da die AG Koenen leider sehr verstreut war. Ihr hattet mich schnell 
aufgenommen, und schon bald waren die Mittagspausen wieder richtig lustig. Vielen 
Dank dafür und auch vielen Dank für die netten Abende die da waren und noch 
kommen mögen. 
Meine lieben Eltern, liebe Ingrid, lieber Klaus. Bis jetzt fiel mir das Schreiben der 
Danksagung relativ leicht, für euren Teil ist das anders. Wohl nicht, weil es mir 
schwer fällt Dinge zu benennen, wofür ich euch dankbar bin, sondern eher weil ich 
nicht genau weiß, wo ich anfangen soll. Auch besteht die Gefahr schon tausendfach 
geschriebenes zu wiederholen. Ich versuche es trotzdem: Nun ist ja schon einige 
Zeit vergangen, dass es mich nach Aachen und dann nach München verschlagen 
hatte und ich euch nicht mehr auf der Tasche liege. Doch eure Unterstützung und 
Fürsorge war nie gebrochen. Egal ob es in München eine Küche aufzubauen gab 
oder ein großes Fest viel Vorbereitung benötigte, gerne habt ihr den langen Weg auf 
euch genommen um für mich da zu sein. Ich denke, dass dies das beste Symbol für 
eure stete Bereitschaft ist große Strapazen auf euch zu nehmen um mir zu helfen. 
Dafür gebührt euch mein größter Dank!  
 
Martin 
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